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The natural history and factors affecting the progression of nephropathy in non-
insulin-dependent diabetes mellitus are poorly understood. The hypothesis that
glomerular filtration declines at a similar rate in NIDDM and IDDM was examined
in a cohort of 87 subjects (55 NIDDM and 32 IDDM). The rate of decline of
calculated glomerular filtration rate (GFR) {Cockcroft-Gault} was significantly
slower in IDDM compared to NIDDM (0.29 vs 0.43 ml.min. 'month"1 p<0.05), in
subjects with a baseline glomerular filtration rate (GFR) of < 80 ml.min"1 followed
for a median of 6.4 years. The rate of decline of GFR was more rapid in Caucasian
than in Afro-Caribbean NIDDM subjects. For all individuals, 24-hour protein
excretion proved the most significant variable associated with the decline of GFR.
Together with diastolic blood pressure these factors accounted for 34% of the
variation of the data. For the NIDDM group, blood pressure treatment at the outset
replaced diastolic blood pressure as a significant associate of decline of GFR. The
effect of percutaneous renal artery angioplasty was evaluated in nine subjects with
NIDDM, nephropathy and renal artery stenosis to determine if this procedure
influences the progression of nephropathy. No benefit was demonstrated.
Twenty-six NIDDM individuals from the above cohort were prospectively studied
over a two-year period. The rate of decline of GFR was 0.48 ml.min.'month"'. Blood
pressure, serum cholesterol and 24-hour protein were all associated with GFR
decline, with 38% of the variation in the data accounted for by the first two factors.
EDTA clearance was compared to calculated GFR and creatinine clearance for 72
patient episodes to determine the clinical value of these surrogate markers of GFR in
NIDDM subjects. Calculated GFR underestimated true GFR by 4%, on average, with
significant differences for the Afro-Caribbean, but not the Caucasian or Asian,
group.
A reliable non-invasive marker of disease progression would be valuable in
established nephropathy. Serum and urine type IV collagen and, using a novel assay,
mixed laminin fragments (MLF) were compared in 55 subjects with diabetic
nephropathy, 33 control diabetic subjects and 42 normal control subjects. The
v
median values for serum type IV collagen were 161, 115 and 94 pg.L"' and for serum
MLF 940, 1000 and 224 pg.L"1 respectively. The level of serum collagen found in the
nephropathic group was significantly greater than diabetic or normal controls
(p<0.001), whereas for serum MLF the nephropathic and diabetic control group were
similar, though both significantly higher than the normal group (p<0.001). Type IV
collagen was undetected in the urine in all normal subjects and all but three diabetic
controls, compared to 50% of nephropathic subjects, whereas MLF were detected in
the urine of 1 of 28 normal, 10 of 28 diabetic control (all <110 pg.mmol Cr"1) and 50
of 51 nephropathic subjects. The level of MLF was greater in individuals with a
more rapid decline ofGFR and suggests a role for MLF in monitoring of progression
in advanced diabetic renal disease.
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Abbreviations and definitions
ACE Angiotensin converting enzyme
ACEI Angiotensin converting enzyme inhibitor
ACEID Angiotensin converting enzyme insertion/deletion gene
polymorphism
AER albumin excretion rate. Measured either as timed overnight collection
or as 24-hour collection.
BMI body mass index. Defined as weight (kg)/ height2(m)
BMT basement membrane thickening
CAPD chronic ambulatory peritoneal dialysis
cGFR estimated GFR using the Cockcroft-Gault formula.
CL IV type IV collagen
CSII continuous subcutaneous insulin infusion
DBP diastolic blood pressure
DEAE diethylaminoethyl
EDTA European Dialysis and Transplantation Authority
EDTA ethylenediaminetetraacetic acid
ESRD End-stage renal disease. Also known as end-stage renal failure.
GBM glomerular membrane thickening
GFR glomerular filtration rate
HbA,/HbAlc glycosylated haemoglobin
HD haemodialysis
HDL high density lipoprotein
IDDM Insulin-dependent diabetes mellitus
ioth iothalamate clearance
LDL low density lipoprotein
LP1.LP2 principal pepsin digest fragments of laminin
MAP mean arterial pressure. Defined as diastolic blood pressure plus one-
third of the SBP-DBP
MDRD modification of diet in renal disease
MLF mixed laminin fragments
mRNA messenger RNA
NCI N-terminal end of type IV collagen
NIDDM Non-insulin-dependent diabetes mellitus
PBS phosphate buffered saline
PCTA percutaneous transluminal angioplasty
PEG polyethylene glycol
PTH parathyroid hormone
RAS renal artery stenosis
RRT renal replacement therapy
S.Cr. serum creatinine
SBP systolic blood pressure
SDS sodium dodecyl sulphate
TBM tubular basement membrane
UAE urine albumin excretion
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In the Kumamoto study, analogous to the DCCT, Ohkubo and colleagues (1995)
examined the effect of intensive insulin therapy on progression of microvascular
complications in NIDDM. Over a six-year period, 110 subjects were randomly
assigned to conventional therapy (1 or 2 insulin injections) or intensive therapy (3 or
more injections). The cohort was further subdivided into a primary and a secondary
prevention group. With reference to nephropathy, those subjects in the former group
had a UAE of <30 mg.24 hr1, whereas the UAE in the latter was <300 mg.24 hr1.
Progression was defined as an increase in one or more nephropathy stages, described
as normoalbuminuria, microalbuminuria or albuminuria (>300 mg.24 hr"1).
Development of nephropathy was observed in 28% vs. 7.7%, conventional vs.
intensive therapy (p = 0.03), of individuals in the primary intervention group and
progression in 32% vs. 11.5%, conventional vs. intensive therapy (p = 0.04), in the
secondary intervention group. Furthermore the authors suggested the glycaemic
threshold for the development and progression ofmicrovascular complications was an
HbAlc of 6.5%.
There are a number of weaknesses in this study. It is not clear exactly how the
classification of nephropathy stage was arrived at in individual subjects and patient
numbers are relatively small for an intervention study. For example of 55 subjects in
the primary prevention group, only 9 showed development of nephropathy. It is quite
possible that misclassification of nephropathy stage could significantly affect the
conclusions reached. Although a glycaemic threshold of an HbAlc of 6.5% is
suggested in the text, examination of Figure 4 suggests the true value should lie
between 7% and 7.5%.
xix
Addenda to section 1.3.4 (at foot of page 16):
More recently, Lam and colleagues (1995) examined the influence of lovastatin, an
HMG CoA reductase inhibitor, in delaying the progression of nephropathy in Chinese
subjects with NIDDM. In a two year study, these workers suggested that lovastatin
caused an attenuation in the rate of decline of GFR, and that this effect only became
evident after two, rather than one, years therapy. However, whilst the GFR was
significantly lower at two years, compared to baseline, in the placebo group, no
statistical difference was observed in GFR between the groups at two years, despite
comparable baseline values. Furthermore it is unclear if efforts were made to exclude
non-diabetic renal disease.
These two additional studies are referenced at the end of the reference section.
Statistical comment
In the prospective study, a single subject - case 5 - exhibited a marked deterioration in
GFR over the observation period. Consequently this may have influenced the
significance of certain of the statistical associations. Statistical advice was sought and,
as documented on page 94, the data re-examined removing this individual. In the
univariate analysis, diastolic blood pressure and 24 hour protein excretion were no
longer associated with decline of GFR. Removing this individual did not affect the
conclusions drawn from the stepwise regression analysis.
Variability in analysis of protein markers of nephropathy progression
There are no data available to determine the intra- and inter-assay coefficient of
variation of laminin. Samples were prepared in duplicate and the mean of the two used
in comparing results of serum and urine from nephropathic, non-nephropathic diabetic
and control subjects. Neither sequential nor large volume samples were available to
determine the CV of the assay, when used to determine the concentration of laminin in
xx
these samples. To minimise bias in the assay equal numbers of samples were analysed
from each of the above groups within each assay. It is acknowledged that a high CV, if
found, would limit the clinical applicability of this assay. The intra and inter assay CV
for collagen, determined by the manufacturer, were 3.9% and 5.2% respectively.
Because of the limited material available, it was decided not to repeat these
measurements but to use it all for the analysis of the samples.
xxi
Corrigenda
page 9; end line 3 : should read 'in the United Kingdom'
page 16; line 24 : -0.25 to -0.21 should read '0.25 to 0.21'
page 19; line 9 : (1990) should read '(1995)'
page 40; line 15 : unpaired should read 'paired'
page 41; line 7 : unpaired should read 'paired'
page 48; table : in line 'Final year' 27 should be 22 and 23 should be 28
page 91; line 12 : 0.91 should read '-0.91'
page 93; table 4.7 : significance for MAP should be 'NS', not p < 0.001
page 98; table 4.8 : decline in GFR should read 0.04 and not 0.44
page 109; the lines' However, whether this seen.' should be removed
page 134; line 7 : should read clearance of 0.73 (slightly stronger in Caucasians
and...)
page 161; add 'The values are the mean of three samples.'
page 169; line 5 : should read '.. serumMLF does not distinguish...'
page 173; line 8 : should read '...nephropathy, compared to normal controls,
(p<0.005)...
page 174; line 18 : for relate to read 'be explained by'




In 1859 Griesenger described the case of a patient with renal failure and non-insulin-
dependent diabetes mellitus, well before the advent of insulin and over 75 years
before Kimmelsteil and Wilson identified the lesions which characterise diabetic
glomerulo-pathy (Griesenger 1859; Kimmelsteil and Wilson 1936). Our
understanding of the pathophysiology and progression of nephropathy in NIDDM
has, until recently, lagged well behind that of IDDM. More is now understood about
the early stages of nephropathy in NIDDM and of those reaching end-stage renal
disease, yet of the intervening period much less is known.
1.1 The scale of the problem
1.1.1 Diabetes mellitus and renal impairment
An inexorable march towards end-stage renal disease (ESRD) and renal replacement
therapy (RRT) is the fate of many diabetic patients with chronic renal impairment,
assuming death from cardiovascular disease does not intervene. Exactly what
constitutes ESRD is unclear (Wing 1992) and many texts use the term end-stage
renal failure. It is assumed here to represent the phase, of varying duration,
immediately before and including RRT (Mogensen 1993). Each year in the United
Kingdom 300 to 350 individuals with diabetes commence RRT (Cameron 1992a).
However, this figure falls well short of the 580 estimated to develop ESRD in a
given year (Joint Working Party 1988 & 1989). Notwithstanding this shortfall, the
proportion of diabetic patients treated for ESRD world-wide has increased
significantly since the first individual started maintenance dialysis over thirty years
ago (Avram 1982). Initial acceptance for those with diabetes mellitus was slow. In
1975 only 1.4% of patients who commenced RRT in the UK had diabetes. By 1985
this had risen to 11.4%, 12.7% by 1988 and in 1992 the figure for all Europe was
17% (Brunner et al. 1988; Cameron 1992a; Vaderrabano 1994). Elsewhere the
proportion is higher. The latest available data for the USA indicate an acceptance
rate of 33.6% in 1993 (United States Renal Data Service Report 1996). In Finland
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the 1985 figure was 34% (almost all IDDM) and for Japan 19% (predominantly
NIDDM) for the period 1982-7 (Brunner et al. 1988; Odaka 1990). Currently in New
Zealand the proportion is 35 - 40% (Dr. PL Drury personal communication).
1.1.2 The increasing proportion of non-insulin-dependent diabetes
mellitus in renal replacement programmes.
An increasing proportion of diabetic patients on dialysis programmes have NIDDM
(Rettig and Teutsch 1984; Gonzalez et al. 1985; Cameron and Challah 1986;
Friedman 1986; Koch et al. 1989; Catalano et al. 1990a; Grenfell et al. 1992).
Between 1983 and 1990 the number of those on the European Dialysis and
Transplant Association (EDTA) registry with NIDDM increased by 263% against
76% for IDDM (Raine 1993), though in part this may have been due to improved
accuracy of classification (see below). In many countries the majority of diabetic
patients receiving renal replacement have NIDDM, e.g. in the USA, in the first six
months of 1988, 57% were so classed (MMW Report 1989). This proportion may be
as high as 86%, depending on the local referral pattern (Friedman 1986).
Misclassification of diabetes type may be responsible for the under-representation of
NIDDM in certain of the published figures. Before 1983 there was no separate code
for IDDM and NIDDM on the EDTA registry (Raine 1993). In France, Zmirou and
colleagues (1992) found that more than one third of all patients with NIDDM were
misclassified, most commonly on the basis of insulin treatment alone. Adjusting for
these errors, this group estimated the relative proportion of IDDM and NIDDM
patients to be 1.4% and 5.5% respectively compared to the official estimates of 3.2%
and 3.7%. Similarly in 1991, Ritz and colleagues in Germany classed only 36% of
diabetic patients as insulin-dependent, compared with the figure of 71% published by
the EDTA registry, despite using the same population base. Almost identical results
were found in Italy by Catalano and colleagues (1990b). Even adjusting for these
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discrepancies it is very likely that the proportion of NIDDM subjects receiving renal
replacement therapy will show a real increase in the future.
1.1.3 Outcomes on renal replacement therapy
Once commenced on RRT the prognosis for the diabetic patient, though improving,
remains poorer than for those with non-diabetic renal disease (McMillan et al. 1990;
USRDS 1996). Using data supplied by the EDTA registry, Brunner and Selwood
(1990) recorded an overall 5 year survival of 13% in diabetic subjects over the age of
65 years on renal replacement, compared to 34% in an age-matched, non-diabetic,
group. Somewhat better survival, 30% at 4 years for all treatment modalities, was
recorded in 51 diabetic patients (combined IDDM and NIDDM) aged 55 years and
over (Grenfell et al. 1992). The best overall survival following renal replacement in a
NIDDM population, 33% at five years, has recently been documented in the Pima
Indians (Nelson et al. 1996a).
It is well established that patients receiving dialysis fare less well than those receiving
a transplant (Matson and Kjellstrand 1988; Najarian et al. 1989; Hirschl et al. 1992;
Nelson et al. 1996a). This is particularly so in diabetes mellitus. Hirschl and
colleagues (1992) found an overall 5 year survival of only 14% in 78 NIDDM
patients on RRT. The figures for transplantation and haemodialysis (HD) were 59% v
2% respectively. Nelson and colleagues (1996a) recorded a median survival of 92
months in 12 Pima Indians with NIDDM, who received a renal transplant, compared
to 35 months in 124 who did not. Recent data suggest that there may be a survival
advantage from haemodialysis compared to chronic ambulatory peritoneal dialysis
(CAPD) in NIDDM. Nelson and colleagues (1996a) recorded a median survival of 45
months in 107 subjects treated with HD against 29 months in 29 individuals treated
with CAPD. However, the small numbers meant the data failed to reach statistical
significance. Similar findings were observed by Bloembergen and colleagues (1995),
though others, including Nolph (1988) have found no difference. In the UK the
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primary treatment for ESRD in diabetes mellitus, particularly NIDDM, is CAPD
(Raine 1993).
In general, overall survival rates for those with diabetes are < 50% for those with
non-diabetic renal disease (Raine and Ritz 1994). It remains inescapable that the
present outlook for diabetic patients, in particular those with NIDDM, is poor once
renal replacement is commenced (Vollmer et al. 1983; Held et al. 1990; Brunner and
Selwood 1992).
1.1.4 Resource implications of diabetic nephropathy
Healthcare costs for diabetes are estimated at 4-5% of the UK health budget
(Department of Health 1991; Williams 1991). A significant proportion of this is spent
on the treatment of complications. In 1993 in the US over $1.5 billion was spent on
ESRD due to diabetes mellitus (United States Renal Data Service: Annual Data
Report 1996). Each person entering a renal replacement programme costs, in 1993
terms, US $43,500 per annum to treat, some US $11,500 more than their non-
diabetic counterpart (USRDS 1996). In Germany the estimated annual cost, at 1991
prices, ofdialysis ranged from US $35-55,000 and for transplantation US $14-35,000
in the first year and US $7,000 per annum in subsequent years (Borch-Johnsen et al.
1993).
Given the considerable number of patients involved, the significant healthcare costs
and the poor outcome on RRT, delaying the start of treatment for ESRD for those
with NIDDM and nephropathy presents an attractive alternative, not just to the
patient, but also to the physician and to the health economist. Fulfilment of these
aspirations requires a greater understanding of the evolution of nephropathy and the
factors that govern progression.
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1.2 Disease progression
1.2.1 Progression to renal replacement therapy in diabetes mellitus
The frequency with which overt nephropathy (defined as a protein excretion of >
0.5g in 24 hours in the absence of other renal disease) leads to the development of
renal failure in NIDDM is not well documented for most populations (Nelson et al.
1993; Nelson et al. 1996b). In IDDM, where the position is clearer, diabetic
nephropathy previously affected over 40% of individuals after 40 years of diabetes
(Anderson et al. 1983). Of these two-thirds progress to end-stage renal disease, the
majority within 25 to 30 years of diagnosis (Mogensen 1993). Analyses of IDDM
cohorts over successive decades show a decline in incidence (Krolewski et al. 1985;
Kofoed-Enevoldsen et al. 1987). The former found that 53% of individuals aged
under 21 years when diagnosed in 1939 developed nephropathy in contrast to the
25% projected for those of similar age diagnosed in 1949 and 1959. Recent estimates
of the prevalence of micro-albuminuria (albumin excretion of 20 to 200 pg.min"1) of
13-15% (Berglund et al. 1987; Parving et al. 1988) suggest that a further decline can
be anticipated.
Accurate data on the prevalence of nephropathy in NIDDM are harder to obtain.
Lack of ascertainment, as significant numbers of those with NIDDM are cared for in
the community (Olivarius et al. 1993), proteinuria due to non-diabetic renal disease
(Parving et al. 1992) and premature death from cardiovascular disease (Deckert
1994) all contribute to this difficulty. Reports that 3-8% ofNIDDM patients progress
to ESRD (Balodimus 1971) clearly underestimate the true prevalence of nephropathy
and, at least in certain populations, the lifetime risk of requiring RRT. Ballard and
colleagues (1988) recorded a 20 year cumulative incidence of persistent proteinuria
of 24.6% in a group of Europid NIDDM subjects from Rochester, Minnesota. In
contrast to the studies in IDDM cited above, this group found no evidence that the
incidence was declining with time. In selected populations the proportion is even
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higher. Studies in the Pima Indians, a native American tribe living in Arizona, shed
considerable light on the evolution of nephropathy in NIDDM, due to the high
prevalence of NIDDM and the young age of onset (Knowler et al. 1978). In this
group 35% develop proteinuria within 15 years and 50% within 20 years of diagnosis
(Nelson et al. 1988; Kunzelman et al. 1989). Similar rates are found in Japan (Sasaki
et al. 1989).
High prevalence of ESRD is described in other non-white populations with diabetes
(Rostand et al. 1982; Eggers et al. 1984; Pugh et al. 1988). Fifteen percent of Pima
Indians develop ESRD {Serum creatinine (S.Cr.) > 442 pmol.L"1} within 20 years of
diagnosis. Once proteinuria is established, 35% will develop ESRD in 10 years and
54% in 15 years (Nelson et al. 1988). These figures exceed the 11% and 17% seen in
individuals in a study in Caucasians (Humphrey et al. 1989), despite a lower
threshold (S.Cr. > 350 pmol.L"1 on two occasions) used to define renal failure.
Few groups have examined the prevalence of ESRD in IDDM and NIDDM patients
simultaneously. Nelson and colleagues (1988) compared their NIDDM population to
a group of IDDM patients attending the Joslin clinic and found a 1.5-fold difference
(15% v 9%) twenty years after diagnosis. Hasslacher and colleagues (1989) observed
no difference - of 496 NIDDM patients without proteinuria at baseline, 27%
developed proteinuria after 20 years, compared with 28% of 312 with IDDM. Of
these 63% and 59% respectively developed renal failure (S.Cr. >120 pmol.L"1)
within five years. Humphrey and colleagues (1989) observed a cumulative incidence
of renal failure of 6.2% for NIDDM and 8% for IDDM after 25 years of diabetes.
Persistent proteinuria is already present in a significant number of individuals with
NIDDM at diagnosis. Ballard and colleagues (1988) recorded proteinuria in 8.2%,
whilst Olivarius and colleagues (1993) found an albumin excretion of > 200 pg.mm 1
(equivalent to 300 mg^dhr"1) in 6% of 1128 individuals in a General Practice-based
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study in Denmark. In the Pima Indians 9% were proteinuric at diagnosis (Kunzelman
et al. 1989), whilst the highest recorded prevalence appears in the Nauruan
population with 24%. (Collins et al. 1989). The latter used a cut off of 300 pg.ml"1
for albumin excretion and the prevalence might be an over-estimate, as it is not clear
what efforts were made to exclude non-diabetic causes ofproteinuria.
The time to onset of persistent proteinuria is naturally shorter in NIDDM than in
IDDM, reflecting the pre-symptomatic period occurring in many individuals (Harris
et al. 1992). The average time from diagnosis to proteinuria was 16 years in 46
NIDDM patients and 20 years for 48 IDDM (Hasslacher et al. 1989). In a group of
mixed races the duration to proteinuria was 10.1 years in NIDDM and 16.9 years in
IDDM subjects (Ordonez and Hiatt 1989); the time interval from proteinuria to the
start of RRT was 5.9 years and 6.5 years respectively. Biesenbach and colleagues
(1994) found the mean (range) interval from proteinuria to dialysis was 77 (44-133)
months in 16 IDDM and 81 (40-124) months in an equal number of NIDDM
patients. There is little evidence from these studies that the time interval from
proteinuria to ESRD differs between IDDM and NIDDM.
1.2.2 Rate of decline of glomerular filtration rate
Observational studies in IDDM patients with nephropathy suggest a rate of fall of
glomerular filtration rate (GFR) of approximately 1 ml.min."1month"1 (Mogensen
1976; Mogensen 1982). Individual rates of decline are highly variable, ranging from
0.13 to 2.47 ml.min/'month"1 (Jones et al. 1979; Parving et al 1981; Viberti et al.
1983). Intervention, particularly with anti-hypertensive therapy, slows the rate of
decline on average to 0.20 ml.min.'month"1, 6 to 10 years after starting therapy
(Parving et al. 1993). Nyberg and colleagues (1986) found similar results with a
mean decline of 0.38 ml.min."'month"1 over a 2 to 3 year period in 29 subjects with a
baseline GFR of approximately 50 ml.min"1; a third of the group maintained stable
renal function throughout the observation period.
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The natural evolution of established nephropathy in NIDDM will remain to a large
extent unknown, since the majority of individuals are already on treatment.
Prospective studies which use a valid technique to measure GFR are few. Friedman
and Gross (1991a) examined seven NIDDM subjects with a baseline GFR of 40-85
ml.min"' over 4 to 25 months. Excluding one subject who developed multiple
myeloma, GFR showed a mean improvement of 0.14 ml.min."'month-1 (range -0.72
to 0.80) over 20 months. A larger series from Gall and colleagues (1993) reported a
mean decline of GFR of 0.48 ml.min.'month"1 in 31 proteinuric diabetic subjects. In
a four-year study in the Pima Indian population, Myers and colleagues (1995)
recorded a more rapid decline ofGFR of 0.75 ml.min."'month-1 in 30 individuals with
clinical proteinuria and a baseline GFR of 108 ml.min"'. Nielson and colleagues
(1991) measured GFR at baseline and at follow up (3-4 years later) in 70 NIDDM
subjects (mean age 63 years) of whom 45 were normo-albuminuric, 18 micro-
albuminuric and 7 proteinuric. The rate of decline varied from 0.08 ml.min."'month"'
in the normo-albuminuric group to 0.61 ml.min."'month-1 in the proteinuric group.
Nelson and colleagues (1996b) examined progression in a group of 34 Pima Indians
with macroalbuminuria and a serum creatinine <115 prnol.L"1. They found that GFR
declined by 35% over a four year period, where the baseline GFR was 124 ml.min"1.
1.3 Determinants of progression of nephropathy
1.3.1 Ethnicity and progression of nephropathy
The high prevalence of nephropathy secondary to diabetes mellitus in many non-
white populations has already been mentioned (section 1.2.1). The greater risk of
these groups requiring RRT is now widely recognised. Cowie and colleagues (1989)
found a 2.6-fold increase in black compared to white Americans, despite correcting
for the higher prevalence of diabetes in the former. Stephens and colleagues (1990),
in a similar analysis, found a 3.6-fold increase, with a slightly greater (non¬
significant) risk for NIDDM. Such figures are small compared to the 20-fold increase
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in risk of ESRD seen in the Ute and Pima Indians of North America (Narva 1985;
Nelson et al. 1988). A greater number of Afro-Caribbeans and Asians with diabetes
mellitus, relative to their total population are entering renal replacement programmes
(Grenfell et al. 1988; Burden et al. 1992).
Though clearly at greater risk of progressing to ESRD, there is divided opinion on
whether non-white subjects progress more rapidly once nephropathy is established.
Brazy and Fitzwilliam (1990) found no difference in the rate of decline of renal
function, using the slope of inverse creatinine, comparing 112 black (racial origin not
identified) with 88 white subjects with progressive renal disease of undisclosed
aetiology. However, Tierney and colleagues (1989) did identify race as an
independent risk factor for progression (along with diabetes and systolic blood
pressure). Cowie (1993) found the time taken from a S.Cr. >159 pmol.L"1 to RRT
averaged significantly longer in black (23.8 months), compared to white (18.5
months), NIDDM subjects.
Several factors have been advanced to explain the higher prevalence of ESRD in
non-white populations, including access to healthcare (Smith et al. 1991), differences
of calcium metabolism (Bell et al. 1985) and blood pressure (Dustan et al. 1987;
Cowie et al. 1989). In the next section the key role of the latter in determining the
progression of nephropathy is considered.
1.3.2 Blood pressure and progression of nephropathy
It is well established that anti-hypertensive therapy is able to reduce the decline of
GFR in IDDM and probably delays the onset of ESRD. In 1976 Mogensen drew
attention to the association of hypertension and declining GFR in proteinuric IDDM
subjects and in a subsequent paper showed apparent therapeutic benefit from
reducing blood pressure in six patients with diabetic nephropathy (Mogensen 1976;
Mogensen 1982). In the latter study the mean pre-treatment decline of GFR was 1.23
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ml.min."1 month"' and mean blood pressure 162/103 mmHg. Following intervention
with various anti-hypertensive agents the blood pressure fell to 144/95 mm Hg and
the mean decline of GFR to 0.49 ml.min."'month1. These results were confirmed by
Bjorck and colleagues (1986) and Parving and colleagues (1983; 1987). Benefit also
occurs once renal failure is established (Zander et al. 1990). Following these studies
the question was no longer whether anti-hypertensive treatment was beneficial, but
rather when should it be started, which agent should be used to lower blood pressure
and by how much. Mogensen and colleagues (1991) argued the case for a target
mean arterial pressure (MAP) of 90 to 95 mmFIg. in those with incipient
nephropathy and 100 to 105 mm Hg in overt nephropathy in IDDM.
Many studies have examined the relative merits of the different classes of agent often
using microalbuminuria as a surrogate marker of progression. All agents slow the
rate of progression, though a claim of superiority is made for angiotensin converting
enzyme inhibitors (ACEI). In a large multi-centre trial comparing captopril with
placebo in addition to other anti-hypertensive therapy, Lewis and colleagues (1993)
demonstrated significant slowing of progression (determined by doubling S.Cr., rate
of decline of creatinine clearance, reaching RRT and death) with captopril in 207
IDDM subjects with overt nephropathy and further showed the benefit derived not
just from control of blood pressure alone. Viberti and colleagues (1994) have shown
a beneficial effect of captopril in slowing progression from microalbuminuria to
clinical proteinuria in 46 normotensive IDDM patients. A summary of intervention
trials of anti-hypertensive therapy is found in Mogensen and co-workers (1993);
selected studies in NIDDM are shown in Table 4.10.
The situation in NIDDM is not so clear cut. Hypertension frequently precedes the
onset of diabetes (Pugh et al. 1993), and may be present in the absence of
microalbuminuria (Schmitz et al. 1991). Furthermore, as discussed below, it may be
systolic, rather than diastolic, pressure which is linked to the progression of
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nephropathy in NIDDM. Retrospective analyses of NIDDM subjects with renal
failure often identify blood pressure as an important determinant of progression. In
16 NIDDM patients, Biesenbach and colleagues (1994) found a slower rate of
decline of GFR, as measured by creatinine clearance; 0.78 ml.min/'month"1 in those
with a systolic blood pressure below 160 mm Hg compared to 1.38 ml.min."'month"'
for those above. Both systolic and diastolic pressure were shown to relate to
progression, with the former being the stronger associate.
In 47 patients with overt nephropathy studied over a mean period of 57 months,
Hasslacher and colleagues (1993) identified systolic blood pressure as the strongest
determinant of progression in a multiple regression analysis. Tierney and colleagues
(1989), in a study in hypertensive adults of whom 41% had diabetes (most NIDDM),
found systolic blood pressure correlated with deteriorating renal function (S.Cr. and
estimated GFR by Cockcroft-Gault). In a very short-term study (mean observation
period 1.4 years), Dillon (1993) found that diastolic, and to a lesser degree systolic,
pressure correlated with decline in estimated GFR in 59 diabetic subjects, of whom
50% were NIDDM.
In the Pima Indians, Nelson and colleagues (1993) found no evidence that the level
of blood pressure at the onset of proteinuria predicted ESRD. It is not clear whether
the time to ESRD was influenced by blood pressure. Subsequent studies (Nelson et
al. 1996b) found no evidence that blood pressure influenced the decline ofGFR in 34
macroalbuminuric subjects, suggesting that it may not do so in this population. Pugh
and colleagues (1993) found that the time from diagnosis of diabetes to ESRD was
significantly shorter in the NIDDM subjects who already had hypertension at
diagnosis (15.5 vs 18.2 years). It is not stated whether the blood pressure was the
same in both groups after diabetes was diagnosed. In 131 diabetic patients (47 IDDM
& 84 NIDDM) recruited from an eye clinic, Walker and colleagues (1990) found
systolic blood pressure in excess of 140 mm Hg was associated with a progressive
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decline of renal function in both IDDM and NIDDM subjects; the association being
more marked in the latter. No significant deterioration in renal function occurred in
those with a systolic pressure <140 mmHg over the 3.5 years of observation. The
principal criticism of this study rests with the use of serum creatinine alone as the
marker of renal function.
Of the prospective studies in NIDDM with overt nephropathy, Friedman and Gross
(1991) and Myers and colleagues (1995) found no association with blood pressure,
whilst Gall and colleagues (1993) only with systolic pressure. In normo- and micro-
albuminuric subjects, Nielsen and colleagues (1993a) demonstrated a correlation of
systolic blood pressure with decline of GFR. The same group also showed an
association of systolic pressure with albumin excretion in 135 NIDDM subjects who
completed six years of follow-up (Schmitz et al. 1994).
Studies in renal disease not due to diabetes reach broadly similar conclusions,
although good prospective, let alone interventional, studies are lacking. Using inverse
creatinine in a retrospective examination of 102 subjects with renal disease of mixed
aetiology, Wight and colleagues (1992) found diastolic, though not systolic, blood
pressure correlated with the rate of progression. In a similar retrospective analysis,
Hannedouche and colleagues (1993) also showed a strong correlation with blood
pressure, this time using estimated creatinine clearance as their end-point. Brazy and
Fitzwilliam (1990) demonstrated, in a study of 200 subjects, that in 45 cases where
the diastolic pressure fell from > 90 mm Hg to < 90 mm Hg the rate of progression of
renal impairment fell from 0.76 ml.min."1month"1 to 0.46 ml.min.'month"'. The same
group had previously demonstrated that the rate of progression was significantly
faster in the upper two quartiles of diastolic blood pressure than the lowest quartile,
when all previous clinic blood pressures were stratified (Brazy et al. 1989). Oldrizzi
and colleagues (1985) had shown similar results where the diastolic threshold was set
at 100 mm Fig.
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1.3.3 Blood glucose and progression of nephropathy
Studies under the umbrella of the Diabetes Control and Complications Trial (DCCT)
established the case for a permissive role for hyperglycaemia in the development of
microalbuminuria in IDDM, and strongly implicated it in the subsequent progression
to overt nephropathy, with a 56% risk reduction in the intensively treated group
(DCCT 1993, 1995). In so doing the trial confirmed the findings of Feldt-Rasmussen
and colleagues (1986) and Dahl-Jorgensen and colleagues (1988), who demonstrated
the therapeutic benefit of strict metabolic control on progression in smaller groups.
Mathiesen and colleagues (1990) observed a threshold effect of glycaemic control,
with only those having an HbAlc greater than 8% progressing from normo- to
microalbuminuria. Krolewski and colleagues (1995) have published similar findings.
These benefits were challenged by the Microalbuminuria Collaborative Study Group
(1995), who found no impact of intensive insulin therapy on progression of
albuminuria in individuals with microalbuminuria.
In a prospective study of 6 IDDM individuals with overt nephropathy, Viberti and
colleagues (1983) demonstrated no significant benefit from strict glycaemic control.
However the mean decline of GFR fell from 1.35 ml.min."'month"1 to 0.69 ml.min."1
month"1 and the graphic data suggest an attenuated decline of GFR in all cases.
However this small study has relatively limited power. In contrast Nyberg and
colleagues (1987) followed 18 IDDM patients over a 21 month period and did show
a significant association between a higher HbA,c and a faster decline in GFR.
As with blood pressure, studies in NIDDM are fewer. Schmitz and Vaeth (1988)
have shown an association between hyperglycaemia and elevated urinary albumin
excretion (UAE). In the United Kingdom Prospective Diabetes Study (UKPDS),
raised blood glucose was associated with UAE at diagnosis and during the three
subsequent years (UKPDS Report 1993). However less than 10% of the variance of
13
the data was accounted for by blood glucose, systolic blood pressure and serum
triglyceride. In a 12-year prospective study into progression of microalbuminuria,
Gilbert and colleagues (1993) found that HbA,c correlated with albumin excretion
rate (AER) in the 22 subjects (9 NIDDM) who showed increasing albumin excretion.
However, when the whole group was divided into 'Progressors' and 'Non-
progressors', on the basis of albumin excretion, no significant relationship with
glycaemic control was observed.
Retrospective studies of those with ESRD do, in certain cases, show association with
raised blood glucose. Higher 2hr blood glucose (post 75g glucose) at the onset of
proteinuria in Pima Indians was predictive of progression to ESRD (Nelson et al.
1993). Within-clinic post-prandial blood glucose was found to correlate with decline
of GFR in 94 nephropathic NIDDM individuals, although mean HbA, performed in
the latter stages did not (Hasslacher et al. 1993). No association of glycaemic control
with progression was noted in 16 NIDDM subjects followed over 81 (40-120)
months (Beisenbach et al. 1994), nor was it seen in the studies of Friedman and
Gross (1991) and Gall and colleagues (1993).
On balance the evidence for an effect of blood glucose on progression is strongest in
the early stages of nephropathy and less so, if at all, in the latter stages in both IDDM
and NIDDM.
1.3.4 Serum lipids and progression of nephropathy
Virchov (1860) is credited with being the earliest to recognise the association
between lipid deposition and chronic renal disease. In their seminal paper,
Kimmelsteil and Wilson (1936) described the pathological hallmarks of diabetic
nephropathy but also noted the presence of widespread lipid deposits in the kidney.
However so abundant were these deposits that they were discounted as being of no
pathological significance. It fell to Wilens and Elster in 1950 to recognise their
14
potential importance by describing the presence of lipid in the renal arterioles and
what has now come to be known as the mesangium in both hypertensive and diabetic
subjects. Thus was the link between mesangial expansion, systemic hypertension,
hyperlipidaemia and diabetes mellitus forged, although it was to be 30 years before
any further significant advances were made. Moorhead and colleagues (1982), citing
studies in patients with nephrotic syndrome, speculated that lipids, rather than the
more fashionable dietary protein (Brenner et al. 1982), could be an additional
permissive factor influencing the progression of renal disease. Although clinical
studies have yet to substantiate this hypothesis there is considerable evidence from
animal studies that lipids may play a significant role in the aetio-pathogenesis of
glomerular disease and in the subsequent progression of renal impairment.
Dietary supplementation with cholesterol was shown by Al-Shebab and colleagues
(1988) to induce glomerular hypercellularity and expansion of the mesangial matrix
in the guinea pig, whereas similar dietary supplementation lead to albuminuria and
focal glomerulo-sclerosis in the Sprague-Dawley rat (Kasiske et al. 1987). More
significantly, micropuncture techniques demonstrated increased glomerular hydraulic
pressure despite there being no change of systemic blood pressure. The principal
proteins in the expanded matrix were shown to be laminin, fibronectin and type IV
collagen (Kasiske et al. 1985). Similar findings have been observed in the Zucker rat,
which is not only a model for NIDDM mellitus but also develops hyperlipidaemia
spontaneously. Once hyperlipidaemia is established in these animals glomerulo¬
sclerosis and then albuminuria develop, although without evidence of raised
intraglomerular pressure (Kasiske et al. 1985, O'Donnell et al. 1985). Rats in which
a renal artery is clipped (Goldblatt model) and have their diet supplemented with
lipid develop more severe glomerulosclerosis (Tolins et al. 1992). Conversely
treating animals with lipid lowering agents limits mesangial expansion and
glomerulosclerosis (Kasiske et al. 1988).
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Studies on the mesangial cell also help establish a link between lipids and
glomerulosclerosis. Exposure of the mesangial cell in culture to cholesterol rich low
density lipoprotein (LDL) leads to cell proliferation (Wheeler and Chana 1993) and
may promote monocyte infiltration, a key player in mesangial expansion, through the
production of monocyte chemoattractant protein (Rovin et al. 1993). LDL has also
been shown to increase the expression of type IV collagen mRNA (Keane 1994).
This subject will be examined in Chapter 6.
Although there is strong evidence from these animal studies that lipids have a
prominent role to play in the initiation and progression of renal disease, data in
humans are scarce and conflicting. Two cross-sectional studies have shown a two¬
fold greater rate of progression in non-diabetic renal disease in individuals with high
lipids (Maschio et al. 1989; Samuelson et al. 1989). These studies were substantiated
by the work of Mulec and colleagues (1990) who showed a link between the
progression of renal disease and serum cholesterol, although there have been a
number of negative studies (e.g. Gall et al. 1993). In a retrospective study in 424
IDDM subjects, Krolewski and colleagues (1994) found that progression of renal
disease, defined as the ratio of serum creatinine at three years to baseline level, was
linked to serum cholesterol and diastolic blood pressure: the highest bands for these
measures showing the greatest proportion of 'Progressors'. Though these data are
interesting, a significant number of individuals did not progress, despite elevated
cholesterol, whilst the differences in some cases were marginal.
Lipid-lowering agents have been shown to retard progression of renal disease
(Rabelink et al. 1990; Bazatto et al. 1992). The claim by the latter that a GFR decline
from -0.25 to -0.21 mkmin/'month"' was significant appears questionable. Other
groups have failed to demonstrate any benefit in NIDDM and IDDM (Neilsen et al.
1993b; Hommel et al. 1992), although both were short-term studies.
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Understanding the link between lipids and progressive renal disease extends beyond
causation. The high mortality associated with proteinuria, renal impairment and renal
transplantation is primarily due to cardiovascular disease (Held et al. 1990; Brunner
and Selwood 1990). Before widespread anti-lipid therapy becomes established
practice the effect of lipids on progression of renal disease needs to be examined
more closely.
1.3.5 Dietary protein intake and progression of nephropathy
Evidence for protein restriction ameliorating the decline of GFR comes largely from
animal studies. Rats subjected to uni-nephrectomy showed progressive renal damage
where the diet was supplemented with protein (Moise and Smith 1927). Subsequent
studies in a wide variety of models, including streptozotocin-induced diabetes,
supported these observations (El-Nahas et al. 1983; Zatz et al. 1985; Hostetter et al.
1986). Despite these findings, benefit is not so clear in humans with renal disease.
Although early clinical studies supported the observations in animals (Rosman et al.
1984; Ihle et al. 1989), many used surrogate markers ofGFR (in themselves sensitive
to changes in dietary protein intake) and were uncontrolled or 'self-controlled'.
The results from the Modification of Diet in Renal Disease (MDRD) were published
in 1994. No benefit was observed from restricting protein intake to less than 0.6
g.kg."1 day"' (and in some cases down to 0.3 g.kg"1) in 840 subjects with various renal
diseases and baseline GFR of 25 to 55 ml.min"1 (Group 1) and 13 to 24 ml.min"1
(Group 2) when followed for approximately 2 years (Klahr et al. 1994). A more rapid
decline in the first four months of intervention was followed by a slight, though non¬
significant, benefit for those in Group 1. Only 3% of the participants had diabetes
mellitus. Previously several studies have examined the effect of protein restriction on
progression in IDDM subjects with nephropathy (Cohen et al. 1987; Walker et al.
1989; Zeller et al. 1991). Zeller and colleagues (1991) examined the decline of GFR
in 20 individuals with a mean baseline GFR of 40 ml.min"1 and demonstrated
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significant benefit from restricting protein to 0.6 g.kg/'day"1 over a 37 month period.
Similar benefit was shown by Walker and colleagues (1989) in a group of nineteen
subjects. Both the above can be criticised on the grounds of confounding variables;
the control group had higher urine protein levels at the outset in the former, whereas
in the latter blood pressure was slightly lower in the intervention group. Attman and
colleagues (1983) found no benefit from dietary restriction in those with more
advanced diabetic nephropathy. No intervention studies exist for subjects with
NIDDM, save for individuals in multi-disease studies, such as the MDRD study
above.
1.3.6 Miscellaneous factors associated with progression of nephropathy
A variety of additional factors have been associated with progressive decline of
GFR. Of these, cigarette smoking has received the most attention. Stegmayr and
Lithner (1987) showed that cigarette usage was greater in 22 uraemic individuals
with diabetic nephropathy compared to a control group. Smoking was associated
with an earlier onset of proteinuria. Progression of established nephropathy may be
more rapid in smokers than non-smokers with IDDM (Sawicki et al. 1994); similar
observations have been made in lupus nephritis (Ward and Studenski 1992).
Haemostatic factors may also influence the progression of renal impairment. Knobl
and colleagues (1993) found significant associations between various thrombogenic
factors and albumin excretion in diabetes mellitus. Gordge and colleagues (1991)
found that serum thromboxane B2 and von Willebrand antigen levels were
significantly associated with progression of nephropathy in both IDDM and NIDDM.
It remains to be seen if these factors have a pathogenic role or whether they are a
reflection of the disease process.
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1.4 Markers of progression of diabetic renal disease.
1.4.1 Identification of at risk individuals
1.4.1. i Familialpre-disposilion
Familial clustering of renal disease in those with IDDM and NIDDM suggests that
genetic pre-disposition plays a role in the development of diabetic nephropathy
(Seaquist et al. 1989; Pettitt et al. 1990; Freedman et al. 1995). In the Pima Indians,
Pettitt and colleagues (1990) recorded proteinuria in 14.3% of subjects where neither
parent had proteinuria; 22.5% if one parent had proteinuria and 45.9% if both parents
were affected. In support of these observations, Freedman and colleagues (1990)
demonstrated an 8-fold increase in the risk of developing nephropathy where there is
a close (up to third-degree) relative with end-stage renal disease. Thirty seven
percent of 52 cases with diabetic nephropathy had a close relative with ESRD
compared to only 7% in a matched group of 45 with no nephropathy. Parents of
IDDM subjects with microalbuminuria have been shown to have higher blood
pressures, compared to normo-albuminuric individuals (Viberti et al. 1987a;
Krolewski et al. 1988). Thus far no genetic linkage has been found to substantiate
these observations, though increased Na+/Li+ counter-transport has been proposed to
account for the latter observations (Mangili et al. 1988; Krolewski et al. 1988).
Not only may parental hypertension contribute to the development of nephropathy so
too may pre-diabetic blood pressure. Nelson and colleagues (1993) measured UAE 5
years after diagnosis and found a close association between the pre-diabetic blood
pressure and the subsequent development of elevated UAE. The presence of
hypertension prior to the diagnosis of diabetes mellitus has also been shown to
influence the time to renal replacement therapy (Pugh et al. 1993).
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1.4.1. ii Renal hypertrophy and hyperfiltration
Glomerular hyperfiltration is a characteristic early feature in IDDM subjects and is
argued by many (Mogensen & Christensen 1985; Rudberg et al. 1992), though not
all (Lervang et al. 1988), to be a strong independent predictor of subsequent
nephropathy. However no such consensus exists in NIDDM. Early work suggested
that hyper-filtration was not a feature in NIDDM (Fabre et al. 1982; Damsgaard &
Mogensen 1986). Support for this view came from Schmitz and colleagues (1989a)
who found no evidence of hyperfiltration in 18 NIDDM subjects with a mean
duration of diabetes of 5 years. They did however show a modest, but significant,
reduction of GFR in 10 newly-diagnosed patients after three months treatment with
diet or diet and an oral agent with a more significant reduction in renal size (Schmitz
1989b). The same group have since shown the ratio of GFR to kidney volume to be
reduced once microalbuminuria develops, suggesting loss of functioning renal tissue
may occur early in the course of progression to proteinuria (Schmitz 1993).
In contrast, in a large controlled study of newly-diagnosed diabetic patients Vora and
colleagues (1992) found hyperfiltration in 45% of 110 NIDDM subjects. In 16% the
GFR exceeded 140 ml.min"1. Follow up studies are awaited. A smaller, uncontrolled,
cross-sectional study from Brazil observed hyperfiltration (definition not given) in
21.1% of 71 NIDDM patients attending an outpatient clinic (Friedman et al. 1992).
Two further studies in non-white groups support these findings. Lebovitz and
Palmisano (1990) in a study in black Americans recorded hyperfiltration (>140 ml.
min"1) in 7 of 20 newly-diagnosed patients (< 2 years). In the Pima Indians, Nelson
and colleagues (1996b) found GFR 16% higher in 30 subjects with newly diagnosed
diabetes, though this did not predict subsequent decline ofGFR.
1.4.1. iii Microalbuminuria
Microalbuminuria, defined as an albumin excretion of 20 - 200 pg.min"' (Mogensen
et al. 1985-6), is a common finding at diagnosis in NIDDM (Collins et al. 1989;
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Schmitz et al. 1989b; Martin et al. 1990; Olivarius et al. 1993). Many cross-sectional
studies are now in the literature relating albumin excretion to various parameters,
including blood pressure, blood glucose and antihypertensive therapy.
In NIDDM, microalbuminuria predicts cardiovascular mortality (Jarrett et al. 1984;
Mogensen 1984). However it is less predictive of subsequent proteinuria and renal
failure than has been shown for IDDM (Mogensen and Christensen 1984). Table 1.1
(overleaf) summarises selected follow-up studies of microalbuminuria in NIDDM.
It is uncertain if microalbuminuria will prove as useful an indicator of progression
of nephropathy in NIDDM as in IDDM. The hypothesis that it reflects more
widespread vascular damage suggests that it may not be the case (Deckert et al.
1988, 1992). Furthermore it remains to be seen if a reduction of microalbuminuria in
NIDDM halts the decline in GFR demonstrated recently in IDDM (Rossing et al.
1994a).
1.4.2 Invasive and non-invasive markers of progression
1.4.2.i Structural -functional relationships in diabetic nephropathy
Over 30 years ago Gellman and colleagues (1959) described the relationship between
the severity of glomerulosclerosis and interstitial fibrosis and plasma creatinine,
blood pressure and proteinuria in a mixed group of those with diabetes mellitus.
Subsequent work in IDDM has shown a close correlation between proteinuria and
ultra-structural changes in the glomeruli of renal biopsies from subjects with
advanced nephropathy (Mauer et al. 1984; 0sterby et al. 1990). Recently the latter
group have examined glomerular structure and renal function in 20 NIDDM subjects
(0sterby et al. 1993). Combining light- and electron- microscopic techniques they
demonstrated a significant relationship between estimated filtration surface area of
each nephron with current GFR. Furthermore a remarkably close association was
observed between structural appearance (quantified as the glomerulopathy index,
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based on the changes in peripheral basement membrane and the mesangial matrix)
and the subsequent decline ofGFR. Somewhat surprisingly no correlation was found
with albuminuria, though both systolic and diastolic pressure were associated.
In a less detailed study over 4 years in a combined group of 41 diabetic subjects, Taft
and colleagues (1994) found significant association of interstitial fibrosis and
glomerular morphology with creatinine clearance. As in the previous study no
correlation between histology and protein excretion was observed. In 19 who
underwent repeat biopsy an increase in fibrosis was seen only in those in whom
creatinine clearance declined significantly. These findings support the earlier work of
Bader and colleagues (1980) and Lane and colleagues (1993) in IDDM.
The degree of interstitial fibrosis and the expansion of the mesangial matrix are thus
closely linked to the decline of GFR. Neither offer a reliable measure of disease
severity nor are they predictive of rapid progression of nephropathy. In any case
routine renal biopsies are neither ethically justifiable nor practically feasible.
1.4.2.1'i Measurement ofglomerularfiltration rate - isotopic and surrogate
methods
In practical terms isotopic methods represent the 'gold standard' for measuring GFR.
Of the techniques available 51Cr ethylenediaminetetra-acetic acid (EDTA) clearance
is the most widely used (Brochner-Mortensen 1972, 1985). These methods have also,
almost completely, replaced inulin clearance in research studies. In diabetic subjects,
albeit with normal renal function, repeated measurements have a coefficient of
variation of 5.3% to 8.8% - though in a few patients this may rise to 25% (Mau
Pedersen et al. 1992; Mogensen et al. 1993). Referring to diabetes mellitus,
Mogensen felt that any study into the progression of renal disease should have a
minimum of three isotopic measurements ofGFR over two years (Mogensen 1993).
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Time and expense limit the use of isotopic methods for the determination of GFR.
Surrogate measures, viz. creatinine clearance and estimated GFR (e.g. Cockcroft-
Gault), are commonplace in clinical practice (Cameron 1992b) and their use quoted
frequently in published work. Whilst the validity of the Cockcroft-Gault formula has
been demonstrated in IDDM nephropathy (Sampson and Drury 1992), it has not been
assessed in NIDDM. These surrogate measures of GFR are discussed in greater
detail in Chapter 5.
1.4.2.Hi Non-invasive markers ofdisease progression
Proteinuria is the hallmark of diabetic nephropathy. Sufferers may be identified by
routine urinalysis, though confirmation is required with 24-hour urine collections.
Prior to effective anti-hypertensive therapy and RRT the onset of proteinuria often
heralded an inexorable decline ofGFR and death from renal failure or cardiovascular
disease. Williams and colleagues (1988) suggested that proteinuria may prove a
useful prognostic indicator of progression of established renal failure. Though
several renal diseases, including diabetic nephropathy, were examined this
association held only for glomerulo-nephritis and chronic pyelonephritis, confirming
the experiences of Idelson and colleagues (1977) and Cameron (1979). These
observations are further substantiated by the recent work of Petersen and colleagues
(1995) and Maschio and colleagues (1996), also in non-diabetic renal disease. 24-
hour urinary protein excretion has not, hitherto, proved reliable in predicting
outcome in either IDDM or NIDDM (Sawicki and Berger 1994). However Rossing
and colleagues (1994a) have shown that an initial anti-proteinuric effect of
antihypertensive therapy predicts an attenuated decline of GFR in IDDM subjects
with early diabetic nephropathy (GFR >70 ml.min"1). Similar findings have been
demonstrated in non-diabetic renal disease (Aperloo et al. 1992). No directly
comparable studies exist in NIDDM, though AER at baseline has been shown
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recently to be related to subsequent decline of GFR in 34 Pima Indians with
macroalbuminuria (Nelson et al. 1996b).
In section 1.4.1.Hi the predictive value of microalbuminuria in NIDDM was briefly
discussed. A variety of other urinary markers of disease progression have been
investigated though none so far has proved helpful in clinical practice. Howard and
colleagues (1991) measured urinary iron in a small number ofNIDDM subjects and
demonstrated a progressive increase in both iron and transferrin as albuminuria
increased. The latter two were closely associated. In both IDDM and NIDDM,
Jerums and colleagues (1989) observed a changing pattern of excretion of IgG and
transferrin with progression of nephropathy. The ratio of IgG to transferrin correlated
with protein excretion in individuals with NIDDM and overt nephropathy. Thus far
no reliable urinary or serum marker of progression in advanced nephropathy is
available. This subject will be examined in Chapter 6, where the role of collagen and
laminin fragments as markers of disease progression is assessed.
I.4.2.iv Angiotensin-converting-enzyme gene polymorphisms and
progression ofnephropathy
The finding of elevated glomerular capillary hydraulic pressure in experimental rat
models of diabetes led to the hypothesis by Hostetter and co-workers (1981) that
haemodynamic factors initiate the development and promote the progression of
diabetic glomerulopathy. Many factors linking hyperglycaemia and intrarenal
hypertension have been proposed (Vora et al. 1994). Of these, angiotensin II,
amongst other substances, has been shown to stimulate the growth of glomerular
cells (Parving et al. 1996a). Serum ACE, which converts angiotensin I to angiotensin
II, has been shown to be higher in those subjects with microvascular complications
(van Dyck et al. 1994). Furthermore ACEI retard the progression of nephropathy in
both human (Bjorck et al. 1986, Lewis et al. 1993) and experimental diabetes
(Kakinuma et al. 1992). The ACE gene, therefore, has been proposed as a candidate
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gene predisposing individuals with diabetes to the development and progression of
nephropathy.
In 1992, Cambien and colleagues demonstrated that serum ACE levels were related
to an insertion/deletion polymorphism (ACEID) of intron 16 of the ACE gene, and
furthermore that this polymorphism was linked to an increased risk of coronary
artery disease. Subsequently, Tarnow and colleagues (1995) examined the
distribution of ACEID in 198 IDDM subjects with nephropathy and 192
normoalbuminuric controls, but found no evidence of segregation, concluding that
possession of this polymorphism did not confer susceptibility to the development of
nephropathy.
Contrasting results have, however, been found in IgA nephropathy. An association of
the homozygous deletion genotype with earlier onset and more severe disease was
found by Harden and colleagues (1995). Yoshida and colleagues (1995) found 43%
of subjects with declining renal function to be homozygous for the deletion
(genotype DD), compared to 16% of those with stable renal function. Furthermore
this group suggested that the specific ACEID predicted the response to ACE
inhibition. However the number of subjects studied was very small.
Recently, Parving and colleagues (1996b) have examined the relationship between
ACE gene polymorphism and therapeutic response to ACEI in 35 IDDM subjects
(11 genotype DD; 24 genotype ID or II). Using historical data on the decline ofGFR
over an average of 7 years, they found the mean decline was 5.7 ml.min/'year"1 in the
homozygous DD group, compared to 2.6 ml.min."'year"' in the ID and II groups,
despite comparable blood pressure lowering. Further studies in IDDM are required
before this polymorphism can be adopted as a marker identifying those subjects who
will fare badly once nephropathy develops.
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1.5 Broad aims of the thesis
1. 'What factors influence the rate of progression of nephropathy in NIDDM
subjects with impaired renal function ?' To try to answer this question the historical
records of all individuals attending a joint diabetic-renal clinic were examined. Data
were available in 87 (32 IDDM and 55 NIDDM) subjects in whom progression could
be determined from the serial serum creatinine measurements. In Chapter 2 the
factors, including race, which may determine the decline of GFR in this cohort are
examined. Furthermore the rates of decline of GFR in NIDDM and IDDM are
compared. The study also seeks to determine whether attendance at such a clinic has
a beneficial effect on ameliorating the rate of decline ofGFR.
2. In the following chapter the influence of renovascular disease on progression
is addressed. All subjects under-going percutaneous renal artery angioplasty in the
clinic were assessed to determine whether this procedure has a beneficial effect in
halting the progression of nephropathy.
3. From the above cohort, 26 individuals with NIDDM were selected for a two
year prospective study. The aims were to determine the decline of GFR using a
validated technique (5lCr EDTA clearance) and to determine the factors which were
associated with this decline.
4. The simultaneous measurement of creatinine clearance and serum creatinine
allowed a direct comparison of surrogate measures of GFR with EDTA clearance.
The objective here was to examine whether either creatinine clearance or estimated
GFR offered a practical alternative to isotopic GFR measurement in NIDDM, as has
been shown in IDDM.
5. Certain individuals with nephropathy appear to progress rapidly to end-stage
renal failure, whereas other, apparently similar, individuals fare much better. Clinico-
27
pathological studies using renal biopsy tissue suggest that structural changes in the
renal glomerulus bear a direct relationship to decline in renal function in NIDDM.
Type IV collagen and laminin are principle components of the basement membrane
and mesangial matrix in the glomerulus. The hypothesis that collagen and laminin
synthesis are increased in those individuals with more aggressive renal disease is
examined in Chapter 6. A recently developed assay for mixed laminin fragments was
used to determine whether the measurement of these proteins in the urine of
nephropathic subjects offers a reliable non-invasive marker of progression of




Observational study in individuals with diabetic
nephropathy and moderate renal impairment attending a
specialist diabetic-renal clinic
2.1 Introduction
The diabetic-renal clinic was set up at King's College Hospital in 1986 and is one of
the largest of its kind in the United Kingdom. All individuals with diabetes mellitus
and renal impairment ('cut-off serum creatinine of 200 pmol.L"1) are referred to this
clinic, both from the general diabetes clinic and direct from General Practice. In the
majority, diabetes is the cause for the renal impairment, although in a small
proportion a different primary renal disease is present. A small number of IDDM
subjects, with less severe renal impairment, are also seen. The primary aim of the
clinic is to concentrate care on those with renal failure in an attempt to slow the
progression of their disease and to respond to the greater clinical need of these
individuals, many of whom suffer the full range of complications of diabetes. In
addition it facilitates co-ordination with the Nephrologists. The frequency of visits
varies from every 1 to 4 months. When the serum creatinine reaches approximately
400-500 pmoLL"1, or when symptoms dictate, individuals (5-8 per year) are
considered for RRT. This is usually CAPD; very occasionally haemodialysis or
immediate transplantation. It is exceptional for a patient to be turned down for
dialysis. Individuals in whom renal function remains stable, or improves, may return
to the general clinic.
This study assessed the first seven years experience of this clinic to determine the
factors associated with disease progression and to examine how effective the clinic
was in delaying RRT. The specific aims were as follows:
2.2 Aims.
• To determine the present rate of progression of renal failure in patients with
diabetes mellitus and renal impairment.
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• To determine if racial differences and type of diabetes influence the rate of
progression of renal impairment.
• To examine the effect of blood pressure and anti-hypertensive therapy on the
rate of decline of glomerular filtration.
• To assess whether regularly measured parameters, e.g. glycosylated
haemoglobin, serum lipids and urinary protein excretion are associated with
the rate of change of glomerular filtration rate.
• To assess whether attendance at a specialist clinic confers benefit by reducing
the rate of deterioration of glomerular filtration.
2.3 Patients andMethods
2.3.1 Data collection
150 individuals attended the joint diabetic-renal clinic in the seven years from June
1986 to May 1993, with 80 - 90 current attendees at the end of the period. The notes
of all patients, including those who had died, were scrutinized and demographic
details, together with all data from each attendance, including the visits prior to
commencing the joint clinic, were entered onto computer (Dell Products, Austin,
Texas; Excel software). A list of all data entered is given in Table A2.1 in the
appendix. In all over 100,000 data entries were made.
Blood glucose was analysed at each visit, whilst HbA,c and serum creatinine were
measured at each combined clinic attendance but only intermittently prior to joining.
All attendees had at least an annual 24-hour urine collection for protein performed.
Only data from those where three collections were available are included in the
analysis. Serum lipids were not measured routinely in the early stages of the renal
clinic and again data are included only if three or more samples were available.
There were few data on HDL and LDL cholesterol. These along with the small
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number of samples of urinary urea and electrolytes were not entered into the
database.
Inevitably blood pressure was measured by a number of observers over the seven-
year period. All were performed, usually at the end of the consultation, using a
standard mercury sphygmomanometer with the patient seated. Early measurements
were often recorded to 5 mmHg, but more recently all have been to 2 mmHg. (BMJ
guidelines - Petrie et al. 1987). Anti-hypertensive and lipid lowering therapy, with
any change, were entered. BMI was calculated from weight(kg)/height2(m) and
estimated GFR (cGFR) from the serum creatinine, using the Cockcroft-Gault
formula (details as given in Chapter 5).
2.3.2 Data analysis
Only subjects with a cGFR below 80 ml.min"1 at the start of the observation period
and in whom a minimum of six serum creatinine measurements had been performed
over at least a two year period were included in this analysis.
All cGFR data points were plotted against time (as shown overleaf in Figure 2.1) for
all individuals. The rate of change of GFR was calculated by linear regression
analysis (the least squares method) using all data points. To determine whether the
decline of cGFR changed significantly over the observation period, a separate
analysis was performed comparing the initial one and two years data with the most
recent one and two years. Before carrying out this analysis each graph was inspected
visually to identify any in which aberrant cGFR measurements (taken as those >
3SD's from the mean) might produce spurious results; such readings were excluded
from the analysis. An example of such aberrant values is shown in the appendix
(Figure A2.1 - middle graph - cluster of three cGFR measurements excluded). Of the
87 graphs examined, single values were excluded in seven cases (3 IDDM; 4
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Figure 2.1: Diagramatic representation of decline of estimated GFR.
a, a' and b, b' delineate the first and last, and the first two and last two
years of observations respectively.
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- above example). Thus for each graph the rate of change of estimated GFR
{mfmin/'month"1} over the first year is calculated for "a". Similar analyses were
performed for a', b, and b', allowing comparison of "a" with "a"', and "b" with "b1"
(see Figure 2.1).
An identical exercise was carried to determine cGFR before and after entering the
joint clinic. For inclusion each individual must have had at least four visits over a 12
month period both before and after entering the joint clinic.
The data were analysed using the 'Cricketgraph II' programme (Stream Valley
Parkway, Malvern, PA, USA) on an Apple Macintosh LC computer.
2.3.3 Statistical analysis
Results are expressed as mean (±SD), unless the data are skewed, where median
(range) is given. The values for 24-hour protein were logarithmically transformed
and the data presented as geometric mean and range. Comparison of the decline in
cGFR between the racial groups and diabetes types over the whole period of
observation was by Student's t-test for unpaired data, whilst comparison of the one
and two year data periods at the beginning and end of observation was by Student's
t-test for paired data. The factors thought to associate with decline in cGFR were
examined initially with a univariate analysis, using Pearson's correlation coefficient.
A multiple regression analysis was then performed. In the first instance all 87
subjects were included with cGFR the dependent variable. The continuous variables
entered were age, duration of diabetes, HbAlc, systolic blood pressure (SBP) and
diastolic blood pressure (DBP), serum cholesterol, serum triglyceride, and log 24-
hour protein as was the dichotomous variable, blood pressure therapy at outset
(classed as present/absent). A sub-group analysis of the IDDM and NIDDM subjects
was undertaken although, as shown below, this lessened the strength of associations
seen for the whole group.
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For both IDDM and NIDDM, the groups were divided into 'Responders' and 'Non-
responders' on the basis of the median decline of cGFR. An individual with a decline
of cGFR of < median was termed a 'Responded, whereas > median a 'Non-responder'.
The parameters measured (i.e. the above independent variables) were then compared
between the 'Responded and the 'Non-responder' group, using the Students unpaired
't-test'. Throughout significance is assumed when p < 0.05 (two-tailed). The
statistical packages 'Statview' (Brain Power, Inc., Calabasa, CA. 91302, USA) and
'Statistica' (StatSoft Inc., Tulsa, Oklahoma) were used throughout.
2.4 Results
2.4.1 Patient groups
Of the 150 subjects who attended the clinic, sufficient data meeting the above criteria
were available for analysis in 96. A further nine of these were excluded on the
grounds of other renal disease {systemic vasculitis 2, amyloidosis 1, HIV
nephropathy 1, unknown - bilateral small kidneys - 5}. The data are presented on 87
subjects; 32 IDDM and 55 NIDDM. All were deemed to have diabetic nephropathy
on the basis of the definition given in section 4.3.1. Hi of Chapter 4. Table 2.1 shows








Age (Current) 50.5 (24.3 - 66.6) 63.0 (39 - 79)
Duration of DM 31.1(15.8-51.9) 18.6(4.1-36.7)
Key: C'auc=Caucasian; At=AtroCanbbean; As=Asian. Age and DM duration are
median (range).
Table 2.1 : Demographic characteristics of the study groups.
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Table 2.2 shows the number of patients followed for at least two and four years. 68
subjects (28 IDDM) were observed for at least 4 years. The median duration of
follow up (that is from the time cGFR falls to 80 ml.min"1, or below, to the most
recent visit) for all subjects was 6.4 years (range 2.0-19.3); for IDDM and NIDDM
the values were 7.4 (2.0-19.3) and 6.0 (2.1-17.9) years respectively (see Table 2.3
overleaf). Of this cohort 36 individuals (17 IDDM) commenced RRT during this
period. The median duration from diagnosis of diabetes to RRT in the IDDM group
was 27 (range 16-48) years and 14 (4-31) years in the NIDDM group.
Observation period Caucasian Afro-Caribbean Asian
IDDM
Two years 31 1
Four years 27 1
NIDDM
Two years 24 25 6
Four years 16 19 5
Table 2.2 : Number of subjects for whom sufficient data are available for
two and four year comparisons.
2.4.2 Change in estimated GFR
The median decline of cGFR for all 87 individuals was 0.39 ml.min.'month"' (range
1.92 to -0.22). The rate of fall was significantly faster in NIDDM (0.43 ml.min."
'month"' vs 0.29 ml.min. 'month"1; unpaired 't-test'; /?<0.05), despite similar baseline
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Figure 2.2 : Decline of cGFR in IDDM and NIDDM subjects. SD bars shown.
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The difference between IDDM and NIDDM is more striking when the Caucasian
subjects are considered alone, with declines of cGFR of 0.29 and 0.73 ml.min."
'month"1, IDDM vs NIDDM respectively (p=0.005) {Table 2.3}. Contrary to
expectation, cGFR declined faster in Caucasians compared to Afro-Caribbeans with
NIDDM.
Not all individuals exhibit a linear decline of cGFR. Table 2.4 segregates subjects by
the mode of decline of cGFR. Non-linear progression is defined as more than one
significant excursion from the regression line and where the regression coefficient
for cGFR v time is <0.8 (adapted from Brazy and Fitzwilliam 1990). Individuals with
a curvilinear decline of cGFR are included in the above analysis as linear. Eight
subjects with a mean baseline creatinine of 170 pmol.L1 (range 117-244) had stable
renal function over the observation period.
Linear Non-linear Stable
IDDM 17 10 5
NIDDM 46 6 3
Total 63 16 8
Table 2.4 : Progression of estimated GFR in diabetic subjects.
Examples of progression are given in the appendix in Table A2.1
The results of comparing the decline of cGFR between the initial and final years are
shown in Table 2.5 (overleaf). All subject comparison suggests a trend toward a
reduction in the decline of cGFR. The two-year comparison shows an improvement
from 0.44 to 0.34 ml.min."'month1, (paired 't-test'; NS) whereas the one-year
38
One year Two year
First Last First last
IDDM (n=32)
Caucasian (n=31) 0.37 0.07 0.38 0.19
Afro-Caribbean (n=l) 0.37 -0.07 0.95 0.02
Total 037 (107 039 (U8
NIDDM (n=55)
Caucasian (n=24) 0.64 0.48 0.41 0.48
Afro-Caribbean (n=25) 0.44 0.37 0.49 0.26*
Asian (n=6) 0.38 0.22 0.75 0.23
Total 046 038 048 0.32
All subjects 0.44 0.23** 0.43 0.34
*
p < 0.02 (Afro-Caribbean subjects, first and last two years comparison)
**
p < 0.05 (All subjects: first and last one year comparison)
The number of subjects are given for the two year comparisons
Table 2.5 : Rate of decline of estimated GFR - comparison of first and last one
and two years data
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comparison shows a significant change from 0.43 to 0.23 ml.min."'month"1 (paired't-
test'; /?<0.05). This improvement appears more marked in IDDM patients, with the
two year comparison improving from 0.38 to 0.19 ml.min/'month"1. However this is
not statistically significant because of the wide variation in the data (two subjects had
a markedly worse decline of cGFR in the most recent year of observation). The
virtual lack of decline of cGFR in the most recent year in the IDDM subjects is
striking.
Of 32 IDDM subjects, only eight (25%) had a decline of cGFR above 0.5 ml.min."1
month"1 in the most recent year. This apparent arresting of decline of cGFR is not
observed in NIDDM subjects, where the average decline of cGFR in the most recent
year of observation is 0.38 ml.min."'month"1.
In NIDDM no difference in the decline of cGFR is seen for Caucasian subjects in
either the one or two year comparisons. However in the Afro-Caribbean group there
is a significant reduction of decline of cGFR from 0.49 to 0.26 ml.min."'month"'
between the initial and final two years (unpaired 't-test'; p<0.02) {Table 2.5}. The
small number in the Asian group precludes a meaningful interpretation of the
apparent improvement seen in their cGFR decline.
2.4.3 Decline of estimated GFR before and after attendance at a joint
diabetic-renal clinic.
Sufficient data, i.e. at least four serum creatinine measurements within a minimum of
twelve months before and after entering the clinic, were available for 58 individuals
(23 IDDM). As shown overleaf (Table 2.6 over) the mean period of observation
before entering the joint clinic was 6.8 (range 1.4 - 15.1) years for the IDDM group
and 4.4 (1.0 - 12.8) years for the NIDDM group. The respective duration of
attendance at the clinic were 2.9 (1.0 - 5.7) and 2.9 (1.0 - 6.2) years respectively.
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The mean (SD) decline of cGFR for IDDM was 0.49 (0.32) ml.min."'monttf' before
and 0.18 (0.32) ml.min."1month"1 after entering the clinic (paired 't-test'; jkO.OOI).
The respective figures for the NIDDM group were 0.48 (0.36) and 0.41 (0.31)
ml.min."' month"1 (paired 't-test'; /?=NS). Systolic blood pressure did not differ in
either group following attendance at the joint clinic. However diastolic blood
pressure fell significantly, from 90 to 84 mmHg in the IDDM group and 94 to 89
mmHg. in the NIDDM group (unpaired 't-test'; both /k0.005). In both groups the
use of anti-hypertensive medication increased significantly, from 9 to 22 out of 23 in
IDDM and 17 to 31 of 35 in NIDDM (Chi-squared test: /?<0.001). As shown below
duration of attendance at the clinic per se does not appear to influence the decline of
cGFR in either IDDM orNIDDM subjects.
Duration Duration Decline of cGFR Decline of cGFR
pre-clinic post -clinic pre-clinic post-clinic
(years) (years)
IDDM (n=23) 6.8 (1.4-15.1) 2.9(1.0-5.7) 0.49 (0.32) 0.18(0.32)*
NIDDM (n=35) 4.4(1.0-12.8) 2.9(1.0-6.2) 0.48 (0.36) 0.41 (0.31)
Key : decline of GFR given as ml.min."'month '. Data given as median (range) for duration of
attendance and mean (SD) for decline of estimated GFR. * /?<0.001.
Table 2.6 : Decline of estimated GFR in IDDM and NIDDM subjects before and
after commencing attendance at the joint diabetic-renal clinic.
2.4.4 Factors responsible for decline in GFR
Figures 2.3 and 2.4 (overleaf) show the results of univariate analysis between cGFR
and selected clinical parameters for IDDM and NIDDM subjects respectively. For
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Figure 2.3 : Association between the rate of decline of estimated GFR and measured
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Figure 2.4: Association between the rate of decline of estimated GFR and measured
clinical parameters in non-insulin-dependent subjects. Univariate analysis.
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Multiple regression analysis reveals a highly significant association of 24-hour
protein excretion (p<0.00005) with the decline of cGFR when all subjects are
grouped together. Diastolic blood pressure is the only other variable to emerge as
significantly associated with decline of cGFR (/?<0.05). No significant association is
seen with BMI, age, duration of diabetes, HbAlc, serum cholesterol, systolic blood
pressure and anti-hypertensive therapy. Proteinuria and DBP together account for
34% of the variation in the decline in cGFR in this group. The following regression
equation (with a standard error of 4.3) links decline of cGFR with these variables:
Annual rate of change of cGFR = 10.2 - 1 .lxlog 24-hr protein - 0.5xDBP
(ml.min/'year"1)
If the groups are subject to a separate multiple regression analyses, being on anti¬
hypertensive therapy at the outset is significantly associated (p<0.05) with decline of
cGFR in NIDDM, but not in IDDM. Diastolic blood pressure is no longer a
significant variable when the group is subdivided by diabetes type.
To determine the factors that may be responsible for the more rapid decline of GFR
in NIDDM the measured parameters were compared between the groups. IDDM
patients are naturally younger than NIDDM and have a longer duration of diabetes.
Table 2.7 (overleaf) shows prevailing systolic and, to a lesser degree diastolic, blood
pressure to be significantly higher in those with NIDDM. When the final two years
are examined separately these differences are less pronounced. As would be expected
BMI is significantly greater for NIDDM, but no differences exist for HbA]c, serum
cholesterol or 24-hour protein excretion.
2.4.5 Is there a difference between those who fare well and those who fare
badly ?
To identify any factor which has a determining effect on renal function both IDDM
and NIDDM subjects have been divided into equal subgroups on the basis of cGFR.
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Parameter IDDM (n=32) NIDDM (n=55) Difference Significance
Age (years) 50.0(11.0) 62.8(9.1) 12.8 ;?<0.001
Duration of DM 32.2 (9.5) 18.7(8.1) 13.5 ^<0.001
cGFR 0.41 (0.42) 0.60 (0.41) 0.29 p=0.03
SBP (mmHg) 154(14) 165(19) 11 p=0.05
DBP (mmHg) 87(7) 91(7) 4 /?<0.05
BMI 25.1 (4.3) 28.8 (4.2) 2.7 ©o©IIa,
HbAlc 11.2(1.5) 10.7(2.5) -0.5 NS
Cholesterol (mmol.L1) 7.0(1.8) 7.0(2.1) 0 NS
24-hour protein (g) 2.9 (2.5) 3.4 (2.6) 0.5 NS
SBP (2 year) 153(21) 167(23) 14 p=0.005
DBP (2 year) 86 (8) 89(9) 3 NS
Data are given as mean (SD). cGFR given as ml.min.'month"1
Key : SBP = systolic blood pressure, DBP = diastolic blood pressure
2 year = last two years of blood pressure recordings
Table 2.7 : Comparison of the measured variables between IDDM and NIDDM. The
data are compared using unpaired 't-test'.
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Table 2.8a: IDDM
Responders Non-responders Difference Significance
Decline of eGFR 0.14(0.15) 0.67 (0.44) -0.53 -
Number (M:F) 16(7:9) 16 (9:7) - -
Age 55.1 (8.3) 44.2(10.8) 10.9 /X0.01
Duration of DM 35.6 (9.0) 28.9 (9.0) 6.7 p<0.05
BMI 25.1 (4.4) 25.1 (4.2) 0 NS
Systolic BP (mmHg) 156(15) 152(13) 4 NS
Diastolic BP (mmHg) 88 (7) 87(6) 1 NS
HbAlc (%) 10.8 (1.2) 11.6(1.8) -0.8 NS
Cholesterol (mmol.LT1) 6.7(1.2) 7.5 (2.1) -0.8 NS
24-hour protein (g) 1.5(1.1) 4.2 (2.6) -2.7 p=0.01
Table 2.8b: NIDDM
Responders Non-responders Difference Significance
Decline of cGFR 0.30(0.12) 0.93 (0.36) -0.63 -
Number (M:F) 28 (19:9) 27(15:12) - -
Race (Cauc:Af:As) 10:14:4 11:14:2 - -
Age 67.3 (6.1) 58.2 (9.4) 9.1 p<0.001
Duration of DM 18.7(8.3) 18.7(8.0) 0 NS
Systolic BP (mmHg) 162(13) 168 (2.3) -6 NS
Diastolic BP (mmHg) 88(7) 93 (7) -5 p<0.02
HbAlc (%) 10.9(2.8) 10.5 (2.1) 0.4 NS
Cholesterol (mmol.L1) 6.7 (2.2) 7.4 (2.0) -0.7 NS
24-hour protein (g) 2.1 (1.4) 4.7 (2.9) -2.6 pO.OOl
Key : GFR = glomerular filtration rate (ml.min."'month"1) as estimated by the Cockcroft-Gault formula.
Results as mean (SD)
Table 2.8: Characteristics of the 'Responders' and 'Non-responders' (for definition -
see text). Insulin-dependent subjects (Table 2.8a) and non-insulin-dependent diabetic
subjects (Table 2.8b). The data are compared by unpaired't-test', significance as
shown.
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Those with a lower rate of decline of cGFR are termed 'Responders' and those with
the greater rate of decline the 'Non-responders'. The results of these analyses are
presented in Tables 2.8a and 2.8b (preceding page).
2.4.5. i IDDM subjects
In IDDM the division was a median decline of cGFR of 0.29 ml.min.'month"1,
giving a mean decline for 'Responders' and 'Non-responders' of 0.14 and
0.67ml.min."1month"1 respectively. Surprisingly age was a significant factor with
'Responders' being, on average, 11 years older than the 'Non-responders' (unpaired't-
test'; p<0.01). Perhaps as a consequence, duration of diabetes was some 6.5 years
longer in the 'Responders' (p<0.05). The only other factor which differed between the
two groups was 24-hr protein excretion, being some three-fold greater in the 'Non-
responders' (p=0.01). Blood pressure (all readings) was not significantly different
between the two groups.
Neither the number of patient visits per year nor the duration of attendance at the
renal clinic differed between the groups. Those attending more frequently were, not
surprisingly, mostly to be found in the Non-responder group. The number of subjects
on anti-hypertensive therapy at the start of the observation period was similar,
approximately 50%, in both groups, whilst at the end the figure was close to 100%.
2.4.5.ii NIDDM subjects
In NIDDM the division was a median decline of cGFR of 0.43 ml.min/'month"1,
giving a mean decline of 0.28 vs 0.91 ml.min. 'month"1, 'Responders' vs 'Non-
responders'. In this group the 'Responders' were again significantly older than the
'Non-responders' by some nine years on average (unpaired 't-test'; p<0.001). In
contrast the duration of diabetes was identical between the groups at 18.7 years;
some 15 years on average shorter than for IDDM patients. As was the case for the
latter mean 24-hour protein excretion is significantly higher in the 'Non-responders',
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averaging 4.67g against 2.14g for the 'Responders' (p<0.001). Mean diastolic and
systolic blood pressure are lower in the 'Responders' but to a significant degree only
in the former (p<0.02). As in IDDM no difference exists with HbAlc, serum
cholesterol nor with visit frequency or duration of clinic attendance. Fewer
'Responders' than 'Non-responders' were treated for hypertension at the start,
whereas the reverse was true at the end of the study.
2.4.6 Anti-hypertensive usage
Tables 2.9, 2.10a and 2.10b (overleaf) show the usage of anti-hypertensive
medication in IDDM and NIDDM subjects. Two factors emerge for both groups.
Many subjects with renal failure were on no anti-hypertensive medication in the first
year of observation despite a cGFR of < 80ml.min' - only 18/32 (56%) IDDM and
32/55 (57%) NIDDM. By the final year of observation this figure was 1/32 (3%) and
5/55 (9%) respectively.
IDDM NIDDM
Responders Non-responders Responders Non-responders
(n=16) (n=16) (n=27) (n=28)
First year 7 8 14 18
Final year 16 15 27 23
Table 2.9 : Number of patients receiving anti-hypertensive therapy in the first
and last year of observation.
During this last year of observation each patient was taking on average two anti¬
hypertensive drugs in contrast to the first year for the IDDM group of 0.72 and 0.64
drugs/patient for the NIDDM group. The rise in usage of the combination of an
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Table 2.10a: IDDM
First year Second year Penultimate
year
Final year
ACE inhibitor 4 7 18 24
Beta-blocker 10 8 3 4
Ca++ channel antagonist 2 2 7 11
Diuretic 6 9 16 23
Other 1 1 0 0
No therapy 18 14 4 1
Average no. drugs/person 0.72 1.00 1.63 1.94
Table 2.10b: NIDDM
First year Second year Penultimate
year
Final year
ACE inhibitor 9 13 33 41
Beta-blocker 8 12 5 4
Ca++ channel antagonist 5 10 25 29
Diuretic 12 15 32 40
Other 1 1 2 2
No therapy 32 22 7 5
Average no. drugs/person 0.64 1.02 1.96 2.07
Table 2.10: Anti-hypertensive usage in insulin-dependent (Table 2.10a) and non-
insulin- dependent (Table 2.10b) diabetic subjects
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ACEI and frusemide mirrors the decline in the use of beta-blockade in both groups.
Five of 28 NIDDM subjects received no drug therapy in the final year of observation
(four were normotensive, BP < 135/80 mmHg, and one unreliable with medication).
The median decline of cGFR for these individuals was 0.26 ml.min."'month"' as
against 0.43 ml.min.'month"1 for all NIDDM subjects.
2.5 Discussion
The natural progression of renal impairment in untreated patients is unknown for
NIDDM nephropathy and is likely to remain so given the established role of anti¬
hypertensive therapy in chronic renal failure. This study has examined the evolution
of renal impairment, and the factors associated with its progression, in a cohort of 87
subjects with diabetic nephropathy under routine clinic conditions.
2.5.1 The progression of renal impairment.
The median decline of cGFR of all subjects, with an initial mean cGFR of 56 ml.
min"1, followed for an average of 6.4 years, was 0.39 ml.min. 'month"'. The rate of
decline was significantly faster in NIDDM, even though baseline cGFR was similar.
No directly comparable published study exists. The closest, by Gall and colleagues
(1993), found a fall of 0.48 ml.min. 'month"1 in 26 Caucasian NIDDM subjects with
biopsy-proven diabetic glomerulosclerosis, though they had slightly better baseline
renal function (mean creatinine 95 vs 135 pmol.L"1 in this study). In a recently-
published work in the Pima Indians, Myers and associates (1995) recorded a decline
of GFR from 108 to 71 ml.min"' over a four-year period (equivalent to 0.77 ml.min."1
month"').
It remains to be determined if the rate of decline of GFR is similar for IDDM and
NIDDM once nephropathy is established. Similar rates of progression were observed
in 32 pre-dialysis subjects by Biesenbach and associates (1994). The rates of decline
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of cGFR at 1.05 and 0.91 ml.min.~'month"1 respectively are significantly more rapid
than seen in this study. Ordonez and colleagues (1989) drew the same conclusion,
based on the time from proteinuria to ESRD. However such a deduction may not be
valid since proteinuria is more likely to be associated with normal GFR in NIDDM.
Others, including Pugh and colleagues (1993) and Friedman and Gross (1991),
suggest that progression may indeed be slower in NIDDM. The reasons for the more
rapid rate of progression for NIDDM subjects in this study are discussed below.
Rutherford and colleagues (1977) were among the first to suggest that the type of
primary renal disease did not influence the rate of disease progression. Their study
included eight individuals with diabetes mellitus. This view has been challenged
(Williams and Mallick 1993) and recent studies indicate disease specific rates of
decline of cGFR, though with considerable individual variation. Diabetes mellitus
compares unfavourably with other conditions and appears to show the greatest
variation.
Williams and colleagues (1988) observed more rapid progression in 14 diabetic
individuals (unclassified for IDDM and NIDDM) compared to 13 with chronic
pyelonephritis and 9 with polycystic kidney disease. In a retrospective study
Hannedouche and colleagues (1989) assessed the progression of renal failure in 167
patients (only four with diabetes - all NIDDM) already on dialysis; all had a
creatinine in excess of 500 pmol.L"1 at baseline. Using the Cockcroft-Gault equation
the mean decline for the four diabetic subjects was 1.06 ml.min."1month"1 comparable
to chronic glomerulonephritis (n=55) at 1.07 ml.min. 'month', though significantly
greater than chronic pyelonephritis, polycystic kidney disease and nephrosclerosis.
Only a small group of individuals with Alport's syndrome progressed more rapidly.
In a dated study, Ahlmen and colleagues (1975) also observed more rapid
progression in those with diabetes. The mean duration from 'elevated creatinine' to
terminal renal failure and dialysis (death for the diabetic subjects) varied from six
months in 24 subjects with diabetes to 18.1 months for 11 with polycystic kidney
disease. The validity of this study must be questioned as data on 'baseline creatinine'
is lacking.
In a recent retrospective study of 159 subjects with non-diabetic renal disease,
Jungers and colleagues (1995) concluded that primary renal disease and the level of
protein excretion were the principal determinants of progression. The baseline
creatinine clearance was comparable to the current study, yet of the various groups
only chronic tubulo-interstitial nephritis showed a slower decline of GFR than seen
in our diabetic group. This supports the assertion that the overall progression in this
cohort is encouragingly slow.
Early studies suggested that the decline of GFR in renal failure was linear (Mitch et
al. 1976). Jones and colleagues (1979) gave substance to this view observing a linear
fall of reciprocal creatinine in 9 subjects with IDDM and a serum creatinine over
200p.mol.L~1. However, Williams and colleagues (1988), in an analysis of 108
patients with various renal diseases (14 with diabetes mellitus), recorded linear
progression in 70 (65%), non-linear progression in 15 (14%) and no progression in
23 (21%). For those with diabetes mellitus linear progression occurred in twelve and
non-linear in two. No subject maintained stable renal function. In miscellaneous
renal conditions, though not including diabetic nephropathy, Stenvinkel and
colleagues (1989), in contrast, found stable renal function in 17 of 108 (16%)
subjects. Despite significant renal impairment, eight individuals (3 with NIDDM) in
our cohort show stable renal function even after 7.5 years of follow-up. This raises
the tantalising prospect of halting the progression of renal failure in diabetes
mellitus, at least in certain individuals, where previously an inexorable slide towards
dialysis was deemed inevitable.
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2.5.2 Factors associated with the progression of renal impairment.
2.5.2. i Gender and age andprogression of renal impairment
A male preponderance in renal disease is well established both for diabetes mellitus
(Krolewski et al. 1985; Kofoed-Enevoldsen et al. 1987) and non-diabetic renal
disease (Finn and Harmer 1979). A significant male excess was seen only in NIDDM
in this study. No difference was observed in the rate of decline of GFR between the
sexes (0.41 ml.min.'month"1 vs 0.43 ml.min/'month"1; male vs female). This
contrasts with the studies of Hannedouche and colleagues (1993) and Jungers and
associates (1995), where the rate of decline is significantly slower in females. The
study of Gall and colleagues (ibid.) included only one female subject. Contrary to
other published studies (Mallick et al. 1987; Gall et al. 1993) increased age was
associated with a slower rate of decline of GFR in this study. In this study the
'Responders' in both IDDM and NIDDM were approximately ten years older than
the 'Non-responders'.
2.5.2.U Ethnic background andprogression of renal impairment
The increased prevalence of diabetic nephropathy and other renal disease amongst
non-white populations in ESRD programmes is the subject of considerable interest
(Easterling et al. 1977; Rostand et al. 1982; Cowie et al. 1989; Pazanias et al. 1991).
It has been variously related to the increased prevalence of diabetes (Cowie et al.
1989; Nelson et al. 1989); to the greater incidence of hypertension (Tierney et al.
1989); to social deprivation; to abnormalities of parathyroid and vitamin D
metabolism (Bell et al. 1985; Rostand et al. 1982) and to a more rapid decline of
GFR, possibly related to hypertension (Smith et al. 1991). Our data do not support
this latter observation. Here Caucasian NIDDM subjects progress more rapidly than
Afro-Caribbean subjects (0.73 vs 0.43 ml.min."'month"1; p<0.05). No difference was
seen in blood pressure or its treatment, protein excretion, glycosylated haemoglobin
or serum cholesterol between the two groups. The recent work of Cowie (1993)
53
supports this finding. She found that the time taken from a serum creatinine of 159
pmol.L"' to RRT was five months shorter in white, compared to black, NIDDM
subjects. A significant decrease in the rate of decline of cGFR in this present study is
also seen in Afro-Caribbean, but not Caucasian, subjects, when observed over four or
more years (see Table 2.4).
2.5.2.M Protein excretion and the progression ofrenal impairment
This study demonstrates a significant association of 24-hour protein excretion with
decline of cGFR both for IDDM and NIDDM subjects. Multiple regression analysis
identifies proteinuria as the foremost factor accounting for variation of cGFR
decline. This agrees with previous findings of Williams and colleagues (1988) and
Wight and colleagues (1992) in non-diabetic renal disease, but is in contrast to the
study of Gall and colleagues (1993) who found no association in NIDDM in a
stepwise multiple linear regression analysis, though it did associate in a univariate
analysis.
Williams and colleagues (ibid.) found that proteinuria was significantly correlated
with progression of renal disease, particularly so in chronic glomerulo-nephritis and
chronic pyelonephritis, although not so marked with diabetes mellitus. Proteinuria
was significantly less in those individuals with stable renal function compared to
those with linear progression, and is in agreement with the findings for both IDDM
and NIDDM in this study where there is a two-fold greater protein excretion in the
'Non-responders' compared to the 'Responders'. Wight and colleagues (1992) using
breakpoint analysis found proteinuria to be the most important factor governing
progression of 102 patients with moderate renal impairment, although only six had
diabetes. Increasing proteinuria suggests progression of renal failure is likely
(Williams and Mallick 1993). However, Sawicki and Berger (1994) doubted the
clinical value of 24-hour protein excretion as a predictor of renal outcome in diabetic
nephropathy. Other researchers suggest a reduction of proteinuria may improve
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prognosis in IDDM (Rossing et al. 1994a). The prospective study reported in
Chapter 4 indicates a more modest association of protein excretion with progression.
2.5.2.iv Bloodpressure andprogression of renal impairment
Multiple regression analysis identifies a modest association of diastolic blood
pressure with progression in all subjects in this study. The association is lost when
the cohort is sub-divided by diabetes type. Furthermore neither systolic or diastolic
blood pressure in IDDM nor systolic pressure in NIDDM differs significantly
between 'Responders' and 'Non-responders'. This may at first glance appear
surprising given the acknowledged importance of blood pressure control on slowing
progression. As will be discussed below, perhaps it is the type of therapy together
with a 'threshold effect', rather than the prevailing blood pressure which are critical.
In addition how long a subjecthas been treated with anti-hypertensive therapy when
studied may be crucial.
Many early studies identified control of blood pressure to be linked to progression in
non-diabetic renal disease (Pohl et al. 1974; Kajiwara et al. 1975; Van der Peet et al.
1977; Oldrizzi et al. 1985) and, more recently, in diabetic nephropathy (Mogensen
1982; Parving et al. 1987; Bjorck et al. 1992; Lewis et al. 1993). Such an association
is not always found e.g. Williams and colleagues (1988), Malangone and colleagues
(1989), Stenvinkel and colleagues (1989) and Wight and colleagues (1993).
Malangone and colleagues (ibid.) reported a retrospective analysis of 402 patients
entering dialysis, of whom 74 (61 IDDM) had diabetic nephropathy. Reciprocal
creatinine was not correlated with either systolic or diastolic pressure in the group as
a whole, nor specifically in those with diabetes. Also using reciprocal creatinine
Stenvinkel and colleagues (ibid.) examined progression in 108 patients with various
underlying renal diseases, though not diabetes. The baseline creatinine ranged from
200-350 pmol.L"1 and subjects were followed for 8-63 months. No correlation was
observed between progression and blood pressure. However when the group was
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subdivided on the basis of rate of progression mean arterial pressure at 110 mmHg
was significantly greater in the 91 subjects defined as 'Progressors' compared to the
17 defined as 'Non-progressors', where MAP was 103 mmHg. The patients showing
progression were also taking more anti-hypertensive drugs, mean 2.5 vs 1.2. A
similar threshold effect was shown by Biesenbach and associates (1994) where the
rate of decline of cGFR was almost two-fold greater in those individuals with a
systolic pressure >160 mmHg, (1.38 ml.min."'month"1 vs 0.78 mkmin/'month"' resp.).
Frohling and colleagues (1989) found a negligible relationship between the rate of
progression and blood pressure in subjects with advanced renal failure comparable to
the degree of renal impairment seen in this study. Wight and colleagues (1993) in a
longitudinal study of 18 patients with advanced renal failure, due to various
underlying diseases, observed no correlation of decline of GFR with systolic or
diastolic pressure. However when the same group was studied prospectively an
association did emerge. Furthermore no improvement in the rate of decline of GFR
occurred when the diastolic pressure was subsequently lowered from 84 to 77 mm
Fig. This suggests that lowering blood pressure below a certain level may confer no
additional benefit in ameliorating the rate of decline ofGFR.
2.5.2.V Anti-hypertensive therapy and progression ofrenal impairment
An earlier report in many fewer patients suggested that the use and choice of anti¬
hypertensive therapy rather than the level of achieved blood pressure is a greater
determinant of the decline of cGFR (Drury et al. 1993). Twice the number of
subjects examined together with extension of the observation period in this study
indicates that this finding holds only in NIDDM. It is perhaps surprising that a
significant proportion («50%) of all subjects were not taking anti-hypertensive
therapy at the start of observation in 1986. This reflects previous local policy,
although undoubtedly a heightened awareness of the importance of anti-hypertensive
therapy in slowing progression of renal impairment in diabetic nephropathy followed
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the studies of Mogensen (1982), Parving and co-workers (1983, 1987), Bjorck and
colleagues (1986, 1992) and most recently Lewis and colleagues (1993). The change
in prescribed anti-hypertensive medication follows recent trends and emphasises the
increasing reliance on the use of ACEI in diabetic nephropathy. The ACEI class of
drugs have been shown by some to be more beneficial than conventional therapy in
slowing progression of renal impairment (Bjorck et al. 1992; Kamper et al. 1992;
Lewis et al. 1993). Such studies are small in scale and of short duration. It remains to
be established whether such agents confer greater longevity or reduced morbidity. A
greater use of anti-hypertensive drugs together with a switch to ACEI from beta-
blockade is observed in this study.
Brazy and Fitzwilliam (1990) examined the effect of blood pressure and anti¬
hypertensive therapy (amongst other factors) on the decline of GFR in 200 subjects
ofwhom 57 had diabetes mellitus. In addition to the level of diastolic blood pressure,
specific agents were associated with a slower decline of renal function (reciprocal
creatinine). Those on no therapy, minoxidil, clonidine and calcium channel
antagonists progressed more slowly than the group on diuretic therapy alone,
although only those treated with minoxidil showed a significant reduction of blood
pressure. No data on patients prescribed ACEI were presented in this study. Claims
of benefit for ACEI exceeding the anti-hypertensive effect alone have been made
(Lewis et al. 1993). Whether these agents do so by reducing intraglomerular pressure
(Zatz et al. 1985), reducing proteinuria (Taguma et al. 1985), reducing the
accumulation of mesangial matrix (Remuzzi et al. 1990) or by some other
mechanism is not yet established.
Normotensive subjects on no anti-hypertensive medication have been shown to fare
better than treated subjects with equivalent blood pressures (Jungers et al. 1995). The
cGFR was lower in the five NIDDM individuals in our study compared with the
treated group, although the difference was not significant due to the small numbers.
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Blood pressure differences may contribute to the faster rate of decline of cGFR seen
in the NIDDM group. Systolic blood pressure was significantly greater throughout
the observation period as well as during the most recent two years in this group,
though diastolic pressure was significantly higher only over the whole period. The
presence of an elevated blood pressure prior to beginning anti-hypertensive therapy
may have a deleterious effect on subsequent disease progression, particularly in
NIDDM. In a mixed racial group, Pugh and colleagues (1993) observed the time
from diagnosis of diabetes to ESRD was on average 2.7 years shorter in individuals
hypertensive at the onset of diabetes.
Haemodynamic factors may contribute to the greater rate of progression seen in
NIDDM, given that atheromatous renovascular disease appears more common than
in IDDM (Ritchie et al. 1988; Brown et al. 1992). The influence of renovascular
disease on progression of renal impairment in NIDDM is discussed in the following
chapter.
2.5.3 Has the specialist diabetic renal clinic conferred benefit on the
attendees?
Comparing the rate of decline of cGFR before and after entering the joint clinic
reveals a significant reduction only in IDDM. However the average duration of
follow-up of three years in both groups is relatively short. The reduction in the rate
of decline of cGFR in Afro-Caribbean subjects, followed-up for four years or more,
suggests that the benefit of clinic attendance may yet emerge in NIDDM. The reason
for improvement may be due to improved blood pressure with a significant fall in
diastolic pressure in both IDDM and NIDDM groups.
No clear association was observed with prescribed anti-hypertensive medication,
although the results of the multiple regression analysis presented above suggest it
may be important. The number of prescribed drugs is greater at the end compared to
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the start of the period of observation. Improved drug compliance cannot be
discounted as a cause for the improvement in cGFR. The benefit of specialised, as
compared to routine, hypertension care has been demonstrated recently in diabetic
nephropathy. In a 5 year follow-up study comparing 46 IDDM patients receiving
routine care with 45 receiving specialised care the latter fared considerably better
(Sawicki et al. 1993). Survival to death or dialysis was significantly longer for those
receiving specialised care. Whilst blood pressure was significantly improved in the
specialist clinic attendees, it is not clear whether the groups were evenly matched for
diabetic complications. Bergstrom and colleagues (1986) have demonstrated the
beneficial effect of more frequent clinic reviews in 17 subjects with chronic renal
failure. However the reduction of the slope of reciprocal creatinine was associated
with a modest, though significant, drop in diastolic blood pressure. They
demonstrated an overall improvement in 50% of cases, although in two cases there
was an accelerated decline. There was no evidence in this current study, either in
IDDM or NIDDM, that more frequent clinic attendance or indeed duration of
attendance conferred greater benefit. Rather the converse; the individuals with the
faster progression were seen more frequently. This observation is not entirely
unexpected.
Although one might feel that attendance at a clinic devoted to patients with specific
long-term complication of diabetes would be an advantage the evidence suggests
only limited benefit to the group as a whole. The lack of a control group and the use
of individuals as their 'own controls' makes it difficult to quantify the factors
responsible for the improvement observed. One may speculate however that the




• The median rate of decline of cGFR for all subjects was 0.39 ml.min."'month"
The rate for IDDM subjects was 0.29 ml.min.'month"' compared to 0.43
ml.min."1 month"1 in NIDDM (p<0.05).
• In the most recent year of observation the median rate of decline of cGFR for
the IDDM subjects was 0.07 ml.min."1month"1.
• Only Afro-Caribbean NIDDM subjects showed a statistically significant
reduction of the rate of decline of GFR when observed over four years or
more, improving from 0.49 ml.min.'month"' to 0.26 ml.min."'month"'
(p<0.02), comparing the first and last two years.
• 24-hour protein excretion emerged as the most significant associate of the
rate of decline of cGFR in both IDDM and NIDDM
• Diastolic blood pressure showed a modest association with the rate of decline
of cGFR in all subjects, though not when sub-divided by diabetes type.
Systolic pressure, glycosylated haemoglobin and serum cholesterol were not
significant factors.
• Antihypertensive treatment at the start of the observation period was
associated with a slower rate of decline of cGFR in NIDDM, though not in
IDDM subjects.
• A significant slowing of the rate of decline of cGFR was observed following
attendance at the joint diabetic renal clinic in IDDM, though not in NIDDM.
That a number of patients, particularly those with IDDM, may have stable renal
function over six or more years despite significant renal impairment should provide
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encouragement not just to those patients but also to their carers and others who see
renal replacement therapy as the inevitable consequence of diabetic nephropathy.
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Chapter 3
Does renal artery angioplasty influence the progression of
renal impairment in diabetic nephropathy ?
3.1 Introduction
Autopsy studies indicate a prevalence of renal artery stenosis (RAS) of 8-10% in
subjects with diabetes mellitus compared to 4% in non-diabetic individuals (Sawicki
et al. 1991). In selected groups, however, the prevalence may be significantly higher.
Shapiro and colleagues (1965) found 44% of a group of 55 subjects with RAS and
hypertension had diabetes mellitus, although in the majority the latter diagnosis was
made only at the time of angiography. A more recent survey of diabetic clinic
attendees with hypertension screened for RAS by digital subtraction angiography
revealed 5 of 24 non-insulin-treated subjects to have a unilateral RAS, compared to
none in an insulin-treated group (Ritchie et al. 1988). The degree of stenosis in this
study was not stated. The only published study confined to diabetic nephropathy
showed significant RAS (defined as a stenosis > 50%) in 10 (30%) of 33 NIDDM
subjects (Brown et al. 1992). Renal artery stenosis was not found in 7 IDDM
subjects in this study, highlighting the relative rarity of this finding in these patients.
Few data are available on the effect of percutaneous transluminal angioplasty
(PCTA) in renal failure due to atherosclerotic RAS. Benefit has been shown by
certain groups (Martin et al. 1988; O'Donovan et al. 1992; Pattison et al. 1992), but
not by others (Luft et al. 1983; Textor et al. 1992). No study has systematically
examined the effect of PCTA on RAS in subjects with diabetic nephropathy. The
impression was gained that such patients in our clinic undergoing PCTA did not
appear to benefit from the procedure. A retrospective analysis of subjects with RAS
and diabetic nephropathy who underwent PCTA was therefore carried out. The data
from these subjects are included in a more comprehensive survey of PCTA in
atherosclerotic RAS, pre-dominantly of non-diabetic origin (Connolly et al. 1994).
The latter study examined 94 patients of whom 24 had diabetes mellitus. The
subjects presented here are confined to those with NIDDM and diabetic nephropathy.
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3.2 Aim
To examine the effect of percutaneous transluminal angioplasty on renal function
and blood pressure in subjects with NIDDM and nephropathy who were found to
have renal artery stenosis.
3.3 Patients andMethods
3.3.1 Patients
Nine subjects with NIDDM, fulfilling the criteria of diabetic nephropathy, were
selected from a group of 14 who underwent PCTA for RAS between 1988 and 1992.
Of the remaining 5, two had no retinopathy, in two the diagnosis of RAS preceded
the diagnosis of diabetes and one had IDDM. All were regular attendees at the
diabetic renal clinic as described in Chapter 2.
The clinical details of these nine cases are given in Table 3.1 (overleaf). NIDDM and
diabetic nephropathy are defined as in sections 4.3. l.ii and 4.3.1.iii respectively. No
subject underwent percutaneous renal biopsy. The values given for serum creatinine
and blood pressure in Table 3.1 are those of the visit immediately preceding
angioplasty. Neither protein intake nor excretion were measured systematically and
dietary protein restriction was not advised throughout the period of observation
despite the advanced nature of renal impairment in several cases. However a cohort
of subjects, including several examined here, followed prospectively showed no
change in 24-hour urea excretion over the period of observation (see Chapter 4).
3.3.2 Indications for angiography
Angiography was carried out in these subjects for the clinical indications as outlined
in Table 3.2 (overleaf). Uncontrolled hypertension was defined as a blood pressure
>160/95 mmHg. despite maximal anti-hypertensive medication, or, as in case 3,
accelerated-phase hypertension. Subjects with renal failure in whom RAS was
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Table3.1:Clinicaldetai softhesu j ctspriorren lt ryngi plasty
Case Indication for angiography Findings
1 Asymmetric kidneys (L) RAS > 90%
2 Fluid overload Multiple bilateral stenoses
3 Hypertension (L) RAS - 30%
4 Resistant hypertension (L) RAS > 90%
Renal failure (R) - occluded
5 Hypertension (L) RAS > 50%
6 Renal failure (L) RAS - 30%
7 Renal failure (L) RAS - 30%
8 Hypertension Bilateral stenoses
(R) > 50%; (L) - 40%
9 Fluid overload Bilateral stenoses
(R) >50%; (L) - 30%
Table 3.2: Indications for and findings at angiography
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thought to be a contributory factor, or who showed a worsening of GFR with the
introduction of an angiotensin converting enzyme inhibitor (ACEI), were considered
for angiography. A size difference exceeding 1.5 cm between kidneys on renal
ultrasound prompted investigation to exclude RAS. Cardiac failure, both acute and
chronic, is a recognised, though rare, presentation of RAS (Pickering et al. 1988;
Missouris et al. 1993). Peripheral vascular disease was recorded as present in those
with a history of intermittent claudication, absent foot pulses or the presence of
stenosis of the iliac, femoral or tibial arteries on peripheral angiograms.
Table 3.2 indicates the findings at angiography. Bilateral stenoses were present in
three cases (2, 8 & 9). In one (Case 4) stenosis in one renal artery was associated
with occlusion of the contralateral artery. Two subjects had numerous peripheral
stenoses in addition to the more proximal stenosis (Cases 1 & 8).
3.3.3 Angioplasty technique
All angioplasties were carried by an experienced interventional radiologist, using a
5-gauge French catheter inserted via the femoral artery. The balloon was dilated up
to 5-7mm in diameter for 30 seconds on average, repeated if necessary, under cover
of an isosorbide dinitrate infusion. All subjects not already receiving aspirin were
commenced on it.
3.3.4 Renal function and blood pressure
Data on renal function were available for a minimum of three (Case 7) to a
maximum of eighteen months before and after angioplasty. Serum creatinine
measurements in the three weeks after angioplasty were excluded from analysis, as
contrast may transiently worsen renal function (Spangberg-Viklund et al. 1989).
Estimated GFR was derived from these creatinine measurements using a
modification of the Cockcroft-Gault formula (Cockcroft and Gault 1976; Hull et al.
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1981). The equation is given below (section 5.3.1) and the subject discussed at
greater length in Chapter 5. The formula has been validated for IDDM (Sampson and
Drury 1992; Rossing et al. 1994b), whilst a strong association is shown between
EDTA GFR and GFR estimated from Cockcroft-Gault (r=0.78; p<001) in NIDDM
subjects (see Chapter 5). A minimum of three creatinine measurements were
recorded before and after angioplasty in all subjects and the mean estimated GFR
compared over equivalent time periods before and after the procedure. The means of
estimated GFR, systolic and diastolic blood pressure were compared over equivalent
time periods before and after angioplasty.
Blood pressures (phase I and V) was recorded in the sitting position at each visit
using a standard mercury sphygmomanometer, reading to the nearest 2 mmHg, by
one of three observers. Anti-hypertensive therapy was recorded at each visit. All
subjects gave informed consent to the procedure.
3.4 Results
All angioplasties were deemed technically successful at the end of the procedure as
judged by angiographic appearances after dilatation. Four subjects had repeat
angiograms, 6-12 months later. Only one (Case 8) required a further angioplasty. The
only complications occurred in case 1 with a large groin haematoma and an intimal
tear to the renal artery; neither required specific intervention.
3.4.1 Changes in renal function
The mean pre- and post- angioplasty values for cGFR are given in Figure 3.1
(below). No benefit from PCTA in attenuation of renal function decline is seen in
this group with estimated GFR higher before angioplasty than afterwards (29.0±12.7
ml.min"1 vs 23.3±12.7 ml.min"1, mean±SD, p=0.02: paired 't-test'). The relatively
short duration of observation precludes a meaningful comparison of the rates of
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decline of GFR before and after PCTA for the whole group. However in the six
subjects observed for > 10 months an approximate fall in GFR can be calculated.
Again there is no significant improvement in GFR; mean fall pre-angioplasty 0.36
ml.min"1.month"1 vs 0.41 ml.min ' month' post angioplasty (p=0.64; paired 't-test'),
although two of the subjects might show a very modest slowing of decline of GFR
(Cases 4 & 8). These figures differ little from the results previously shown with a the
median decline of 0.43 ml.min."1 month"1 seen for all 55 NIDDM subjects recorded in
the observational study (see Chapter 2). The mean follow-up for these nine cases was
12 months. Extrapolating from the median decline of cGFR (above), the average
expected decline of cGFR over the period following angioplasty would be 5.2
ml.min"1, compared to the observed of 5.7 ml.min"1.
In all subjects, except Case 9, the procedure itself appeared to have a slight adverse
effect on renal function. Individual profiles showing the effect of angioplasty on
renal function are shown in Figure 3.2 (overleaf).
3.4.2 Changes in blood pressure
Figure 3.3 (overleaf) shows mean systolic and diastolic blood pressure before and
after angioplasty, demonstrating no benefit from intervention in this group. Both
systolic (178±36 vs 188±44; p=0.37) and diastolic blood pressure (90±14 vs 95±15;
p=0.12) rose slightly, albeit non-significantly, after angioplasty. In only two or three
cases could there be described a modest fall of blood pressure. In addition there was




















Figure 3.1: Mean estimated GFR before and after angioplasty.
Values are means over equivalent time periods.
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Figure 3.2 : Decline in estimated GFR in individual patients. Angioplasty denoted by arrow.
























in blood pressure before and after angioplasty. Values
means over equivalent time periods.
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3.5 DISCUSSION
It is eighteen years since the original description by Gruntzig and colleagues (1978)
of renal artery angioplasty in a patient with renovascular hypertension due to
atheromatous RAS. Fostered by a series of reports advocating its benefits it has
become both an attractive and commonplace procedure. A critical analysis of the ten
largest series published prior to 1987 challenged this approach (Ramsey and Waller
1990). These authors considered that one in three of all subjects with RAS did not
benefit from the procedure. Even fewer of those with RAS due to atheroma benefit
when compared to those with fibromuscular hyperplasia. Most studies ofPCTA have
examined the effect of angioplasty on blood pressure; studies in diabetic subjects are
rare. An exception is the recent study of Martin and colleagues (1992) who
demonstrated improved blood pressure control following angioplasty for ostial RAS
in four of six patients with NIDDM and three of eight with IDDM (no data on the
effect of angioplasty on renal function are given).
Fewer studies have examined the effect of angioplasty on renal function, and none
exclusively so in diabetic nephropathy. Table 3.3 (over) summarises the results of
these studies. Direct comparison between them is difficult because different criteria
for success are used. For instance Bell and colleagues (1987) used a fall in creatinine
of 50pmol.L"', Pattison and colleagues (1992) and Connolly and colleagues (1994) a
fall of 20% from the pre-angioplasty value, while Luft and colleagues (1982)
considered benefit occurred only if the post-angioplasty creatinine bettered the pre-
angioplasty level.
It is clear from these studies, however, that a number of patients appear to benefit
from the procedure in terms of improved renal function. Furthermore sub-groups of
patients do better than others. Martin and colleagues (ibid.) demonstrated the greatest
benefit in those with bilateral stenoses. In contrast Pattison and colleagues
72
No. of subjects Improved Stable Deteriorated Reference
10 2(20) 7(70) 1(10) Schwarten (1980)
2 2 (100) - - Sos (1983)
12 3(25) NS 4(33) Luft (1983)
20 7(35) 10(50) 3(15) Bell (1987)
79* 34 (43) NS NS Martin (1988)
9 3 (33) 2(22) 4(45) McDonald (1988)
9 3 (33) 6(67) - Kim(1989)
17 7(41) 4(24) 6(35) O'Donovan (1992)
60 24 (60) NS 6(10) Pattison (1992)
52 2(4) 36 (70) 14 (26) Connolly (1994)**
Key : NS = not stated; figures in parenthesis are percentages
*- includes 7 non-atheromatous subjects ** - data given for 12 month follow-up
Table 3.3 : Effect ofPCTA on renal function in previous studies ofpatients
with atheromatous renal artery stenosis
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(ibid.) found the greatest improvement in those with stenosis in one renal artery, with
a non-functioning or absent contra-lateral kidney (in a number of these the benefit
may have been due to the correction of additional reversible renal disease), while
limited benefit was seen in those with bilateral stenosis and none for unilateral
stenosis. In addition they found that the greatest benefit was found in individuals
showing the most rapid reduction in GFR prior to angioplasty.
Few authors indicate the diabetic status of the patients studied. Of 17 elderly subjects
examined by O'Donovan and colleagues (1992), 8 had diabetes. Whether or not
these individuals fared differently from the remainder is not stated. Bell and
colleagues (1987) suggested that patients with end-stage renal disease or severe
intra-renal atheroma (as seen in two of our cases) may not benefit from angioplasty.
The majority of these studies are, however, relatively short-term and all are
uncontrolled. Examined over a longer time period outcome from angioplasty may
not prove so successful (Textor et al. 1992).
Definition of what constitutes a successful angioplasty is disputed. As indicated
above end-points in the various studies differ. The observation that renovascular
disease is progressive (Schreiber et al. 1984, Dean et al. 1981) led Connolly and
colleagues (1994) to conclude that intervention leading to stable renal function
represented success. It could be argued that since none of the subjects presented here
showed an accelerated decline of GFR some degree of benefit accrued. In practice it
appears that angioplasty had neither a beneficial nor a detrimental effect on renal
function in these subjects. Certainly the individual patient profiles of decline of
estimated GFR presented in Figure 3.2 do not suggest that intervention has altered
the natural progression of the condition. It is clear from the data presented in Chapter
2 that an amelioration in the decline of estimated GFR may occur in certain
individuals (and certain groups). This further emphasises the lack of benefit observed
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from angioplasty in this group. However the absence of direct imaging or functional
studies makes is difficult to draw firm conclusions on the influence of renovascular
disease (and intervention) on the progression of diabetic nephropathy.
Failure to demonstrate any benefit from angioplasty in this study may have arisen
due to a number of factors. The lesion may not have been haemodynamically
significant, particularly those with 30% stenoses. The decision to perform
angioplasty was made by the radiologist performing the angiogram. Neither venous
sampling for renal vein renin nor a captopril renogram was performed to demonstrate
a functional stenosis. Restenosis may have occurred, as in Case 8. However three
others showed no evidence of restenosis on repeat angiography. The presence of
intrarenal arterial stenosis may have a greater influence on the outcome of
angioplasty than the successful dilation of the proximal lesion (Dean et al. 1985).
Similarly it is possible that renal parenchymal disease may determine the outcome of
angioplasty. Studies have suggested that the degree of glomerular hyalinisation may
determine whether or not renal function is recoverable after revascularisation (Vidt et
al. 1972; Zinman et al. 1977). If this is the case then subjects with diabetic
nephropathy may not benefit from dilation of an associated RAS.
3.6 Concluding remarks
In this small study no individual appeared to benefit from angioplasty in terms of an
improvement in renal function or significant slowing in its decline, nor in the level of
blood pressure control or reduction in anti-hypertensive therapy. As all nine
individuals failed to show a sustained improvement in renal function and blood
pressure a type 2 error is unlikely. Where diabetic nephropathy is established either
clinically or by renal biopsy then it may be that dilation of an associated RAS does
not alter the natural decline of renal function. Given the increased usage of ACE
inhibitor therapy, particularly in subjects with diabetic nephropathy, a rise in renal
75
failure due to renovascular disease seems likely. The beneficial effect of PCTA in
RAS in such individuals remains to be established.
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Chapter 4
A prospective study of the factors influencing the
decline of glomerular filtration rate in NIDDM subjects
with nephropathy
4.1 Introduction
Prospective studies of the progression of nephropathy in NIDDM are few. Although
there are a number of studies ofNIDDM subjects with micro-albuminuria (Cooper
et al. 1988; Schmitz and Vaeth 1988; Vora et al. 1992), only four, using a validated
technique for the measurement of GFR exist in those with more advanced
nephropathy. The earliest, by Friedman and Gross (1991), included only seven
subjects, one of whom had multiple myeloma, and the majority had near-normal
GFR. Gall and colleagues (1993) examined almost exclusively male Caucasian
subjects with less severe renal impairment than in this present study. The two most
recent, by Myers and colleagues (1995) and Nelson and colleagues (1996b) in the
Pima Indians, used iothalamate clearance. Again the renal impairment was modest;
in the former the subjects had a mean baseline GFR of 108 ml.min"1 whereas in the
latter the value was 124 ml.min'.
In the retrospective analysis presented above in Chapter 2 a remarkably slow rate of
progression of GFR was witnessed, particularly in IDDM. However the study was
limited both by the retrospective nature, and by the use of a surrogate measure of
GFR. Thus a prospective study was conducted in 26 NIDDM subjects to determine
whether the rate of decline of GFR was comparable when an isotopic clearance
method was used and to identify the principal factors associated with the recorded
decline. Inevitably such a study was time-limited, with the individuals being
followed for up to two years.
4.2 Aims
• To determine the rate of decline of renal function in a well characterised
group of subjects with NIDDM and nephropathy.
• To examine whether racial differences exist in the rate of decline of
glomerular filtration rate.
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• To assess the relationship between the rate of decline of glomerular filtration
rate and several measured variables, including glycaemic control, blood
pressure, 24-hour protein excretion and serum lipid concentration.
4.3 Patients andMethods
4.3.1 Patients
4.3.1. i Patient selection
The 26 subjects selected were attendees at the diabetic outpatient clinic at King's
College Hospital. Twenty-three attended the joint diabetic-renal clinic as previously
described (details in Chapter 2), while three were recruited from the general diabetic
clinic. Of 38 NIDDM patients attending the joint clinic potentially suitable for study
15 were excluded; 9 (5 Afro-Caribbean; 3 Caucasian; 1 Asian) declined to
participate, 3 (all Afro-Caribbean) were near end-stage failure or were on
intermittent dialysis and 3 had a history of erratic clinic attendance. At the time of
selection all subjects had a serum creatinine of >140 pmol.L"1 (normal range 50-105
prnol.L"1), although in one case this had improved to 129 pmol.L"1 when the study
commenced. All subjects were deemed to have NIDDM {4.3.1.0) and to fulfil the
criteria for diabetic nephropathy {4.3.1. in).
Of the 26 subjects within the group 21 were male. Eleven were Caucasian, ten Afro-
Caribbean and five of Asian extraction. The median age at entry was 65.5 years
(range 43-78) with a duration of diabetes of 13.5 (3-24) years at the start of the study.
See Table 4.1 (overleaf) for details.
4.3.l.ii Definition ofnon-insulin-dependent diabetes mellitus
Patients were recognised as having NIDDM where treatment was with diet alone or






























































M AF 67 25 29 195
M C 65 16 34 129
M C 69 3 30 156
M AS 61 11 22 154
M C 66 8 31 154
F c 46 14 48 296
F AF 43 9 23 216
M AF 60 6 34 263
F C 72 17 30 226
M AS 56 8 27 187
M AF 74 17 25 191
M C 76 18 21 220
M AS 78 27 27 257
M C 71 18 30 141
M c 49 9 30 351
M AF 59 13 27 241
M AF 67 10 21 336
F AF 64 16 32 337
M AS 67 10 28 218
M AF 74 6 31 159
M C 70 10 26 236
F AF 58 20 26 302
M C 64 13 29 224
M c 61 21 23 361
M AF 60 14 30 165
M AS 47 14 30 286
65.5 13.5 29 222
43-78 3.0-24.0 21 -48 129 - 3<
Characteristics of the nephropathic subjects entering the study
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diagnosis. In no subject was there a history of ketoacidosis. All subjects were aged
thirty years or more at the time of diagnosis with a median body mass index (BMI) at
entry was 29 (range 21-48). Measurement of basal or stimulated C-peptide was not
carried out. These criteria take account of the published guidelines for the diagnosis
of diabetes mellitus {WHO Technical report (1985); Hother-Nielson and colleagues
(1988)}.
4.3.1.M Criteria for the diagnosis ofdiabetic nephropathy.
Diabetic nephropathy is here defined as a urinary protein excretion of greater than
500 mg in 24 hours in the absence of urinary tract infection, cardiac failure or other
renal disease. In most cases diabetic retinopathy and hypertension are present but
neither are pre-requisites for the diagnosis, although the lack of the former should
prompt a search for an alternative renal diagnosis. This definition is based on that
given by Viberti and colleagues (1992).
Non-diabetic renal disease was excluded by the absence of serological markers (see
below), by the finding of a normal renal ultrasound and by the absence of red cell
casts, frank haematuria or significant pyuria in a freshly voided urine specimen (see
below). Percutaneous renal biopsies were not routinely performed.
4.3.1.iv Exclusion ofother renal disease
All subjects had a renal ultrasound performed before entry into the study. Subjects
were excluded if bilateral small kidneys (<10 cm.), asymmetric kidneys (size
difference >1.5 cm.), evidence of urinary obstruction (hydronephrosis or
pelvicalyceal dilatation) or a mass lesion within the kidney were demonstrated.
All subjects had blood taken for taken for auto-antibodies (anti-nuclear factor [ANF]
and anti-neutrophil cytoplasmic antibody [ANCA]), complement [C3, C4] and serum
protein electrophoresis. Subjects were excluded if positive ANA or ANCA found,
unless a renal biopsy confirmed glomerulosclerosis (Cases 1 & 6 in Table 4.2). A
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sterile midstream specimen was examined microscopically and cultured and a
random sample of urine was examined for Bence-Jones protein where clinically
indicated.
Five subjects underwent a percutaneous renal biopsy to establish the diagnosis,
where doubt was raised from preliminary clinical and laboratory assessments. One
further subject (Case 6) had a second biopsy four months after commencing the
study on account of a very rapid decline in renal function and was found to have
amyloidosis in addition to diabetic glomerulosclerosis. A previous renal biopsy had
shown only diabetic glomerulosclerosis with no evidence of amyloid deposition. The
indications for and the findings at biopsy are given in Table 4.2 (below).
Case Indication for biopsy Findings
1 ANF positive Diabetic glomerulosclerosis
No evidence of SLE
2 No retinopathy Diabetic glomerulosclerosis
3 No retinopathy Diabetic glomerulosclerosis
4 No retinopathy Diabetic glomerulosclerosis
5 Rapid rise in creatinine Diabetic glomerulosclerosis
Amyloidosis
6 ANCA positive Diabetic glomerulosclerosis
Table 4.2 : Indications for and findings in subjects undergoing renal biopsy.
4.3.1. v Non-renal diabetic complications
All but two individuals had diabetic retinopathy at the start of the study (in both,
renal biopsy confirmed diabetic glomerulosclerosis). Background retinopathy was
present in 6 (23%) whilst 20 (77%) had undergone laser photocoagulation, 5 for
proliferative retinopathy and 15 for maculopathy. Of the two subjects not initially
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exhibiting retinopathy one developed maculopathy (VK) and one proliferative (LR)
during the study period; both required laser photocoagulation.
Nine of the twenty-six (35%) subjects had initial evidence of peripheral vascular
disease as documented by absent foot pulses or by significant stenoses on peripheral
angiography. None had undergone a significant amputation, although two subjects
(AR and MT) had toes amputated. Fourteen (54%) had known ischaemic heart
disease, defined as a myocardial infarction, substantiated by ECG changes and/or
cardiac enzyme elevation, angina with documented ECG changes at rest or on
exercise, or cardiac failure. Six (23%) had cerebrovascular disease, either a
completed stroke or a transient ischaemic attack.
Twelve (46%) had clinical evidence of a peripheral neuropathy, as judged by an
appropriate history with absent ankle reflexes; of these eight had confirmatory nerve
conduction studies. Only one subject was known to have autonomic neuropathy,
although few had the standard cardiovascular autonomic function tests to exclude
this complication. Details of non-renal complications are given in Table 4.3
(overleaf).
4.3.1. vi Treatment regimens
At the start of the study fourteen of the twenty-six patients were receiving insulin
and the remainder sulphonylurea therapy. No additional subject was converted to
insulin during the study. Twenty-three of the twenty-six were receiving anti¬
hypertensive drug therapy at entry. One patient commenced anti-hypertensive
treatment after twelve months. The details of the date of diagnosis of hypertension,
its relationship to the diagnosis of diabetes and the individual treatment regimens are
given in Table 4.4 (overleaf).
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Case PVD Retinopathy
Present Amputation IHD CVD Status Treatment
1 + + + BGR
2 + Maculopathy Laser
3 + Maculopathy Laser
4 + Maculopathy Laser
5 + BGR




10 + Maculopathy Laser
11 + + + Maculopathy Laser
12 + + Maculopathy Laser
13 + BGR
14 + + + Proliferative Laser
15 + + Proliferative Laser
16 Maculopathy Laser
17 + BGR
18 + Maculopathy Laser
19 Maculopathy Laser
20 Maculopathy Laser
21 + Proliferative Laser
22 + Proliferative Laser




Key : BGR = Background retinopathy
Table 4.3 : Associated complications in patients with diabetic nephropathy
83
Case Hypertension Interval Initial BP Final BP Diab
year of (years) therapy therapy Rx.
diagnosis
1 1989 23 E(5) E(15),F(20) I
2 1981 6 E(15),B(2),H( 100) E(15),B(2),H(100) s
3 1985 -2 C(37.5),F(40) died s
4 1982 2 M( 100),C(50),F(40) M(50),F(40) s
5 1982 -1 E(15),F(40),N(40) E(20),F(40),V(240) s
6 1990 13 E(15),F(40) E(15),F(80) I
7 1992 10 none V(240) I
8 1985 -1 E(20),F(80),A( 100),V(240) E(20),F(40),V(240) s
9 1975 1 E(10),F(40) E(10),F(40) I
10 1984 1 E(5) E(5),(40) s
11 1986 12 E(5),F(200) Q(5),F(200) I
12 1989 16 N(40) N(40),E(5) I
13 1986 22 E(20),F(80) E( 10),F(40),N(40) s
14 none - none died I
15 1986 4 C(50),N(40) N(40) s
16 1990 12 A(50),C(100),F(40) dialysis I
17 none - none none I
18 1990 15 C(37.5),F(40) dialysis I
19 1985 4 L(5),F(40) L(20),F(80) s
20 1984 -1 N(40),A(50) A(50),N(40) s
21 1981 0 N(40),B(5) E(2.5), F(40) 1
22 1989 18 E(20),F(40) E(20),F(40) I
23 1983 5 N(40) N(60) I
24 1990 18 L( 10) L( 10),B( 1),V( 120) s
25 1985 6 L(2.5),V(240) L2.5),V(240) I
26 1986 7 E(10),F(40) E(10),F(40) s
: A = Atenolol E = Enalapril L = Lisinopril Q = Quinapril
B = Bumetanide F = Frusemide M = Metoprolol V = Verapamil
C = Captopril H = Hydralazine N = Nifedipine
Diab. Rx. : I = Insulin; S = Sulphonylurea
ble 4.4 : Duration of hypertension, prescribed anti-hypertensive medication at the start and
sh of the study period. The interval between the diagnosis of diabetes and hypertension is
en in Column 3: negative indicates hypertension preceded the diagnosis of diabetes.
: figures in parenthesis are drug dosages given in mg.
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The aim of anti-hypertensive treatment for NIDDM patients attending the joint-
diabetic clinic was to maintain blood pressure below 160/90 mmHg. Efforts to
achieve these targets were tailored to the individual patient, taking account of age,
drug-induced side-effects (principally postural hypotension) and the rate of decline
of renal function. Towards the end of the study period more rigorous guidelines
(Mogensen 1991) were introduced aiming to achieve a pressure of 140/80 mmHg.
However this did not extend to the patients participating in the study. The preferred
anti-hypertensive regimen was an ACEI, supplemented where necessary with a loop
diuretic followed by a calcium channel antagonist. At the start of the observation
period of the 23 subjects treated, 2 (9%) were on ACEI alone, 13 (56%) ACEI and
diuretic, 3 (13%) triple therapy (ACEI, diuretic and calcium channel antagonist) and
5 (22%) on miscellaneous regimens (Table 4.4).
All subjects were maintained on their normal diabetic diet. Attempts were made to
improve glycaemic control when the HbA,c exceeded 8% (N range 4.3-6.0%).
Protein intake was not significantly restricted although efforts were made to keep
intake below 1 mg.kg."'day"'. Potassium intake was restricted where the serum level
exceeded 5.5 mmol.L"' (Reference range 3.5-5.0 mmol.L"1).
4.3.1.vii Ethical approval
All subjects gave informed consent for the study, which was approved by the




The study protocol is outlined in Figure 4.1 (overleaf). EDTA clearance was
performed on an annual basis. At the same visit subjects had a full clinical
examination to assess progression of established complications or identify any newly
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emerged. Additional measurements performed at this visit are shown in Figure 4.1.
and described below (Sections 4.3.2.Hi and 4.3.2.iv). Figure 4.1 also shows the
measurements performed at the three and six monthly visits. As all the EDTA
clearance studies were personally performed only two subjects were seen for the
annual visit each week. Thus it took three to four months to complete the group.
4.3.2.U Isotope measurement ofGFR
GFR was measured using the 'single shot' 51Cr EDTA method of Brochner-
Mortensen (1972). All subjects attended at 0930 hrs. in a non-fasted state (insulin
administered as usual) and for the duration of the clearance study were requested to
refrain from smoking, drinking coffee, tea or alcohol and consuming meat.
70pCi («3MBq) of 5lChromium labelled Ethylenediaminetetraacetic acid (EDTA)
were injected through a butterfly needle (Venisystems) placed in an ante-cubital
fossa vein and the syringe flushed with the patient's own blood. The time of injection
was accurately recorded. Ten ml of venous blood were drawn at regular intervals
from an in-dwelling cannula or butterfly needle in an opposite forearm vein (flushed
with heparinised saline) between two and four hours after the isotope was injected.
Accuracy of timing rather than exact spacing of samples is crucial. The drawn blood
was placed in a lithium heparin tube and gently mixed by hand. Within the hour
samples were centrifuged at «1200 G (260 rev.min"1 Clandon T52 centrifuge) for six
minutes. Duplicate 2 ml samples were then aliquoted (Gibco 1ml pipette) into
labelled plastic sample tubes. These together with duplicate 2ml 'Standards' and
empty tubes (background count) were counted on a Gamma counter ('Cobra').
Data on the sampling times, mean counts from samples, 'standard' and background
together with patient surface area (obtained from nomogram of height and weight)
were entered into the standard computer programme for the determination of GFR in
the department of Nuclear Medicine. Measurement of the rate of loss of the isotope
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from the blood after equilibration with the extra-vascular fluid gives a clearance rate
constant and extrapolation of the clearance data back to the time of injection gives a
measure of the volume of distribution. The GFR is calculated from these two values.
The result is corrected for a standard body surface area and to an inulin equivalent
clearance rate. Where the estimated error in the calculation exceeded 10% the data
were re-entered omitting sample 1.
Due to a policy change in the department of Nuclear Medicine midway through the
study two different methods were used to calibrate the isotope used to measure GFR.
For the first twelve months the procedure involved counting the emitted radioactivity
from a syringe pre-filled with a known weight of 5lCr EDTA on a scintillation
counter before and after injection of the isotope. Each study therefore required a
fresh sample and standard to be made up. For the remainder of the study batches of
20 samples with a single standard were made up and could be used for up to one
month. This obviated the need to count the radioactivity as the standard and the
samples decayed in proportion and the single standard could be used for all 20
studies. Samples were also used for clinical studies. Both methods gave virtually
identical GFR results (y=1.00x - 0.01). All the GFR studies were personally
performed by myself whilst holding an Administration of Radioactive Substances
Advisory Committee (ARSAC) licence.
4.3.2.M Laboratory measurements
All subjects participating in the study were familiar with the collection of 24 hour
urine. Subjects were however given written instructions with each collection and
asked to perform the collection the day prior to their visit. Table A4.1 (in appendix)
indicates the methods used to determine urine protein, urea, calcium, phosphate and
sodium. Also shown in Table A4.1 are the methodologies for measuring plasma
glucose, creatinine, calcium, phoshate, alkaline phosphatase, serum cholesterol (total,
FIDE and LDL) and triglycerides. HDL and LDL cholesterol could not be measured
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where the serum triglyceride exceeded 3.6 mmol.L"1. Haemoglobin was also
measured at each visit. The method used to measure glycosylated haemoglobin was
changed by the laboratory during the study. For the first year HbA, was measured
using the Corning method (Corning electrophoresis; CIBA-Corning Diagnostics
Ltd., Halstead, UK.). Thereafter HbAlc was measured by DCA 2000 system (Abbots
Diagnostics Limited). For the purposes of analysis all data are presented as HbAlc
using the formula, derived in-house, to convert HbA, to HbAlc as follows:
HbAlc = 0.61 x HbA, + 0.90
4.3.2.iv Bloodpressure measurement
Blood pressure was measured using a Hawkesley random-zero sphygmomanometer
(Wright and Dore 1970). All subjects had the pressure measured in the right arm in
the seated position after at least five minutes rest. The mean of three readings taken
to nearest 2 nimHg at two minute intervals was recorded. Height and weight were
recorded at each visit enabling body mass index (BMI) to be calculated.
4.3.3 Statistical analysis
The analyses were performed on the 19 subjects who completed the study. The
results are expressed as mean ±SD, unless otherwise stated when median (range) is
given. Prior to analysis the data for 24-hour protein were logarithmically
transformed, with the data presented as geometric mean and range. However this
transformation did not alter the significance of the results compared to 24-hour
protein alone. The decline of GFR was determined from the measurements of EDTA
clearance using the least squares method in a linear regression analysis and the
results expressed as ml.min."1 month"1.
The data at the start and finish of the study were compared using paired Student's't-
test'. The Pearson's correlation coefficient was used in the univariate analysis of
measured variables against decline of GFR. These variables, namely age, duration of
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diabetes, BMI, systolic and diastolic blood pressure, HbAlc, serum cholesterol and
triglyceride, serum phosphate, calcium-phosphate product and albumin, urinary
protein, sodium, phosphate and urea were then entered (F factor set at 3 for inclusion
in the model) into a forward stepwise linear regression analysis to determine those
exerting a significant influence on the decline ofEDTA GFR.
On the basis of median decline of GFR the subjects were subdivided into
'Progressors' and 'Non-progressors'. Each independent variable was compared
between the 'Progressors' and the 'Non-progressors' using the Student's unpaired't-
test'. Significance throughout is assumed whenp < 0.05 (two-tailed).
The statistical packages 'Statview' (Brain Power Inc., Calabasa, USA) and Statistica
(StatSoft Inc., Tulsa, Oklahoma) were used throughout.
4.4 Results
4.4.1 Progression of nephropathy
4.4.1. i Subjectfollow-up
Nineteen of the 26 subjects who entered the study were followed for a mean of 21
months (range 20-24). Of the remaining seven, two (Cases 3 and 14) died from
cardio-vascular disease within one year, two proceeded rapidly to dialysis, whilst
three completed only 6-12 months of follow-up (Cases 24-26). Both subjects who
started dialysis did so within one year of commencing the study, despite an initial
GFR exceeding 25 ml.min"1 Although both had biopsy proven diabetic
glomerulosclerosis, one (Case 16) had a 'horseshoe kidney' and the other (Case 18) a




Data on renal function in individual subjects are presented in Table 4.5 (overleaf).
The median GFR of all subjects at baseline was 42.6 ml.min"' (range 11.4 - 105.9). In
only one subject (JE) did the GFR exceed 80 ml.min"1. By the end of the study the
GFR had fallen significantly to 30.1 ml.min"1 (8.3 - 58.4), /k0.05. The comparable
creatinine value rose from 225 pmol.L"' (139-351) to 279 pmol.L"' (129 - 567),
/?<0.05. 24-hour protein excretion varied widely at baseline, ranging from 0.22 to
15.7 g (median 2.3 g). The protein excretion did not change significantly during the
follow-up period (see Table 4.5). Notably the two subjects who commenced dialysis
had protein excretions exceeding 10 g.24 hr"'.
4.4.1.Hi Rate ofdecline of GFR
The median decline of GFR for the 19 subjects was 0.48 ml.min."'month"' (range -
0.91 to 3.98). The values for the individual subjects are shown in Table 4.5. Racial
differences existed in the rate of decline ofGFR as shown in Table 4.6 (below).
Caucasian Afro-Caribbean Asian
Nos 8 74
Decline ofGFR 1.12 (1.24)** 0.56 (0.53)* -0.28 (0.5)
Table 4.6 : Rate of decline ofGFR in different racial groups. * p<0.03 v
Asian; ** p=0.06 v Asian. Caucasian v Afro-Caribbean NS.
Despite the small numbers the four Asian subjects declined at a significantly slower
rate than the Afro-Caribbeans, whilst the comparison with Caucasians just fails to
achieve significance.
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Case GFR (mLmin1) Decline of GFR Creatinine Protein excretion Study
(ml.min.1month"1) (pmoLL"1) (g.24-hr"1) period
Start Finish Start Finish Start Finish (months)
1 51.2 56.2 -0.06 142 140 224 702 20
2 57.0 43.0 1.52 139 129 1650 618 21
3* 66.0 - - 159 - 1150 - 8
4 25.2 43.4 -0.91 154 151 805 1020 20
5 105.9 17.4 3.98 154 412 9730 3590 21
6 28.1 17.2 0.48 296 425 6270 6630 21
7 31.5 10.3 1.06 252 421 7440 4600 20
8 43.9 32.1 0.59 263 248 1760 2600 20
9 22.5 21.3 0.09 226 235 308 907 21
10 54.2 58.4 -0.44 186 189 1420 2320 24
11 32.5 36.6 -0.18 191 198 1400 3170 20
12 43.0 16.7 1.14 220 321 1570 4750 24
13 26.7 24.8 0.02 257 286 4930 3290 24
14* 74.5 - - 151 - 1440 - 12
15 26.4 8.3 0.81 351 567 7350 2670 20
16** 34.1 - - 241 - 10890 - 11
17 31.2 19.3 0.48 336 435 4800 1040 24
18** 27.1 - - 337 - 15700 - 7
19 32.6 29.4 0.20 218 275 5010 2530 20
20 77.4 52.4 1.22 159 188 1250 1610 20
21 33.4 21.4 0.40 236 297 2250 478 24
22 41.2 25.9 0.80 302 430 1680 2280 20
23 39.3 25.9 0.55 224 261 1960 957 24
24 11.4 21.3 -0.83 361 282 2290 1460 12
25 63.8 49.5 2.39 165 216 3850 3380 6
26 28.2 30.6 -0.4 286 314 6780 6710 6
Median 34.1 25.9 0.48 224 275 1760 2320
p<0.02 p<0.03 ns
Table 4.5 : Measures of renal function at the start and end of the study in all 26 subjects.
(2 died* and 2 started dialysis**). Cases 24 - 26 were excluded from the analysis (see text)
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The rate of decline of GFR does not correlate with initial GFR when considering all
subjects with a GFR < 100 ml.min"'. If subject 5 is included in this analysis then a
higher baseline GFR is significantly associated with a more rapid fall in GFR.
4.4.2 Clinical parameters and the decline of GFR.
4.4.2.i Characteristics ofsubjects at baseline andfollow-up.
The mean values for the measured variables at baseline and at the final visit for the
19 subjects who completed the study are to be found in Table 4.7. Systolic blood
pressure fell significantly from 162 to 150 mmHg. Both diastolic and mean arterial
blood pressure fall during the study, but in neither case was this significant.
Parameter Baseline End of study Difference Significance
GFR (ml.min"1) 42.3 (20.6) 29.5 (15.0) 12.8 p<0.02
BMI 29 (6) 29 (5) - NS
SBP (mmHg) 162 (30) 150(25) 12 p=0.05
DBP (mmHg) 88(13) 82 (9) 6 NS
MAP (mmHg) 113 (15) 104(11) 9 ^<0.001
HbA,lc 8.0(1.6) 7.4 (2.6) 0.6 NS
Cholesterol (mmol.L"') 7.2 (2.4) 6.0(1.4) 1.2 p<0.01
Triglyceride (mmol.L'1) 3.8(3.4) 2.6(1.4) 1.2 NS
UProtein (g.24hr"') 3.2 (2.8) 2.4(1.7) 0.8 NS
UPO4 22.3 (8.7) 20.2 (8.4) 2.1 NS
UNa 148 (30) 122 (41) 26 J9<0.01
UUrea 346(102) 334 (124) 12 NS
Table 4.7 : Measured variables at baseline and follow-up. Data as mean (SD).
Comparison is by paired 't-test', significance as shown.
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Of the remaining factors only serum cholesterol and 24-hour urine sodium excretion
are significantly different at the end of the study. The reduction in urinary sodium
does not correlate with the drop in blood pressure in individual subjects. Prescribed
anti-hypertensive medication did not change significantly during the study (Table
4.3), although the more frequent clinic attendance may have ensured greater drug
compliance.
4.4.2.U Factors which associate with the decline in GFR.
Univariate regression analysis comparing the decline of GFR with the measured
clinical variables identifies a significant correlation of systolic blood pressure,
diastolic blood pressure and mean arterial pressure with decline of GFR. Also
significantly associated are serum cholesterol and 24-hour protein excretion.
Flowever if Case 5 (JE) is excluded from the analysis (as being an extreme value)
only systolic blood pressure, mean arterial pressure and serum cholesterol remain
significant. This result highlights the influence such a value can have on data
analysis where the numbers studied are small. These data are presented graphically
in Figures 4.2 to 4.4 and summarised in Table A4.2 (appendix).
Forward stepwise regression analysis identifies seven variables with an F to enter
value above 3. Of these systolic blood pressure (p<0.005) and serum cholesterol
(p<0.005) are highly associated with the decline of GFR. Diastolic blood pressure is
also associated, although to a less significant degree (p<0.05). The remaining four
factors, namely 24-hour protein, age, BMI and serum albumin have p values between
0.05 and 0.1. The decline of GFR is related to SBP, DBP and serum cholesterol in
the following regression equation:
Decline ofGFR (ml.min."'month"') = -12.3 + 0.02 SBP + 0.15 DBP + 0.22 cholesterol
These three factors account for 38% of the variability of the decline ofGFR.
94
Rate of decline of EDTA GFR (ml.min.'hiionth"')
Figure 4.2 : Relationship between decline of EDTA GFR and the measured
parameters of age, duration of diabetes, BMI, cGFR, HbA jc and
CaP04 product. Univariate analysis.
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Rate of decline ofEDTA GFR (ml.min."'month"1)
Figure 4.3: Relationship between the decline of EDTA GFR and blood
pressure and serum lipids. Data presented as mean of all







Rate of decline of EDTA GFR (ml.min."'month"')
Figure 4.4 : Relationship between the rate of decline of EDTA GFR and the urinary







Age (years) 63.5 (10.5) 66.0 (9.5) -2.5 NS
Duration ofDM 11.8 (5.2) 14.8 (6.7) -3.0 NS
BMI 29 (4) 29 (7) 0 NS
SBP (mmHg) 167(18) 142(18) 25 p<0.01
DBP (mmHg) 89(11) 82 (7) 7 NS
HbA,c (%) 7.9 (2.7) 7.7(1.4) 0.2 NS
Serum cholesterol 7.6(1.6) 5.5 (1.0) 2.1 p<0.01
Serum triglyceride 3.7(2.5) 2.7(1.6) 1.0 NS
CaP04 3.06 (0.41) 2.93 (0.62) 1.03 NS
24-hr protein 3.78(3.15) 2.46(1.92) 1.32 NS
24-hr phosphate 22.9 (7.5) 20.1 (6.4) 2.8 NS
24-hr sodium 142 (22) 140 (32) 2 NS
24-hr urea 352 (132) 320(100) 32 NS
Decline in GFR 1.22 (1.03) 0.44 (0.43) 0.78 -
Table 4.8 : Measured variables in 'Progressors' and 'Non-progressors' (see text for
definition. The data are presented as mean (SD). Comparison between the
groups is by unpaired 't-test'; significance as shown. Decline in GFR in ml.
min."'month"1
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4.4.2.iHi Differences between the 'Progressors' and the 'Non-Progressors'
The subjects were then divided into two groups, 'Progressors' and 'Non-progressors'
on the basis of decline ofGFR (Table 4.8 preceding page). The mean decline ofGFR
in the 'Progressors' (n=10) was 1.22(1.03) ml.min."'month"1; mean(SD) compared to
-0.04 (0.43) in the 'Non-progressors' (n=9). Of the variables measured only systolic
blood pressure {167(18) vs 142(18) mmHg; /?<0.01} and serum cholesterol {7.6(1.6)
vs 5.5(1.0) mmol.L"1; /?<0.01} were significantly different between the 'Progressors'
and 'Non-progressors'. 24-hour protein excretion was slightly higher, but not
significant, in the 'Progressors' (3.78 v 2.46g; />=ns), whereas HbAlc and BMI were
almost identical in both groups.
4.5 Discussion
4.5.1 General comments
GFR declined at a rate of 0.48 ml.min."'month"1 (equivalent to 5.76 ml.min. 'year"') in
the 19 subjects who completed the two years of follow-up in this prospective study.
This figure is identical to that found by Gall and co-workers (1993), and very similar
to the decline seen for NIDDM subjects in the retrospective analysis presented in
Chapter 2. The range in decline for individual subjects is wide, from -0.91 to 3.98
ml.min."'month"1 (-10.1 to 47.8 ml.min."'year"') a feature common to all studies. The
published series in diabetic subjects in whom progression is assessed by isotope
clearance methods are shown below (Table 4.9 overleaf). These indicate that the
observed decline of GFR was wlOml.min/'year"1, some ten-fold greater than the
natural decline of »1.3ml.min."'year"' (Davies and Shock 1950a; Wesson 1969;
Rowe et al. 1986). The studies in IDDM subjects (Mogensen 1982; Parving et al.
1983; Bjorck et al. 1986) indicate that following the introduction of anti¬
hypertensive treatment there was an «50% reduction in the decline of GFR to levels
currently demonstrated in NIDDM subjects. No data exist on the rate of progression
in untreated NIDDM subjects. The data in treated patients suggest that the limit to
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arresting the decline of GFR may have been reached with the current treatment
strategies. It is not yet certain whether the observed reduction of the rate of decline
can be sustained in the long-term although the findings in this study would suggest
that this may indeed be the case.
Studies based on isotope clearance methods (see Table 4.9) suggest that the rate of
progression of nephropathy is similar in IDDM and NIDDM, although that of
Friedman and Gross (1991) is a clear exception. These authors found no decline of
GFR in six subjects with a baseline GFR of » 60 ml.min'month"1 over a period of six
months. On the basis of this small study and the findings from the study of Fabre and
associates (1982) these authors considered the rate of decline of GFR to be slower in
NIDDM than IDDM. The results of the more recent studies suggest these claims are
unjustified. This subject is discussed at greater length in Section 2.6.1.
A weakness of this prospective study is the short observation period. This was
inevitable given the constraints of time. Mogensen (1992) regarded three isotopically
determined GFR measurements performed over a two year period as the minimum
necessary for the reliable determination of the decline of GFR. Though these criteria
have been met, a longer observation period with more EDTA clearance
measurements would have been desirable. The same author (Mogensen 1976)
however demonstrated that short-term studies could predict long-term decline of
GFR (r=0.96,/?<0.01). Comparing the data from this present study for the 16 subjects
where adequate follow-up data were available (first two years predicted GFR - data
presented in Chapter 2 vs isotope GFR) showed a significant, albeit less strong,
correlation (r=0.62,/><0.01).
The striking feature, however, as demonstrated in the retrospective analysis, is the
minimal progression seen in certain individuals. This observation alone should give
encouragement to those with renal impairment. If the reasons for this slow
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progression can be identified treatment might be better targeted for those who
progress more rapidly.
4.5.2 The factors associated with progression of nephropathy
4.5.2.i Ethnic origin andprogression ofnephropathy
The reason for the higher prevalence of non-Caucasoid subjects entering renal
replacement programmes has exercised many (Grenfell et al. 1988; Pugh et al. 1988;
Cowie et al. 1989; Stephens et al. 1990). Broadly speaking there could be three
explanations - (1) a higher prevalence of diabetes; (2) a higher prevalence of renal
disease in those with diabetes mellitus (often ascribed to hypertensive
nephrosclerosis); or (3) a more rapid progression once nephropathy is established.
This subject is discussed at greater length and referenced in Section 2.6.2. Of the
above this study has examined only the last mentioned and has found no significant
difference in progression between Afro-Caribbean and Caucasian subjects. The
progression if anything was more rapid in the latter and confirms the impression
gained in the retrospective survey (Section 2.4.2). The wide variance and small
numbers studied combine to ensure that these differences are not statistically
significant. That the four Asian subjects decline at a more modest rate than the
Caucasian group may be atypical, though this again is in agreement with the findings
in the retrospective survey.
Generally speaking the studies performed in nephropathy have used surrogate
markers of progression and as demonstrated below (Chapter 5) should be interpreted
with caution. In subjects with nephropathy secondary to essential hypertension, for
example, Rostand and colleagues (1989) recorded black race (unspecified) as being
associated with more rapid progression. Given that all the subjects in this study had a
baseline creatinine of < 135 pmol.L"1 and progression was defined as a rise of > 35
pmol.L"1 the legitimacy of this claim must be questioned. Brazy and Fitzwilliam
(1990) found no racial differences in progression as determined by reciprocal
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creatinine. In a recent study, Cowie (1993) has shown that the time taken from a
serum creatinine of approximately 160 pmol.L"1 to renal replacement is significantly
longer in black compared to white subjects, supporting the above findings. That the
prevalence of renal disease is higher in non-white populations is generally accepted,
although whether such subjects progress more rapidly to ESRD remains contentious.
There are no studies to my knowledge which have examined progression of renal
impairment using isotope clearance in non-white populations.
4.5.2.U Bloodpressure andprogression ofnephropathy
In contrast to the findings reported in Chapter 2, stepwise regression analysis shows
that elevated blood pressure, both systolic and diastolic, is associated with a more
rapid decline of GFR. However, when the group is divided into 'Progressors' and
'Non-progressors' only systolic pressure is significantly different, being higher in the
former. Given that control of blood pressure has an established place in the
management of patients with progressive renal disease it is surprising that not all
studies identify blood pressure as a significant variable.
Systolic, rather than diastolic, blood pressure is emerging as the more significant
factor in the progression of nephropathy, although recently published data from
Rossing and colleagues (1994a) in IDDM subjects suggests the converse. Nielsen
and co-workers (1993a), in 24 normoalbuminuric and 13 microalbuminuric NIDDM
subjects, found a more rapid decline of GFR in those with higher baseline and mean
systolic blood pressure throughout study. These results should be interpreted with
caution since GFR was measured only twice, at the beginning and again at the end of
the study. The same group found no effect of blood pressure in a previous study of
seven proteinuric subjects (Nielsen et al. 1991), perhaps due to the small number of
subjects examined.
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In a retrospective analysis of hypertensive Japanese subjects with NIDDM, Babo and
colleagues (1990) observed a more rapid decline of GFR in those with systolic
hypertension (Table 4.10 overleaf). Hasslacher and associates (1993) and Biesenbach
and associates (1994) also identified systolic blood pressure as an important
determinant of decline of GFR, as did Gall and colleagues (1993). The latter
demonstrated it to be the dominant influence over the decline of GFR. No
association with blood pressure was observed in the other two published prospective
studies in NIDDM {Friedman and Gross (1991); Myers et al. (1995)}.
An increase in urinary albumin excretion has been suggested by some as a marker of
progression of nephropathy (Mogensen 1993), although this is questioned (Lane et
al. 1992; Tsalamandris et al. 1994). Conversely a decrease in albumin excretion is
equated with a reduction in progression of diabetic (Rossing et al. 1994a) and non-
diabetic renal disease (Apperloo et al. 1992). In a six-year follow-up study of 278
NIDDM subjects with varying degrees of protein excretion, Schmitz and colleagues
(1994) observed that progression of UAE was associated with systolic, though not
diastolic, blood pressure. Furthermore when the subjects were divided into
'Progressors' (n=46) and 'Non-progressors' (n=132) on the basis of protein
excretion, the former had higher systolic, but not diastolic, blood pressure.
Unfortunately no assessment of renal function was made to complement these
findings. By contrast Cooper et al. (1988) found no association with blood pressure.
It is argued that a raised UAE precedes the development of hypertension in IDDM
(Mogensen 1993), but that the reverse may be the case for NIDDM (Nelson et al.
1993). In this present study in only three subjects did the diagnosis of hypertension
precede diabetes, although this is most probably an underestimate. In the remainder,
eight years on average elapsed before hypertension was diagnosed. If it is the case, as
has been suggested (Pugh et al. 1993), that diabetic subjects developing hypertension
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attention to the diagnosis and treatment of hypertension will be required. Nelson and
colleagues (1996b) found no association between baseline blood pressure and
subsequent rate of decline of GFR. It is not clear whether anti-hypertensive therapy if
started early, as suggested by Marre and colleagues (1988) and Mathiesen and
colleagues (1991), will have an effect greater than that suggested by short-term
studies.
Understanding of the role of systemic hypertension in progressive renal disease has
been facilitated by studies of animal models. The remnant kidney and diabetes-
induced rat models provide insights into the mechanisms of initiation and
progression of glomerular injury. Micropuncture techniques reveal a compensatory
increase in GFR in the remaining nephrons after 5/6th ablation of renal tissue (Olson
et al. 1979; Hostetter et al. 1981). Amongst various histological sequelae of this
procedure is an increase of mesangial matrix. Steffes and co-workers (1978)
performed a uni-nephrectomy in streptozotocin-induced diabetic rats and found that
the degree of mesangial deposition was greater in these rats compared to control
diabetic animals.
Hostetter and colleagues (1982) showed subsequently that hyperfdtration occurred in
single nephrons in such animals. Also using streptozotocin-induced diabetic animals,
Mauer et al. (1978) clipped one renal artery (Goldblatt model) and demonstrated
increased glomerulosclerosis in the undipped kidney of the hypertensive diabetic
animals compared to contralateral clipped kidney and the control diabetic animals.
Indeed the clipped kidney showed less glomerulosclerosis than seen in these control
animals. Similar findings were observed in a patient with diabetic nephropathy and a
unilateral renal artery stenosis (Berkman and Rifkin 1973). The role of mesangial
matrix expansion is discussed further in Chapter 6.
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The studies of Andersen et al. (1985, 1986) demonstrate the effect of anti¬
hypertensive therapy on glomerulosclerosis and proteinuria in Munich-Wistar rats
who underwent 5/6th renal ablation. Animals treated with the ACE inhibitor
captopril showed a reduction of glomerulosclerosis and proteinuria. In a second
study, triple anti-hypertensive therapy failed to reduce both transcapillary hydraulic
pressure in the nephrons and glomerulosclerosis compared to captopril, despite
comparable systemic blood pressure levels. Similar findings were recorded by Zatz
and coworkers (1986) in diabetes-induced rats.
This study was not designed to examine the benefits of specific anti-hypertensive
agents, although the value of ACEI in diabetic nephropathy is emerging (Lewis et
al. 1993). Only four individuals, two 'Progressors' and two 'Non-progressors' were
not on ACEI at the start of the study. By the end one from each of these groups had
been commenced on that agent. The usage of anti-hypertensive drugs is discussed at
greater length in Chapter 2.
It is no longer the case of whether to use anti-hypertensive therapy and which agent
in diabetic nephropathy. The question is now when to start treatment and at what
level of blood pressure? These remain to be answered but in general a MAP of
approximately 100 mmHg is advocated in microalbuminuric and proteinuric IDDM
subjects (Mogensen et al. 1991). Given the mean blood pressure of the 'Non-
progressors' in this study of 142/82 mmHg, a MAP of 100 mmHg may also be a
reasonable target in NIDDM.
4.5.2.M Proteinuria and the progression ofnephropathy
The relationship of proteinuria to progression of renal disease has been examined at
some length in Chapter 2, both for diabetic and non-diabetic renal disease, and brief
comment only is made here. This present study has identified 24-hour urinary protein
as being associated with progression both for univariate and stepwise regression
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analysis, albeit not statistically significant (p=0.07) in the latter. However when the
groups are subdivided, there is no significant difference between 'Progressors' and
'Non-progressors', although protein excretion is greater in the former. Similar results
were found by Gall and colleagues (ibid). The reasons for the difference between the
retrospective and the prospective studies are not clear. The influence of blood
pressure appears greater in the latter and may as a consequence lessen the importance
of protein excretion. ACEI have been shown to diminish proteinuria and, in theory,
could limit the influence of this factor in multiple regression analysis. The published
studies which show a significant association of proteinuria with progression of
nephropathy are older and, in most cases, retrospective, thus supporting this
suggestion. The protein excretion in the NIDDM group in the retrospective analysis
at 3.4 g.day"1 is little different from the 2.4 g.day"' observed at the end of the
prospective study.
4.5.2.iv Serum lipids and the progression ofnephropathy
A strong association between serum cholesterol and decline of GFR has been
demonstrated in this study both in univariate analysis (r=0.65, /><0.01) and in
stepwise regression. Further, by subdividing the group into 'Progressors' and 'Non-
progressors' the serum cholesterol is found to be significantly higher in the former.
Interest in the role of lipids in progressive renal disease has been rekindled recently
(Moorhead et al. 1982; Klahr and Harris 1989). Whilst there is strong evidence for a
causative association in animal models (French et al. 1976, Kasiske et al. 1985,
Kasiske et al. 1988) and suggestive evidence from in vitro studies (Wheeler et al.
1993), clinical studies are few.
In non-diabetic subjects with proteinuria, Maschio and colleagues (1989) found the
rate of decline ofGFR in subjects with high serum cholesterol and triglyceride levels
to be twice that of subjects with normal lipid levels. In African-American and
Hispanic children with nephrotic syndrome, Ingulli and associates (1991) observed a
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more rapid progression to renal failure in those with higher lipid levels. Most studies
in diabetes have shown no association between lipids and progression of renal
disease. The strongest evidence comes from Mulec and colleagues (1990) and
Krolewski and colleagues (1994). In the former study, primarily designed to compare
two different anti-hypertensive regimens in IDDM subjects, the authors observed a
significant association of decline of GFR with serum cholesterol. When the group
was divided on the basis of serum cholesterol throughout the study, the mean decline
of those with a total cholesterol <7 mmol.L"' was significantly lower at 0.19 ml.min."
'month ', compared to 0.7 ml.min."'month"1 in those with a value >7 mmol.L"1. In
addition baseline cholesterol was significantly associated with decline of GFR. A
similar analysis performed on the participants in this study is shown in Table 4.11,
subdivided on the basis of a serum cholesterol of 6 mmol.L"'.
< 6 mmol.L"1 > 6 mmol.L"1
Subjects 9 10
Decline of GFR 0.04 1.14*
MAP 105 107
24-hour protein 2.05 4.02
Table 4.11 : Decline ofGFR (ml.min."'month"') in subjects with low
and high cholesterol levels. (* p<0.01; MAP, 24 hour protein NS).
This indicates that a significantly slower decline of GFR occurs in those with a
serum cholesterol under 6 mmol.L"1. However whether this is a direct effect or a
consequence of the association between cholesterol and protein excretion (Figure 4.5
overleaf) remains to be seen.
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No association was observed between serum triglyceride and progression in this
study. Others have recorded similar findings (Gall et al. 1993), whereas Hasslacher
and colleagues (1993) did demonstrate triglyceride, but not cholesterol, as a
significant factor determining progression (predicted by Cockcroft-Gault) in
proteinuric NIDDM subjects. Attman and colleagues (1992) also showed levels of
total cholesterol, LDL and HDL cholesterol, and triglyceride to be directly related to
decline of GFR in a cross-sectional study in a study of 24 IDDM subjects.
Apolipoprotein CIII and E levels were significantly higher in subjects with a GFR <
20 ml.min"1.
Published studies examining the effect of lipid-lowering agents in the progression of
renal disease are equally scarce. Two uncontrolled studies, one in nephrotic
syndrome secondary to non-diabetic renal disease (Rabelink et al. 1990) and the
other in NIDDM (Sasaki et al. 1990), using HMG-CoA reductase inhibitors observed
a reduction of albuminuria. The lack of a control group weakens these studies
significantly. In a 12-week randomised placebo-controlled study, Hommel and co¬
workers (1992) found no change ofGFR (baseline 70 ml.min"1) in 10 IDDM subjects
given simvastatin. In a comparable, though longer, study in 18 NIDDM subjects also
using simvastatin Nielsen and colleagues (1993b) drew similar conclusions. Whilst
total and LDL cholesterol were significantly lowered, no significant effect was
demonstrated on GFR and albumin excretion. It should be noted, however that the
mean GFR in the placebo group fell by 8.3 ml.min"1 compared to 0.6 ml.min"1 in the
treated group over the six month period.
The role of lipids (and their treatment) remains to be established in progressive renal
disease. It is important to define whether the current empiric administration of lipid
lowering agents to patients with renal impairment confers benefit to the patient by
slowing disease progression or by protecting against cardiovascular disease and, if
so, at what stage should they be introduced.
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4.5.2.V Glycaemic control andprogression ofnephropathy
This study has demonstrated no association of glycaemic control with decline of
GFR. Furthermore the mean HbAlc is virtually identical in the 'Progressors' and the
'Non-progressors'. Opinion differs as to the effect of glycaemic control on
progression once clinical nephropathy is reached. In an early interventional study in
6 IDDM subjects Viberti and colleagues (1983) demonstrated no statistical benefit
using continuous subcutaneous insulin infusion (CSII) over 24 months on the decline
of GFR. However if the graphic data are examined in 5 cases there is an apparent
arresting of the decline of GFR. By contrast, Nyberg and co-workers (1987) found
better control was associated with slower progression in 21 subjects followed for 30
months. In NIDDM Gall and colleagues (1993) and Hasslacher and colleagues
(1993) found no association of HbAlc with decline in GFR thus supporting the
finding in the present study. It appears likely that improving glycaemic control does
not influence the progression of established nephropathy, although no intervention
studies have been undertaken in this group. It cannot be recommended however that
clinicians ignore glycaemic control once this stage is reached, since to do so may
accelerate other microvascular and macrovascular complications and prejudice the
health of a transplanted kidney were this to be the outcome.
4.5.2.vi Miscellaneous factors andprogression ofnephropathy
Protein intake was not assessed directly in this study. Urea excretion measured here
is a surrogate marker from which protein intake may be derived (Isaksson et al.
1982; Maroni et al. 1985). Neither 24-hour urinary urea nor calculated protein
ingestion was associated with decline of GFR nor did levels differ between
'Progressors' and 'Non-progressors'. Gall and colleagues (1993) and Jameel and
colleagues (1992) also found no association, although small intervention studies in
IDDM have demonstrated benefit (Walker et al. 1989; Zeller et al. 1991). In the
former six subjects followed for 24 months showed a 75% reduction in the rate of
111
decline of GFR on a diet of 0.6 mg.kg."' day"', although the study was not controlled
throughout for blood pressure. However this level of protein restriction is severe and
is unlikely to gain widespread acceptance by the majority.
In the wider context of all renal disease controversy on the benefit of protein
restriction has reigned for sometime. The early clinical studies of El Nahas and
colleagues (1984) (though benefit was shown only for tubulo-interstitial disease),
Rosman and colleagues (1984) and Oldrizzi and colleagues (1985) espoused the
value of reducing dietary protein, conclusions supported by similar studies in the
'Remnant kidney' rat model (Hostetter et al. 1986) and in rats with experimental
diabetes mellitus (Wen et al. 1985; Zatz et al. 1985; Mauer et al. 1989). A meta¬
analysis of low protein diets and progression of renal disease found in favour of
restriction (Fouque et al. 1992), although several studies including that of Williams
and colleagues (1991) demonstrated no benefit from either protein or phosphate
restriction in renal failure of various aetiologies. The recent evidence from the
MDRD study (Klahr et al. 1994) indicating no advantage of protein restriction in
moderate renal impairment (25 to 55 ml.min"1) should spare many from the
deprivations of a low-protein diet. Here 840 subjects with chronic renal disease of
diverse aetiology were subject over a two year period to a standard, low (0.58 g.kg."1
day"1) or very low (0.28 g.kg."'day"') protein diet, depending upon their baseline
GFR. Only in those with severe renal impairment (13 to 24 ml.min"1) did severe
restriction show a modest, non-significant slowing of the rate of decline of GFR.
Thus individuals with diabetic renal disease should no longer be subjected to rigid
protein restriction, although no intervention study exists in NIDDM. The American
Diabetes Association and National Kidney Foundation recommendation is 0.8 g.kg."'
day"' (Consensus Statement).
There is no evidence from this study that serum calcium, phosphate or the CaP04
product is related to the decline of GFR. Unfortunately parathyroid hormone levels
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were not measured, as Massry (1977) and Frohling and colleagues (1989) have
suggested the PTH level may accelerate progression of renal disease. The latter
group considered a "moderately-low" protein diet supplemented with ketoacids
could partially offset the adverse effect of hyperparathyroidism.
Of other putative factors influencing progression smoking behaviour was not
assessed. Stegmayr (1990) and Sawicki and associates (1994) have highlighted the
adverse effects of smoking on progression of nephropathy in retrospective and
prospective studies in IDDM subjects. However the number of subjects progressing
in each study was small and other factors, e.g. glycaemic control and non-statistical
differences in blood pressure may have contributed. In theory smoking may advance
progression by accelerating macrovascular disease. Ritz and colleagues (1991) have
suggested that ischaemic nephropathy secondary to large vessel disease may
accelerate progression in NIDDM subjects. This subject is addressed in Chapter 3.
That renal disease may progress remorselessly to end-stage failure despite removal
of the original insult argues for continuing tissue destruction at the cellular level. The
detail of this process remains to be worked out for many renal diseases including
diabetes mellitus. This subject is considered in greater detail in the Chapter 6 along




In this prospective study of progression of nephropathy in NIDDM 19 of the 26
subjects who entered the study were followed for an average of 20 months.
• The median rate of decline ofGFR for all subjects was 0.48 ml.min."1month"1.
• Despite the small numbers the rate of decline was slower in Asians (-0.28
ml.min.'month"1) compared to either Afro-Caribbeans (0.56 ml.min."1 month"1
p<0.03) or Caucasians (1.12 ml.min. 'month"1; p=0.06).
• In a univariate analysis systolic and diastolic blood pressure, serum
cholesterol and 24-hour urinary protein were shown to be significantly
associated with decline in GFR in all subjects(all p<0.01). Stepwise
regression analysis identified SBP and serum cholesterol as the most
important factors (p<0.005).
• When the group was subdivided equally into 'Progressors' and 'Non-
progressors' systolic blood pressure (p<0.01) and serum cholesterol (p<0.01)
were the only measured variables significantly different between the two
groups.
• The rate of decline of GFR in NIDDM was virtually identical in the
retrospective and prospective studies, yet a clearer association of blood
pressure and serum cholesterol emerged in the latter.
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Chapter 5
Assessment of the methods ofmonitoring progression
of renal impairment in NIDDM
5.1 Introduction
A reliable indicator of progression is a prerequisite for the monitoring of a chronic
disease and for the evaluation of any therapeutic intervention. To be effective, such
an indicator should be accurate, precise and convenient to measure (Levey 1989).
Inulin clearance has been the 'gold-standard' for renal disease since its development
(Shannon and Smith 1935; Smith 1951), however it is not only complicated to
perform and therefore impractical for clinical use but inulin is limited in its
availability and technically difficult to measure (Levey 1990). As a consequence
isotopic methods of measuring glomerular filtration rates have evolved with 51Cr
ethylenediaminetetra-acetic acid (EDTA) being the most widely used in Europe
(Brochner-Mortensen 1985). These too have drawbacks. They are also time-
consuming to perform, involve exposure of the patient to radiation (with the
exposure increasing as renal function worsens), and are expensive. Thus they are
unlikely to be widely adopted in routine clinical practice, but will remain applicable
for clinical research studies.
Prior to the establishment of inulin and isotopic clearance methods clinicians relied
on either plasma clearance of creatinine (Miller and Winkler 1938) or serum
creatinine to monitor progression of renal disease. The latter is not a reliable measure
of renal function, given that 70% of functioning renal tissue may be lost before
creatinine rises (Brochner-Mortensen 1985; Mitch 1986). The measurement of
creatinine clearance is the most widely used assessment of glomerular filtration in
clinical practice (Cameron 1992b), although its validity is also questioned. Those
who discredit it do so largely on the grounds of lack of repeatability (Bauer et al.
1982; Payne 1986). Differences in diet and muscle mass, incorrect urine collection
and lack of precision at low GFR serve to reduce the accuracy of this measurement.
Despite these reservations Gabriel (Editorial, 1986) concluded that 'creatinine
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clearance with urine collected under control conditions remains the simplest,
cheapest and most useful measure of renal function'.
In 1976 Mitch and colleagues suggested that the reciprocal of serum creatinine
plotted against time provided a simple method for monitoring the progression of
chronic renal impairment. Whilst this approach has been criticised (Modena et al.
1991) as over 20% of subjects do not show a linear decline of GFR (for further
discussion see chapter 2), it is still widely employed in clinical practice. In the same
year that Mitch and colleagues demonstrated the predictive value of reciprocal
creatinine, Cockcroft and Gault (1976) published their formula for estimating GFR
based on serum creatinine, corrected for gender, age and body weight. This surrogate
marker has recently been shown to estimate GFR accurately (Sampson and Drury
1992) and the decline of GFR (Rossing et al. 1994b) when compared to isotopic
methods in IDDM subjects with proteinuria and GFR <100 ml.min"'. The validity of
GFR determined by the Cockcroft-Gault formula has not, to our knowledge, been
tested in NIDDM subjects with nephropathy.
This study compares several measures of renal function namely reciprocal serum
creatinine, creatinine clearance and estimated GFR (Cockcroft-Gault) with true GFR
as measured by 5lCr EDTA in NIDDM subjects with renal impairment. The specific
aims of this study were as follows:
5.2 Aims
• To compare 5lCr EDTA GFR with surrogate measures of GFR, namely
reciprocal creatinine, creatinine clearance and GFR estimated by the
Cockcroft-Gault formula in a cohort of patients with NIDDM and diabetic
nephropathy with renal impairment.
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• To determine whether age, body mass and racial origin affect the validity of
GFR, estimated by Cockcroft-Gault, when compared to true GFR.
• To determine whether the Cockcroft-Gault formula can be used to provide a
reliable index of decline ofGFR.
5.3 Study design and data analysis
5.3.1 Patients and methods.
The patients studied were the participants in the prospective study described in
Chapter 4. An additional five subjects who had a single EDTA clearance carried out
but who did not subsequently enter the study are included. These NIDDM subjects
also fulfilled the criteria for diabetic nephropathy. The measurement of 5lCr EDTA
has previously been described (Chapter 4). Creatinine clearance was measured on a
24-hour urine sample collected the day prior to attendance for the EDTA GFR.
Serum creatinine was sampled with the first (2 hour) sample drawn during the
measurement of EDTA clearance. Estimated GFR (cGFR) was calculated from the
serum creatinine using the formula of Cockcroft-Gault (1976) as follows:
(140-age{years} x body weight {kg} x KJ serum creatinine (pmol.L"1),
where K = 1.23 for men and 1.05 for women.
As previously, estimated GFR is denoted by cGFR and EDTA clearance by EDTA
GFR.
5.3.2 Data analysis
EDTA GFR was compared to estimated GFR and creatinine clearance for all
subjects, and by racial origin, gender and body mass index. Mean values were
compared by Students paired 't-test'. Data for all subjects were examined for
agreement by Pearson's univariate linear regression analysis and the slope and 'y'
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intercept determined. Similar analyses were also carried out comparing the decline of
GFR as determined by EDTA clearance and creatinine clearance, estimated GFR and
reciprocal creatinine. A better measure of agreement is obtained by plotting the
average of the two methods (horizontal axis) against the difference between the two
methods (vertical axis), (Bland and Altman 1986). Limits of agreement were drawn
on the same graph as mean ±2SD of the difference. What represents acceptable limits
to the degree of agreement is a matter of personal judgement. All the calculations
were performed using the Statview software package (BrainPower Inc., Casablasas,
CA, USA). Data are given as mean ±SD and a p value of <0.05 was considered
significant.
5.4 Results
Data were available for 72 patient episodes, comprising 19 subjects measured thrice,
3 subjects twice and four subjects once in the study with the additional five
individuals who did not subsequently enter the study measured once only. Only one
subject had an EDTA GFR above 100 ml.min"1 and this value was excluded from
further analysis.
cGFR EDTA GFR Significance
Afro-Caribbean (n=28) 32.9(18.5) 39.8 (15.7) p<0.02
Asian (n=14) 32.7(10.6) 35.9(13.6) NS
Caucasian (n=29) 31.5 (16.7) 33.6 (21.3) NS
All subjects 32.3 (16.3) 36.5 (17.8) ^<0.01
Key : NS = not significant
Table 5.1: Comparison of estimated GFR (cGFR) and EDTA clearance for
all measurements ofGFR, subdivided by racial group.
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The mean EDTA GFR for the 71 measurements was 36.5 (17.8) ml.min"1 {mean
(SD)} compared to 32.3 (16.3) for cGFR giving a significantly higher EDTA GFR of
4.2 ml.min1 on average (Table 5.1 preceding page). The difference is greatest in
Afro-Caribbean subjects where EDTA GFR exceeds cGFR by 6.9 ml.min"1 (p<0.02).
Although EDTA GFR is on average higher for Asian and Caucasian subjects the
differences are not significant.
The values for EDTA GFR and cGFR measured simultaneously are plotted for all
subjects in Figure 5.1 (overleaf) and are significantly associated (r=0.77; /kO.OOI).
Figure 5.2 (overleaf) shows the same analysis subdivided by race with the r values
ranging from 0.80 to 0.85. The data for reciprocal creatinine (r=0.73; /?<0.001) and
creatinine clearance (r=0.82; /><0.001) against EDTA GFR are plotted on Figures 5.3
and 5.4 respectively (overleaf). Figure 5.5 (overleaf) shows cGFR plotted against
creatinine clearance, indicating these also are associated (r=0.78; /kO.OOI). No
improvement in the degree of correlation follows correcting the predicted GFR data
for surface area (corrected to 1.73 m2), although the data lie closer to the identity line
(see Figure A5.1 in the appendix). Figure 5.6 (overleaf) shows the same data
subdivided by gender. All the observations on the female subjects have a EDTA
GFR < 45 ml.min"1. Racial differences exist in the degree of correlation between the
various measures of renal function, although these differences are, not surprisingly,
slight (Table 5.2 - see page 129). Somewhat unexpectedly creatinine clearance
appears more closely correlated with EDTA GFR than either reciprocal creatinine or
cGFR, although the data are more widely scattered. Regression equations comparing
the different measures of renal function in the racial groups are given in the appendix
(Table A5.1).
The influence of gender, body weight and serum creatinine on the degree of
correlation between the measures of renal function is shown in Table A5.2 in the




















Figure 5.1: Relationship between the simultaneously measured plasma clearance of
51Cr EDTA and glomerular filtration rate predicted from the Cockcroft-
Gault formula for all subjects (n=71 obsevations; y = 0.82x+ 10.2;
r=0.78; p<0.0001). The line of identity (dashed) is indicated.
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Figure 5.2 : Relationship between the simultaneously measured plasma
clearance of 51Cr EDTA and glomerular filtration rate pre¬
dicted by the Cockcroft-Gault (cGFR) formula subdivided


























0 20 40 60 80
EDTA Clearance (ml.min"1)
Figure 5.3 : Relationship between simultaneously measured plasma clearance
of 51Cr EDTA and the reciprocal of serum creatinine for all subjects
(n=71 observations; y = 0.78x + 1.35; r=0.74;p<0.0001). The line of
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Figure 5.4 : Relationship between simultaneously measured plasma clearance
of 51CrEDTA and endogenously measured creatinine clearance
in all subjects (n=71 observations; y=0.79x + 6.8; r=0.82; p<0.0001).




Figure 5.5 : Relationship between simultaneously measured endogenous
creatinine clearance and glomerular filtration rate predicted
from the Cockcroft-Gault formula (cGFR) in all subjects
(n=71 observations; y = 0.93x + 7.6; r=0.78; p<0.0001). The
line of identity is denoted by the dashed line.
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Figure 5.6 : Relationship between simultaneously measured plasma
clearance of 51CrEDTA and glomerular filtration rate
predicted from the Cockcroft-Gault formula. Gender as















































mean of estimated GFR and EDTA GFR
(ml.min"1)
Figure 5.7: Difference between EDTA clearance (EDTA GFR) and GFR
estimated by the Cockcroft-Gault formula (cGFR) vs mean of
the two methods for all observations (n=71). The mean and SD
as shown. Bland-Altman plot. Individual graphs are shown in
Figure A5.2 (appendix).
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Figure 5.8 : Relationship between the rate of decline of glomerular filtration
rate as measured by EDTA clearance and that estimated by the
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Figure 5.9 : Difference between the rate of change in measured GFR
(EDTA clearance) and GFR predicted from Cockcroft-Gault
(calculated GFR) vs mean of the two methods. Regression
line shown (r=0.84; pcO.OOl)
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cGFRvsEDTA1/S vsEDTACrClvscGFRvsCrCl
Afro-Caribbean-0.85=761. 7 Asianr=0.8456931 Caucasianr=0.8037 Totalr=0.78382
Key:Sc=serumcr atinine;EDTAclearancC Cltini el anc Table5.2:Correlationm rixbetweetheasur sfnalfunctionidifferentracigroup
studied. For subjects in excess of 80 kg reciprocal creatinine and creatinine clearance
agree more closely with EDTA GFR than cGFR. The latter measure is undoubtedly
biased by the weight correction. The correlation of cGFR with EDTA GFR is
surprisingly poor where creatinine exceeds 300 pmol.L"1.
The data can be examined in another way. The Bland-Altman plot (Bland and
Altman 1986) demonstrates the agreement rather than the strength of the association
(denoted as r) between two variables. Such a plot comparing cGFR against EDTA
GFR is presented in Figure 5.7 (above). This shows that the agreement between the
two methods is weaker at the higher GFR measurements, where the Cockcroft-Gault
underestimates true GFR. Figure A5.2 in the appendix shows this to be the case for
Afro-Caribbean (r=0.3; p=NS) and Asian subjects (r=0.44; p=NS) but not for
Caucasians.
The rate of decline ofEDTA GFR against cGFR for the subjects studied in Chapter 4
is plotted in Figure 5.8 (above). The relatively good correlation between the methods
(r=0.78; /?<0.001) is weighted by one subject with a marked decline of GFR. When
the same data are plotted by the Bland-Altman method (Figure 5.9 above) an
unexpected result is obtained. This suggests that the faster the GFR declines the
greater the under-estimate as determined by cGFR (r=0.84; /kO.OOI). There are too
few data to examine racial effects.
5.5 Discussion
5.5.1 Is predicted GFR a suitable alternative to EDTA clearance ?
This study has demonstrated a significant correlation between isotopically
determined GFR (EDTA clearance) and GFR predicted by the Cockcroft-Gault
formula in NIDDM subjects with diabetic nephropathy where the GFR is < 80
ml.min"1. The degree of association, however, is weaker than that observed in two
comparable studies in IDDM subjects with nephropathy, though both were almost
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exclusively in Caucasian subjects (Sampson and Drury 1992; Rossing et al. 1994b).
In the study of Sampson and Drury, the authors found a strong correlation between
predicted GFR (Cockcroft-Gault) and true GFR (EDTA clearance) in 20 subjects.
The correlation was improved by correcting cGFR for surface area. No such finding
was observed in this study. Although Figure A5.1 (in appendix) shows that
correction for surface area brings the data closer to the identity line no improvement
is seen in the degree of association (r=0.76 vs 0.78). The agreement between paired
observations in Sampson and Drury's subjects was strengthened by the exclusion of
GFR measurements >100 ml.min"1. In a more recent study in IDDM subjects,
Rossing and colleagues (1994b) observed a correlation of 0.91 between measured
GFR (EDTA clearance) and estimated GFR (Cockcroft-Gault) in 43 subjects, with a
GFR ranging from 35 to 150 ml.min"1. Others do not observe such strong
associations. Gross and colleagues (1993) performed 96 assessments in 43
normoalbuminuric IDDM subjects and 61 assessments in 55 normoalbuminuric
NIDDM subjects and compared them to GFR estimated by Cockcroft-Gault and
found a significant, though relatively poor, correlation between the measures (r=0.53
and r=0.56 for IDDM and NIDDM respectively). The degree of discrepancy between
these measurements may reflect the high GFR of many subjects. Similar findings
were observed by Waz and colleagues (1993) in 72 children with IDDM. They found
a poor correlation (r=-0.46; /k0.05) between isotopically measured GFR (l25I-
iothalamate) and predicted GFR (Cockcroft-Gault). For all levels of GFR, cGFR
consistently underestimated true GFR and this underestimate increased as GFR
increased. This is supported by the findings of Trollfors and colleagues (1987) who
demonstrated a stronger association between EDTA clearance and predicted GFR,
where GFR was in the range 20 to 90 ml.min"'. In their study EDTA GFR was
consistently 10 ml.min"1 greater than cGFR. In our present study the difference
between the two measures was not so marked and averaged 3-4 ml.min"'. Only in the
Afro-Caribbean group was this difference significant. Lemann and colleagues (1990)
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found a positive correlation (r=0.82) between iothalamate clearance and predicted
GFR (Cockcroft-Gault) in 136 IDDM subjects over a wide range of GFR
measurements (16 to 175 ml.min"1) as part of a prospective study of angiotensin
converting enzyme inhibition in diabetic nephropathy.
The Bland-Altman plot (Figure 5.7 above) indicates a good measure of agreement
between true and predicted GFR, particularly where GFR is below 50 ml.min"1. As
GFR increases the discrepancy between true GFR and predicted GFR becomes more
pronounced, a finding common to many studies (Sampson and Drury 1992; Trollfors
et al. 1987; Rossing et al. 1994b). This discrepancy is evident in Asian and Afro-
Caribbean subjects (Figure A5.2 in appendix). It may, however, be a gender rather
than a racial effect since all the Asian subjects and the Afro-Caribbean subjects with
a GFR > 40 ml.min"1 were male. Against this hypothesis is that this feature was not
seen in Caucasian males.
The poor correlation between cGFR and EDTA GFR for females (see Table A5.2 in
appendix) almost certainly reflects the small number of subjects studied, especially
since three of the observations were in one woman whose weight exceeded 120 kg.
There is no theoretical reason why there should be a gender difference. Somewhat
surprisingly a weaker correlation is observed in subjects with a serum creatinine
>300|amol.L"' (Table A5.2). This is contrary to what would be expected given the
greater degree of agreement between GFR, predicted from Cockcroft-Gault, and
EDTA GFR as GFR worsens as shown in Figure 5.7 (above). Again this may reflect
the small numbers in this group. That weight influences the degree of association
between predicted and measured GFR is of no surprise. However the correlation is
not improved by correcting the data for surface area. Rolin and colleagues (1984)
found that renal function, predicted by Cockcroft-Gault, was inaccurate in the elderly
and very obese in a study of 500 paired observations; although the prediction in this
case was improved by correcting for surface area. Similar observations were made by
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Sawyer and colleagues (1982), leading Gault and colleagues (1992) to recommend
adjusting all predicted GFR measurements to ideal weight to correct for obesity,
oedema and muscle wasting.
The comparison of the decline of GFR as measured by EDTA clearance and
predicted GFR is shown in Figure 5.8 (above). Interpretation of the results should be
cautious due to the influence on the results of the outlier with the most rapid decline
of GFR. Furthermore, as Rossing and colleagues (1994b) argue, reduced precision of
the results occurs where follow-up is less than 3 years. This study has only two years
of data. The observation that the more rapid the decline of GFR the greater cGFR
underestimates the decline as measured by EDTA clearance (Bland-Altman plot) is
puzzling (Figure 5.9 above). There is no obvious explanation for this finding. Whilst
serum creatinine may take time to stabilise if perturbed this would not be expected
on this timescale. Mitch and Walser (1978) have shown that it takes urine creatinine
approximately three weeks to stabilise after a change in muscle mass. This finding
underlines the importance of using EDTA clearance to measure GFR, where the loss
of function is marked.
5.5.2 Is there a role for serum creatinine ?
Serum creatinine is the measure of renal function most commonly performed in the
clinic, and is used directly or indirectly by many as both an indicator of (dys)function
and serially as a marker of progression. However serum creatinine is very insensitive
in the detection of early renal impairment and as such is of little value (Brochner-
Mortensen 1985; Levey et al. 1988). It is equally insensitive for monitoring
progression at least in the early stages of diabetic renal disease (Parving et al. 1985;
Viberti et al. 1987b). This is due largely to the day-to-day variation of serum
creatinine and to enhanced tubular secretion of creatinine which compensates for
reduced filtration at this stage. Serum creatinine may also change throughout the day
(Sirota et al. 1950).
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Reciprocal serum creatinine has been used to monitor progression and to predict the
time to renal replacement therapy in non-diabetic (Mitch et al. 1976) and diabetic
subjects (Jones et al. 1979) with chronic renal impairment. Such measures rely on the
decline of GFR being linear, although this often not the case. Few studies compare
reciprocal creatinine against isotopically-measured GFR. Those that do record
broadly similar experiences. This study found an all subject correlation between
reciprocal creatinine and EDTA clearance of 0.77 (slightly stronger in Asians and
Afro-Caribbeans), whilst Norden and colleagues (1987) observed a similar
association (r=0.81) in 50 IDDM subjects measured on a total of 128 occasions.
Although the degree of association was fairly strong for the group, GFR could not be
predicted in individual subjects from serum creatinine. A poorer correlation (r=0.63)
was found by Lemann and colleagues (1990) in 136 subjects. Gretz and colleagues
(1983) concluded that reciprocal creatinine was a more reliable indicator of
progression where serum creatinine exceeded 240 pmol.L"1. By contrast Walser and
colleagues (1989) who studied progression in 17 subjects with severe renal
impairment due to a variety of diseases concluded that the use of reciprocal
creatinine gave false readings in 40% of cases. Based on a number of assumptions
and the work of Steinman and colleagues (1989), Davies and Shock (1950b) and
Brochner-Mortensen and Rodbro (1976), Levey (1990) argues that serum creatinine
(and by inference GFR derived from creatinine) is a more precise measure of renal
function where GFR < 50 ml.min"1 whilst the converse is true where renal function is
normal. Unfortunately the lack of agreement between reciprocal creatinine and
measured GFR, due to variability of creatinine production, secretion and extrarenal
clearance in individual subjects reduces the value of inverse creatinine as a marker of
progression.
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5.5.3 What of endogenous creatinine clearance ?
There are several practical reasons why creatinine clearance may not be the ideal
measure of renal function in subjects with renal insufficiency, particularly those with
diabetic nephropathy. It is reliant on accurately-performed urine collection, which
may be not be feasible due to diabetic cystopathy (Frimodt-Moller 1980). Whilst the
subjects in this present study were not routinely assessed for autonomic neuropathy
nor specifically for bladder emptying, all had renal and bladder ultrasound
examination. None had a residual urine volume in excess of 50 ml. The subjects
studied here were familiar with 24-hour urine collections. Consecutive 24-hour urine
collections, as advocated by some (Brochner-Mortensen and Rodbro 1976; Wibell
and Bjorsell-Ostling 1973), were not performed. Even supposedly 'reliable' subjects
may have a wide coefficient of variation ofmeasurement (up to 22%) on consecutive
samples over a one month period (Edwards et al. 1969). Furthermore urine
collections are less likely to be accurate in the elderly (Goldberg and Finkelstein
1987). Despite these reservations a significant association (r=0.82; p<0.001) was
observed between EDTA GFR and endogenous creatinine clearance (Figure 5.4
above) although the scatter of paired observations was wide. A similar association
(r=0.70) was observed by Lemann and colleagues (1990) in 136 IDDM subjects with
a creatinine <221 pmol.L"1, although again the degree of scatter was wide.
Endogenous creatinine clearance overestimates EDTA clearance due to tubular
secretion of creatinine, the difference increasing with progression of renal disease
(Miller et al. 1952; Carrie et al. 1980; Shemesh et al. 1985; Norden et al. 1987). In
most studies this is in the order of 10-15 ml.min"1, although there was surprisingly no
significant difference in this study (Figure 5.4 above). Heavy proteinuria has been
found to significantly increase endogenous creatinine clearance when compared to
measured GFR (Brod and Sirota 1948; Shemesh et al. 1985). There was no evidence
of this in this study (see Figure A5.3 in appendix). Friedman et al. (1991) advocated
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abandoning the 24-hour urine collection for assessing renal function based on their
finding of a poor correlation between endogenous creatinine clearance and EDTA
clearance in 30 diabetic subjects.
Guillausseau and colleagues (1988) compared endogenous creatinine clearance
against GFR derived from serum creatinine in 33 IDDM and NIDDM subjects with a
serum creatinine <130 pmol.L"1 and surprisingly concluded that such methods were
suitable for routine clinical practice. A reasonable correlation was obtained between
derived GFR (several methods) and endogenous creatinine clearance (r=0.73-0.75;
/?<0.001) despite wide coefficients of variation for creatinine clearance (28%) and
estimated GFR (17%) on simultaneous samples taken on consecutive days. A
stronger association between estimated GFR and creatinine clearance was observed
in this study (r=0.78; /?<0.001) with less scatter of the data points than the other
comparisons (Figures 5.5 cf. 5.2 - 5.4 above). In an analysis of ten published studies
(that of Guillausseau and colleagues was not included) comparing endogenous
creatinine clearance to cGFR, Gault and colleagues (1992) found a mean correlation
coefficient of 0.83 (range 0.60 - 0.95) between these measures. The number of paired
observations ranged from 28 to 722. The difficulties inherent in accurate 24-hour
collections in elderly patients with diabetes mellitus probably precludes its use as a
reliable marker of progression, although there may be a role in obese individuals
(Table A5.2 in appendix).
5.5.4 Isotopic methods of measuring GFR - can they be relied upon ?
The drawbacks to using isotopic methods for measuring GFR have already been
alluded to (see Introduction to this chapter). Despite these concerns they remain
central to the monitoring of GFR progression in research studies and are advocated
for clinical practice. In Europe the single injection technique, using 5lCr EDTA
(Brochner-Mogensen et al. 1985-6) is the most widely used. Due to extra-renal
clearance plasma clearance overestimates renal clearance by 3-5% (Brochner-
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Mortensen, Giese and Rossing 1969). In effect this means 4 ml.min"1 with normal
renal function and 0.5 to 1 ml.min"1 where renal function is significantly impaired
(Jagenburg et al. 1978; Brochner-Mortcnsen and Freund 1981). This discrepancy is
probably of no clinical importance since most studies demonstrate that inulin
clearance exceeds the renal clearance of isotopes (5% of chelate is reabsorbed by the
tubule) (details see Brochner-Mortensen 1985). The programme used to calculate
EDTA clearance in this study corrected for this discrepancy in inulin clearance.
The accuracy of GFR determination using isotopes depends upon a constant rate of
clearance over the sampling period. However plasma clearance of the isotope may be
biphasic thus making calculation of clearance difficult (Mitch 1986). Furthermore
where renal function is severely impaired or in the presence of significant oedema
with or without ascites, the time to achieve a steady state may exceed the normal
sampling period (Maisey et al. 1969; Manz et al. 1977; Brochner-Mortensen and
Freund 1981). No allowance was made for this in the present study which may
account for the large percentage error (up to 12.6%) seen in a small number of
subjects with more severe renal impairment. The development of oedema as often
seen in NIDDM subjects approaching renal replacement therapy would also be
expected to lead to inaccuracies in predicted GFR.
It is tacitly assumed that a prime objective of monitoring the progression of renal
disease is to define with accuracy the point at which renal replacement will be
needed. Such end-points are determined not by absolute GFR levels or by serum
creatinine, but rather by symptoms and the personal judgement of the supervising
physician. This limits the need for a precise and accurate measure of GFR. The
accurate monitoring of GFR by isotopic methods is helpful in determining benefit
from intervention (e.g. Parving et al. 1987) but may be less valid for the individual in
the clinic. The greatest value is to identify the individual in whom there is a poor
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correlation between serum creatinine and true GFR and who exhibits a greater than
average decline ofGFR.
5.6 Concluding remarks
• Glomerular filtration rate predicted by the Cockcroft-Gault formula is
significantly associated with EDTA clearance (r=0.79; p<0.0001). The
correlation is increased where EDTA clearance is < 50 ml.min"1.
• Predicted GFR underestimates EDTA clearance on average by approximately
4 ml.min1. This underestimate is significant in Afro-Caribbean subjects
(p<0.02), but not in Caucasian or Asian subjects.
• Reciprocal serum creatinine and endogenous creatinine clearance are
similarly correlated (r values, 0.74 and 0.82 resp.; both p<0.0001) with
EDTA clearance in all subjects.
• The measurement of endogenous creatinine clearance may have a role in
monitoring progression in obese subjects.
• The more rapid the rate of decline of EDTA clearance the greater the
discrepancy between the rate of decline measured by EDTA clearance and
that by predicted GFR.
• Predicted GFR may be valuable to monitor progression in certain individuals
but is probably too imprecise to be applied universally.
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Chapter 6
Serum and urinary type IV collagen and mixed laminin




Histological examination of renal tissue from subjects with progressive renal disease
reveals a variety of changes in both the glomerulus and tubule. These include tubule
atrophy, capillary closure, cell infiltration and expansion of the extracellular matrix.
Although not exclusive to diabetes mellitus, basement membrane thickening (BMT)
and expansion of the mesangium characterise this condition.
BMT was first demonstrated in diabetes mellitus in the retinal epithelium
(Friedenwald 1950). Detailed analysis by 0sterby (1975) demonstrated similar
appearances in the glomerular basement membrane (GBM) and by showing the
thickening developed some 12 to 24 months after diagnosis refuted the previously
held view that these changes preceded, or coincided with, the onset of diabetes.
Observations that the GBM increased in thickness with the duration of diabetes
(Lazarow 1969) were not sustained upon closer examination (Mauer et al. 1984). The
latter group found that the volume of mesangial matrix, but not basement membrane
thickening, correlated with clinical measures of progressive renal disease including
hypertension, protein excretion and diminished glomerular filtration rate in insulin-
dependent diabetic individuals.
6.1.2 The composition and function of extracellular matrix
The extracellular matrix is composed of the basement membrane and the mesangium.
The mesangium forms the interstitial portion of the glomerular lobule and comprises
the mesangial cells and associated matrix. The mesangial cells not only contribute to
the synthesis of the mesangial matrix but also play an important role in the
remodelling of the basement membrane (Striker et al 1989). Type IV collagen is the
principal constituent of the mesangial matrix and together with laminin and heparan
sulphate proteoglycans is synthesised by visceral epithelial cells also known as
podocytes (Abrahamson et al. 1987). Both resident and circulating (monocytes)
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macrophages and lymphocytes are found within the mesangium and may contribute
to progressive glomerulo-sclerosis either by degradation of collagen within the
mesangium (Nathan 1987) or by promoting collagen synthesis (Klahr et al. 1988b).
A variety of substances, including platelet-derived growth factor (Williams 1986),
Interleukin I (Werber et al. 1987) and transforming growth factor p (Roberts et al.
1992) are known to stimulate the production of collagen by mesangial cells and
fibroblasts.
The principal components of the GBM, as in the mesangium, are glycoproteins,
collagens and proteoglycans; specifically type IV collagen, laminin and heparan
sulphate proteoglycans. Other minor components include nidogen, also termed
entactin (Carlin et al. 1981), fibronectin (Courtoy et al. 1982) and amyloid P-
component (Dyck et al. 1980) with doubtless others still to be identified. The
basement membrane is a specialised form of extracellular matrix in which the above
macromolecules self-assemble to produce discrete laminated structures, with the
main framework provided by type IV collagen (Kefalides 1973; Timpl et al. 1980).
Monomeric type IV collagen is a 400 nm triple helical structure with two non-
collagenous domains, a C-terminal globular domain (NCI) and the N terminal end
(7S) (Trueb et al. 1982). These monomers self assemble by forming central
tetrameric structures that resemble 'chicken-wire', based on the alignment of the 7S
terminals of four monomers (Yurchenco and Furthmayr 1984). The NCI ends join to
form dimers as indicated in Figure 6.1 (overleaf). The full complexity of type IV
collagen is only now emerging. Originally conceived as formed from two distinct
alpha chains ({alpha 1 (IV)2} and {alpha2 (IV)1}), three further chains (alpha 3 to 5
(IV)}have now been added (Weber 1992). In addition to providing structural support
type IV collagen also provides a matrix for cell adhesion (Grant et al. 1990) and







Figure6.1:Monom lic,dime icandtetramerifo sfypIVcollagen(sche at c representation).Thtri lehelic lelement(TH)isthoughbantiit ofintactcollagen.NC=non-colla enousdom i .
(Weber 1992). Type IV collagen is found almost exclusively within the lamina densa
(Laurie et al. 1984).
Laminin, the principal glycoprotein in the basement membrane, is composed of three
polypeptide chains, connected by disulphide bonds to type IV collagen, nidogen and
heparan sulphate proteoglycans. Whilst intact laminin is yet to be extracted from
normal tissue (Timpl and Dziacek 1986) it is easily obtained from tumour tissue and
the principal laminin fragments, LP1 and LP2, are readily measurable in serum
(Risteli et al. 1981). Laminin is thought to act as a bridge between cells, e.g.
glomerular podocytes, and the basement membrane (Fukatsu et al. 1988) and as a
link between the various macromolecules, e.g. type IV collagen, etc. In addition it
also has a modulating effect on cell behaviour (Kleinmann et al. 1985). In contrast to
type IV collagen it is located principally within the lamina rara (Madri et al. 1980).
6.1.3 Localisation of type IV collagen and laminin in diabetic nephropathy
Immunohistochemical analysis of renal tissue from those with diabetic nephropathy
and animal models confirm the localisation of type IV collagen in the basement
membrane and mesangial matrix, particularly the nodular lesions, of the glomerulus.
Falk and colleagues (1983), using a semi-quantitative method examined, expansion
of basement membrane constituents in renal biopsies from IDDM subjects and found
that type IV collagen was increased in both the mesangium and the GBM in the early
stages of nephropathy, but was decreased in the late stages. In contrast the level of
collagen remained high in the tubular basement membrane (TBM) throughout all
stages of nephropathy. Bendayan (1985), using a protein A-gold staining technique
in diabetic rats confirmed the findings of Falk and colleagues (ibid) that collagen was
deposited in the sub-endothelial region of the GBM. Kim and associates (1991) have
recently suggested that the collagen components differ in the mesangium and GBM
in diabetic nephropathy. They localised the 'classical' collagen antigens (a, and a2) to
the mesangial matrix (and to a lesser degree the GBM), whereas the 'M28' antigens
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(including Goodpasture's) and the Alport antigen were confined to the GBM.
Furthermore with progressive glomerular sclerosis they observed a loss of the
'classical collagen' antigens in the glomerulus, whereas the M28 and Alport's
antigens persisted, echoing the findings of Falk and colleagues (1983) and
Shimomura and Spiro (1987). The differential expression of these antigens in
diabetic nephropathy closely resembles that found in Alport's nephritis and has also
been described in normal renal tissue (Butkowski et al. 1989).
Scheinman and associates (1980) observed laminin in the mesangium and both the
sub-endothelial and sub-epithelial surfaces of the GBM. As they had shown for
collagen, Falk and colleagues (1983) found the amount of laminin increased in the
mesangium and GBM early in the course of nephropathy but decreased in the latter
stages and again constantly increased throughout the disease in the TBM. A similar
reduction of laminin content in the GBM with disease progression was observed by
Shimomura and Spiro (ibid).
6.1.4 Measurement of extracellular matrix components in disease states
Once reliable quantitative assays became available to measure type IV collagen and
laminin (Risteli et al. 1981; Dixit et al. 1981) it was only a matter of time before they
were used in the investigation of progressive renal disease. The original assays were
based on polyclonal antibodies to the 7S and NCI antigens of type IV collagen and
the LP1 and LP2 fragments of laminin. Elevated levels of 7S collagen were found in
diabetic subjects with and without microangiopathy (Risteli et al. 1982; Hogemann et
al. 1986; Torffvit et al. 1989). Interestingly the latter study did not find elevated
levels in IDDM subjects with nephropathy. Similar findings were recorded in animal
models with elevated 7S collagen in streptozotocin-diabetic rats (Risteli et al. 1982;
Brocks et al. 1985). Hypertension augmented this rise (Hasslacher et al. 1987) and
insulin returned the levels to normal (Hasslacher et al. 1984; Brocks et al. 1985). The
production of 7S collagen was enhanced by increased glucose concentration in rats
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(Hasslacher et al. 1987) supporting observations on the influence of glucose on the
production of 7S collagen by mesangial cells (Ayo et al. 1991). Animal studies have
demonstrated that the production of collagen precedes basement membrane
thickening (Hasslacher et al. 1984). Serum and urine levels ofNCI are also elevated
in glomerulonephritis in humans (Keller et al. 1990).
The levels of 7S and NCI collagen measured in the serum probably represent both
newly synthesised monomers and dimers and the collagenase breakdown products of
type IV collagen. A one-step sandwich enzyme immunoassay against intact type IV
collagen (central triple helical domain) has recently been developed (Obata et al.
1989). It is thought to measure newly-synthesised collagen. Elevated levels of type
IV collagen have been demonstrated in the serum and urine of diabetic subjects
(Matsumoto et al. 1990; Hayashi et al. 1992) with higher levels recorded in those
with more advanced complications (Matsumoto et al. 1990). This finding led the
authors to suggest that assay of intact collagen might be helpful in monitoring the
progression of renal disease in subjects with diabetic nephropathy. In this chapter I
examine whether high levels of Type IV collagen are indeed found in the serum and
urine of individuals who have more advanced complications and investigate whether
the claim for their use as a disease marker is justified.
The measurement of laminin fragments, principally LP1, has proved of some value in
malignant disease and liver fibrosis (Price et al. 1993), but has proved unreliable in
renal disease. Hogemann and colleagues (1986) found no difference in the levels of
LP1 in the serum of diabetic as compared to normal subjects, whilst Pietschmann and
co-workers (1988) found elevated levels only in subjects with advanced nephropathy.
Elevated serum LP2 levels have also been observed in streptozotocin diabetic rats
(Risteli et al. 1982). However it has proved impossible to measure LP1 and LP2 (the
principal pepsin digests of laminin) successfully in urine (Price and Taylor 1993).
Recently these researchers have created a new assay to detect laminin fragments in
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the urine (Price et al. 1994) and have found measurable quantities of laminin
fragments in individuals with diabetes and those exposed to perchlorethylene and
other hydrocarbons.
The method of preparation of the laminin fragments and subsequent steps in the
assay are described in detail in Price and co-workers (1994). In brief, this involved
the pepsin digestion of human placenta after the method of Dixit (1985). The
digested placenta was precipitated and resuspended before running it through a
DEAE-sephacel column. The laminin rich material subsequently eluted was purified
with collagenase before running through a gel-filtration column. Eight specific peaks
were identified. SDS-polyacrylamide gel electrophoresis identified bands ranging in
size from > 500 to < 10 Kd. Three ofMW 150, 100 and 50 Kd (coded N3U, N3L and
N5) were selected for further study. Suspensions of these proteins were then injected
into rabbits and all induced a significant antibody response. There was no evidence
of cross reaction to intact laminin, either intact or the NCI fragment of Type IV
collagen or human albumin. However cross-reaction of the antibody raised to N3U
did occur to N3L, N4 and N5. These four laminin fragments are collectively described
as 'mixed laminin fragments' (MLF).
This assay has been used to examine the levels ofMLF in the urine of subjects with
NIDDM and nephropathy and to determine whether they have a role in monitoring
disease progression.
6.2 Aims
• To measure intact type IV collagen in the serum and urine of subjects with
NIDDM and nephropathy.
• To determine if subjects showing more rapid disease progression have higher
serum levels of type IV collagen
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• To ascertain whether urine type IV collagen could be used a marker of disease
progression in more advanced diabetic nephropathy.
• To measure the levels of mixed laminin fragments (MLF) in the serum and
urine of subjects with NIDDM and nephropathy using a newly developed
assay.




Serum and urine samples were obtained from 55 subjects with NIDDM and
nephropathy. Serial samples were available for those subjects who participated in the
prospective study of progression of renal impairment (see Chapter 4). Samples were
also obtained from 33 'diabetic controls' and 42 'normal controls' (clinic staff,
hospital visitors and partners of diabetic patients). Whilst diabetic and normal control
subjects were excluded if urinalysis was positive for protein, no effort was made to
exclude those with evidence ofmicroangiopathy, although data on presence/absence
of complications were recorded for each subject. In all groups individuals with a
history of cancer or liver disease were excluded. All non-diabetic subjects had a
random blood glucose and serum creatinine measured. In addition all diabetic
subjects had a glycosylated haemoglobin measured. Details of the clinical parameters
for each group are presented in Table 6.2 (page 156).
6.3.2 Ethical approval
Informed consent was obtained from all subjects recruited. The study received
approval from King's College Hospital medical ethics committee.
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6.3.3 Assay of human type IV collagen
The assay for type IV collagen was based on an enzyme immunoassay kit supplied
by Fuji Industries Ltd., Japan. A schematic representation of the solid phase assay is
shown in Figure 6.2 (overleaf). The epitope thought to represent the antigen of intact
type IV collagen is shown in Figure 6.1. The sample is allowed to react
simultaneously with anti CL-IV antibody immobilised on a bead and with enzyme
labelled anti CL-IV antibody directed at distinctly different antigen sites on the CL-
IV molecule. For composition of the solutions see Table A6.1 in the Appendix.
Immunoreaction:
All samples and standards were prepared in duplicate. 50 pi of patient/control serum
and urine were pipetted into Nunc polystyrene maxisorp immunotubes (4ml; Gibco
BRL Ltd.). 300pl of enzyme-labelled anti CL-IV antibody solution {Horseradish
peroxidase labelled monoclonal antibody} were then added to each tube and a single
anti-CL-IV antibody coated polystyrene bead {Mouse anti-human CL-IV antibody}
added to the mixture, taking care to permit excess solution to drain from the bead.
The tubes were then incubated at 10 - 30 °C for 60 minutes without shaking. This
reaction was then stopped by adding 1ml of washing solution {100ml concentrated
buffer (lOOmM phosphate buffer, pH 7, containing 1M NaCl}. The contents of the
tube were then aspirated and the bead washed a further four times with 3.5 ml of the
washing solution. The bead was then aspirated to dryness.
Enzyme reaction:
300 pi of the freshly prepared substrate solution {0.4 ml of TMDZ-DMF added to 40
ml of 100 mM acetate buffer (pH 5.5) and mixed gently} were then added to the bead
in each tube followed by lOOpl of substrate {10 mM acetate buffer, pH 5.5,
containing 0.015% hydrogen peroxide}. TMBZ is 3,3',5,5' -tetramethyl benzidine,
the chromogen, and is dissolved in N,N dimethyl formamide (details see appendix































Aspirate to dryness Read at 450 nm
Figure 6.3 : Assay of Type IV collagen in serum and urine
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shaking. The reaction was halted by adding 1ml of stopping reagent (1.33N sulphuric
acid) to each tube. Figure 6.3 (above) outlines the assay procedure. The specimens
and the standards (see below) were then read at 450 nm on an Atom 388
Spectrophotometer (Biotron SA Spain). The tubes containing the beads were read
directly in the spectrophotometer. De-ionised water was used as the blank.
Preparation of Standard curve:
The standard curve was prepared with the use of CL-IV standard {human collagen
2pg.ml"'}. 150 pi of dilution buffer {10mM phosphate buffer, pH 7, with 1% BSA
and 10% horse serum} is added to 150 pi of the CL-IV standard giving a
concentration of 1000 pg.L"1. Subsequent standards were prepared by removing 150
pi of the previous standard and adding 150 pi of dilution buffer to produce the
standards given in Table 6.1 (below). 50 pi of each standard are then assayed as in
the reaction outlined above and as in Figure 6.3.
CL-IV concentration (pg.L1) 1000 500 250 125 62 31 16 0
CL-IV standard solution 150 150 150 150 150 150 150 0
Dilution buffer 150 150 150 150 150 150 150 300
Standard solution {volume (pi)} 300 300 300 300 300 300 300 300
Table 6.1 : Collagen assay - standard curve concentrations.
The standard curve for Type IV collagen (Figure 6.4) is to be found on the following
page. The data were corrected for absorbence at 0 pg.L"1. The data for urinary
collagen are corrected for urine flow and are presented as pg.mmol Cr'.
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5 10 16 31 62 125 250 500 1000
Concentration ofCL-IV (/fg.L-1) - Log scale
Figure 6.4 : Standard curve for Type IV collagen (CL-IV)
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6.3.4 Assay of mixed laminin fragments.
All the assays were performed in Nunc Polystyrene Maxisorp Immunotubes (4 ml
Gibco BRL Ltd.) and Pyrex (6ml) glass tubes. Each sample (and standard) was
analysed in duplicate.
Step 1: Preparation of the antigen coated tubes.
A stock solution of mixed laminin fragments (1 mg.mP' in PBS/0.04%) was first
prepared and divided into 500 pi aliquots which were then stored at -70 °C. The stock
solution was diluted with 0.05M sodium carbonate buffer (pH 9.6) to give a
concentration of laminin fragment of 400 ng.ml"'. 1000 pi of this solution were added
to each tube, which were then stored at 4°C for 48 hours. The tubes were then washed
twice with 1600 pi of the 'washing' solution (PBS/0.04% Tween 20) before adding
1200 pi of the 'blocking' solution (0.5% casein in PBS/0.04% Tween 20) and
incubating at 37 °C for two hours.
Step 2: Preparation of standard curve and sample tubes.
The standard curve was produced by preparing a 1:10 dilution of the stock laminin
fragment solution (above) in glass tubes and thence by doubling dilution to obtain a
standard curve ranging from 100 pg.ml"1 to 100 ng.ml"1. The volume in each tube was
600pl (preparation as shown in Table 6.1, allowing for the different volumes). 120 pi
of sample (serum or urine) were then added to a clean labelled glass tube and diluted
with 480 pi of PBS/0.04% Tween 20. The tubes were covered with 'cling-film' and
left at room temperature until the addition of the primary antibody. 600 pi of the
primary antibody (anti-N3U laminin fragment diluted 1:500 in PBS/0.04% Tween 20
containing 0.1% casein) was added to all the tubes to give a total volume of 1200 pi.
The samples were then incubated at 37 °C for 90 minutes timed to coincide with the
completion of incubation of the antigen tubes (step 1). Duplicate samples of diluted
primary antibody (600 pi with 600 pi of PBS/0.04% Tween 20) and blanks (1200 pi
of PBS/0.04% Tween 20) were prepared and incubated as per standard samples.
152
Step 3: Addition of the second antibody.
After incubation the Nunc tubes (step 1) were washed a further time with 1600 pi of
PBS/0.04% Tween 20 and 1000 pi of the primary antibody mixture (prepared in step
2) transferred to each tube and the samples incubated for a further 90 minutes at
37°C. The contents were then discarded and the tubes washed thrice with 1600 pi of
PBS/0.04% Tween 20. 1 ml of the second antibody (alkaline conjugated goat anti-
rabbit IgG, Sigma Ltd., No. A-8025 diluted 1:1000 with PBS/0.04% Tween 20) was
then added to each tube and all incubated once more at 37 °C for 60 minutes. The
tubes were then washed three times with PBS/0.04% Tween 20. The sample tubes
were then transferred to a 37 °C water bath and 1000 pi of ImM SLPr-phosphate
substrate (Pyridium 4-[2- {4-phos-phoroyloxy-3,5-dimethoxyphenyl}-vinyl]-1 -
propyl-quinolinium iodide; PPR Diagnostics Ltd., London, UK. in 1 M
diethanolamine buffer {pH 9.6} - pre-incubated to 37 °C - was added to each tube.
The samples were left for 15 minutes.
Step 4: Reaction termination and sample analysis.
The reaction was terminated by the addition of 250 pi 'stopping' buffer {0.2 M
dipotassium hydrogen phosphate with 100 mM EDTA (pH 9.6)}. A green-blue
colour developed and the samples were read at 545 nm on an Atom 388
Spectrophotometer (Biotron SA, Spain). The optical density values obtained were
then converted to percentage activity by comparing each to the antigen-free tubes
(100% activity).
For each sample the percentage inhibition was calculated as :
% inhibition = 100 - % activity
The standard curve of% inhibition plotted against concentration ofMLF is shown in
Figure 6.5 (overleaf). The concentration of MLF in each serum and urine sample is
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Log {mixed laminin fragments) (//g.L "*)
Figure 6.5 : Standard curve with mixed laminin fragments as antigen.
Data points are mean of three samples.
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then read from this graph. The same standard curve was used for both serum and
urine. However to adjust for urine volume the data for the urine concentration of
MLF were corrected for urinary creatinine concentration. Thus the data for urinary
laminin are presented as pg.mmol Cr"1.
6.3.5 Statistical analysis:
Median and interquartile ranges and mean and standard deviation were calculated as
appropriate for the groups. Comparison between groups was by the Mann-Whitney
test for non-parametric data and unpaired Student's 't-test' for normally distributed
data. The Pearson correlation coefficient was used to examine the relationship
between the serum and urine levels of type IV collagen and MLF and between these
variables and serum creatinine and glycosylated haemoglobin. P values < 0.05 were
deemed significant.
6.4 Results:
6.4.1 Sample and clinical data
Serum was analysed for type IV collagen and mixed laminin fragments in all 42
normal control and 33 diabetic control subjects. 96 samples were obtained from 55
diabetic subjects with nephropathy and comprised 3 from each of the 19 individuals
studied prospectively (Chapter 4), single samples from the four who ended the study
prematurely and two from three who were followed for one year. Single samples
were obtained from a further 29 individuals with NIDDM and nepropathy. The
number of urine samples processed in the three groups was fewer due to an





Gender (M:F) 21:21 19:14 42:13#
Age 61.5 (9.3) 63.3 (10.6) 63.6 (9.8)
Random glucose (mmol.L"1) 5.9(1.6) 11.8 (4.1) * 11.7(6.9) *
HbA,c - 8.1 (1.9) 7.8 (2.2)
Serum creatinine (pmol.L"1) 91 (20) 87 (20) 261(94)f
Type IV collagen (pg.L1) 94 (71-126) 115 (83-140) 161 (119-217)ft
Laminin fragments (pg.L"1) 224 (154-590) 1000 (580-1300)*** 940 (220-2240) **
Key : All data are presented as mean (SD), with the exception of the collagen and laminin values,
which are given as median and interquartile range *= p< 0.01, **= p< 0.005, *** p< 0.0001 vs
normal controls; |= p<0.001, tt=p<0.0001vs normal and diabetic controls (Mann-Whitney). # - two
or more samples from each individual.
Table 6.2 : Serum Type IV collagen and mixed laminin fragments in subjects with
diabetic nephropathy, normal and diabetic control subjects.
The mean age of the three groups was similar (Table 6.2 above). There was a male
preponderance in the group with nephropathy. However no significant differences in
either type IV collagen or the levels of MLF were observed when the data were
analysed separately by gender. Neither glycosylated haemoglobin nor glucose taken
simultaneously differed between diabetic controls and nephropaths. Predictably
serum creatinine, at 261 pmol.L"1, was significantly greater in the nephropathic
group.
6.4.2 Type IV collagen
The median (interquartile range) for serum type IV collagen in normal subjects was
94 (71-126) pg.L"1 (Table 6.2). The level in nephropathic subjects was significantly
higher than both the normal and diabetic control groups (p<0.0001; Mann-Whitney
test). Examination of Figure 6.6 (page 158) reveals a marked overlap of the
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individual values between the three groups. Of the 96 samples in the nephropathic
group only 11 exceed the upper limit observed in the normal group.
In contrast the urine levels are consistently higher in the nephropathic group. Figure
6.7 shows that type IV collagen is undetectable in all normal controls and all but
three diabetic controls, whereas it is detected in 40 of 81 (49%) nephropathic
samples. The levels of type IV collagen in the serum, but not urine, are slightly
higher in those with more advanced renal disease, though the differences are slight
(Figure 6.8 overleaf). Neither serum nor urine type IV collagen appears related to
glycosylated haemoglobin (Figure 6.8 overleaf).
In the group of 19 individuals studied prospectively there is no difference in the
serum level of type IV collagen in those who progress and those who do not (Figure
6.9 overleaf). However in only 3 of 10 'Non-progressors' was collagen detectable in
the urine, in contrast to all bar one of the 'Progressors' (Figure 6.9 overleaf). In these
19 subjects there is a suggestion that both serum and urine type IV collagen are lower
in those showing a more gradual decline of GFR (Figure 6.10 overleaf), though the








Figure 6.6 : Level of Type IV collagen in the serum of individuals
with diabetic nephropathy together with diabetic and
normal controls. Median (interquartile ranges as shown).
Type IV collagen is higher in the nephropathic group


















Figure 6.7 : Level of Type IV collagen in the urine of individuals
with diabetic nephropathy together with diabetic and
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Figure 6.8 : Relationship between serum creatinine, glycosylated haemoglobin and serum and



















Figure 6.9 : Serum and urine type IV collagen in individuals
with NIDDM nephropathy, subdivided by rate of
progression. Median (IQ range) as shown for serum,














































Mean decline of GFR (ml.min.^month-1)
Figure 6.10 : Relationship between the decline in GFR and serum
and urine Type IV collagen in all subjects. Each point
represents the mean of the samples for each individual.
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6.4.3 Mixed laminin fragments
Twenty-eight samples were available from normal controls, 51 from diabetic controls
and 84 from nephropathic subjects. The median (interquartile range) for serum MLF
in the normal subjects was 224 (154 - 590) pg.L"1. Both the diabetic control (1000
jag.L"1; p<0.0001) and nephropath (940 pg.L"1; p<0.005) groups had significantly
higher MLF levels compared to the normal control group (Table 6.2 above).
However no difference in the level ofMLF was observed between the control group
with diabetes and those with nephropathy (Figure 6.11). In only a few cases in the
nephropathic group does the level exceed 5000 pg.L"1.
The levels of MLF in the urine are shown in Figure 6.12. Laminin was detected in
the urine of only one normal subject, whereas in the nephropathic group in all save
one was laminin detectable. 10 out of 28 diabetic controls had measurable MLF, but
all were <110 pg.mmol Cr"1.
As with serum type IV collagen, MLF in the serum was not associated with serum
creatinine (Fig 6.13). A modest rise in urine MLF was observed with increasing
creatinine and with poorer glycaemic control (same figure).
In contrast to the situation for collagen there is a suggestion that a more rapid decline
of GFR is associated with greater levels of urine laminin (Figure 6.14). This figure
shows only two of ten 'Non-progressors' with urine MLF in excess of 200 pg.mmol
Cr"1. Of these one subject had the largest decline ofGFR (0.5 ml.min."1month"1) in the
'Non-progressors' group. However Figure 6.15 shows that this association is not
perhaps as strong as is suggested in Figure 6.14.
Figure A6.1 (in appendix) shows that there is no relationship between serum and
urine collagen, serum and urine laminin, and serum levels and urine levels of































Figure 6.11 : Concentration of mixed laminin fragments in the serum of
diabetic subjects with and without nephropathy and that of
normal controls. Median (interquartile range) displayed.
*p<0.005 nephropathic and diabetic control group vs normal
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Figure 6.12 : Level of mixed laminin fragments in the urine of patients
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Figure 6.13 : Relationship between serum creatinine, glycosylated haemoglobin and serum and urine





































Figure 6.14 : Serum and urine laminin in subjects with NIDDM
nephropathy, subdivided into 'Non-progressors' and
'Progresors'. Each value plotted is the mean of three































Mean decline in GFR (ml.min.^month"1)
Figure 6.15 : Relationship between the decline in GFR and serum mixed
laminin fragments in 19 nephropathic subjects. Each point
represents the mean of three samples.
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6.5 Discussion
This study fails to substantiate claims that the measurement of type IV collagen
provides an effective index of disease progression in diabetic nephropathy
(Matsumoto et al. 1990). In any case the current assay is probably too expensive («£2
per sample) for routine clinical use. Likewise serum MLF does distinguish between
diabetic control and nephropathic subjects. However these preliminary studies
suggest that the measurement of urinary laminin fragments may prove useful in the
identification and monitoring of disease progression, given that higher levels are
observed in those who progress more rapidly.
The antibody used to measure type IV collagen in this study is thought to recognise
the intact molecule and furthermore it is hypothesised that such collagen is excess to
that incorporated into the matrix (Obata et al. 1989; Matsumoto et al. 1990). If this is
the case then the levels measured should reflect the rate of deposition of collagen at a
given time. Our study has demonstrated that, though type IV collagen is measurable
in the serum, the overlap of individuals with nephropathy, normal and diabetic
controls precludes its use as a marker of disease let alone progression. Only 11
samples from nephropathic individuals had collagen level in excess of the upper limit
of the normal range. These results contrast markedly with those of Matsumoto and
colleagues (1990) who observed significant differences between normal and diabetic
subjects, with and without complications. Using the same assay we have found
consistently higher levels in each group with greater variability within each group.
Both studies were closely matched for age and the groups had comparable renal
function. The nephropathic group in both show the greatest variability in the data.
Whilst it appears from this study that type IV collagen has no role as a serum marker
of disease progression in diabetic nephropathy, is this the case for urine collagen?
Initial examination of Figure 6.7 would suggest it may have a role. Intact type IV
collagen was undetectable in the urine of the 10 normal and in all but 3 samples from
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diabetic control subjects. Since intact type IV collagen has a molecular weight of
500000 and would not pass through the intact glomerulus, such findings are not
surprising. Collagen was detectable in approximately 50% samples from
nephropathic subjects. Only a few urine samples from patients with advanced
nephropathy analysed by Matsumoto and colleagues (1990) yielded a positive result.
The authors concluded that their assay was not sufficiently sensitive to detect the low
concentration of collagen present in urine.
Banu and colleagues (1994) describe a novel method of concentrating urinary type
IV collagen using precipitation with polyethylene glycol (PEG), based on the method
of Ramshaw and colleagues (1984). Concentration of urine enabled the authors to
detect type IV collagen in diabetic individuals with nephropathy and, more
surprisingly, normal subjects. It is most unlikely that the latter represented filtered
protein and presumably the origin was tubular secretion or else the assay was not
measuring intact collagen. This raises the question as the relative contribution of the
glomerulus and tubule to urinary collagen in the nephropath group. Falk and
colleagues (1983) would argue the latter, observing that type IV collagen was
increased in both the mesangium and the GBM in the early stages of nephropathy in
renal biopsy tissue from IDDM subjects but decreased in the latter stages. In contrast
the amount of type IV collagen was increased in the renal tubular basement
membrane in more advanced disease.
There are no comparable studies to the above in NIDDM though one of three
subjects described by Woodrow and colleagues (1992) had NIDDM. However their
immunohistochemical studies, using immunogold on renal biopsies reported only on
the glomeruli and did not mention the tubular basement membrane. Hayashi and
colleagues (1992) filtered and concentrated urine by dialysing against PEG, prior to
analysis. They too found measurable quantities in normal subjects. Given these
findings it is perhaps not surprising that so many individuals had detectable collagen.
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Were it possible to repeat the study with PEG precipitation then it might have been
detected in many more. Donovan and colleagues (1994) have recently described
increased urinary levels of type IV collagen in the urine of a small group of diabetic
subjects, using an 'in-house' assay. Although highly sensitive (measuring down to 1
pg.L"1) the assay unfortunately measures both 'intact' and 'degraded' collagen.
Torffvit and colleagues (1989, 1991) in their studies on NCI levels in the urine found
elevated levels in the patients with microalbuminuria but not in those with
proteinuria. The authors interpret their findings in the light of the changing pattern of
type IV collagen deposition in progressive disease described in the immuno-
histochemical studies described above. The small number of subjects studied
precludes definitive conclusions being drawn.
It is hard to envisage a role for the measurement of type IV collagen in diabetic
nephropathy. Serum measurement appears to be of no clinical benefit, although urine
measurement may merit further investigation. It has no obvious advantage over
protein excretion, though may identify those individuals who are likely to fare badly.
Only a greater understanding of the individual and temporal variation in urine levels
together with an assessment of outcome would determine if it had any diagnostic or
prognostic worth.
Although established as markers of hepatic fibrosis (Matsumoto et al. 1989) and
proposed for metastatic disease (Yamamoto et al. 1992), laminin fragments have not
yet been shown to be of clinical benefit in diabetic nephropathy. This new assay has
revealed significantly elevated levels of MLF in sera from individuals with diabetes
compared to normal controls; though in those with established nephropathy the level
is not significantly different from those without. Pietschmann and colleagues (1988)
have previously demonstrated increased laminin PI in IDDM and NIDDM subjects
with advanced nephropathy, though not in those with micro-albuminuria. A similar
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finding was made by Hayashi and colleagues (1992), though only in eight subjects
with renal impairment.
This assay has detected MLF in virtually all the urine samples from the nephropathic
subjects, compared to only one of 42 normal control and <30% of diabetic controls.
One individual in the nephropathic group had values in excess of 1000 pg.mmol Cr"1.
Price and colleagues (1994) reported a similar elevation of MLF in a pilot study.
Mixed laminin fragments was significantly raised in those with clinical proteinuria
though the levels in the 'micro-albuminuric' group did not differ from normal.
Hayashi and colleagues (1992) found LP1 be elevated in the urine of a small group of
NIDDM subjects, with and without nephropathy. The level of LP1 did not segregate
with stage of nephropathy.
It is probable that the assay used in this present study measures the degradation
products of laminin. The antibody raised to the LN3U fragment did not cross-react
with whole laminin, but cross-reaction did occur to other fragments. As yet it is not
known what the relative contribution of each of these antigens is to the total
measured. It remains to be seen whether any or all will prove helpful in monitoring
the progression of nephropathy. Figure 6.14 suggests that MLF may be important in
the identification of those individuals in whom nephropathy progresses more rapidly.
No such separation is observed for serum. Unfortunately when the levels of MLF in
the sequential urine samples were examined in these 19 subjects no consistent trend
emerged, i.e. the 'Progressors' did not show increasing levels, nor did the 'Non-
progressors' decline or even remain stable. Marked variation in urinary MLF
occurred in sequentially obtained samples from several individuals, ranging from 180
to as much as 2500 gg.L"1, yet in others the level of MLF remained remarkably
constant over the two years.
172
MLF and, to a lesser extent, type IV collagen merit further study to determine
whether they are of value in identifying those individuals with nephropathy who are
destined to fare badly. Some support for this is provided here though more subjects
need to be examined.
6.6 Concluding remarks
• Serum type IV collagen from subjects with diabetic nephropathy is higher
than found in diabetic control and normal subjects (both p<0.0001)
• Serum MLF was significantly higher in diabetic subjects with nephropathy
(p<0.005), but was no different from diabetic control subjects.
• The levels of type IV collagen and serum MLF are not closely related to the
degree of renal impairment.
• MLF was identified in the urine of almost all cases of diabetic nephropathy,
and type IV collagen in approximately 50%.
• MLF and type IV collagen were not detected in urine from normal subjects
and rarely in diabetic controls without proteinuria.
• Mean levels of urinary MLF and type IV collagen segregated with the rate of
progression of nephropathy in the majority of cases, particularly the former.
• It is doubtful whether serum laminin or type IV collagen has a role in the
clinical assessment of diabetic nephropathy,
• Further studies are warranted to determine whether urinary MLF have a use




Without treatment someone with NIDDM, proteinuria and near normal renal function
can anticipate starting dialysis within 6 to 7 years. Even with anti-hypertensive
therapy the interval may be as short as 40 months (Biesenbach et al. 1994). This
study has demonstrated a decline of isotopically measured GFR of 0.48 ml.min."1
month"1 over a two year period in 19 subjects with a mean baseline GFR of «50
ml.min"1 and agrees closely with the only directly comparable study by Gall and
colleagues, published in 1993. Translated, this suggests a doubling of the interval
between the onset of proteinuria and dialysis to 12 to 15 years with current
therapeutic regimens.
The observational study presented in Chapter 2 suggest an even more optimistic
outlook for IDDM subjects. Although retrospective and based upon estimated GFR
the data suggest a similar rate of decline of GFR in the most recent two years of
observation, 0.20 ml.min.'month"1, to that seen in closely monitored intervention
studies (Parving et al. 1987). The retrospective study shows a more rapid rate in the
decline of GFR in the NIDDM compared to the IDDM group and contrasts with the
findings of Friedman and Gross (1991) and Humphrey and colleagues (1989), where
it was slower in NIDDM and Biesenbach and colleagues (1994), where the rate was
similar. Part of the reason for the difference seen here may relate to the findings of
Parving and colleagues (1987), who observed that the rate of decline of GFR fell in
successive time periods after initiation of anti-hypertensive therapy. It will be
interesting to see whether this improvement will be maintained in IDDM (as might
be suggested by our most recent one year data) and whether a similar pattern will
emerge in NIDDM.
Certain individuals show no decline at all of estimated GFR over a five year period,
despite a baseline GFR of <50 ml.min"1. Of these eight individuals, three had
NIDDM. Although these data are most encouraging, the variation in the rate of
decline of GFR is wide and certain subjects progress rapidly to end-stage renal
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disease, with loss of function up to 2 ml.min.'month"1. Indeed in the prospective
study the rate of decline of GFR in one individual was nearly double this over a 20
month period. Investigation of this subject revealed no additional renal disease, with
a renal biopsy showing only glomerulosclerosis and no evidence of renal artery
stenosis on arteriography. Because of the small numbers studied this case skewed the
data and strengthened certain of the associations, but did not alter the overall
conclusions. What then accounts for the variability in the rate of decline of GFR seen
in this and other studies ?
Several differences were observed between the retrospective and prospective studies
regarding the factors associated with the decline of GFR. Blood pressure, principally
systolic, and serum cholesterol, emerged as significant variables in the prospective
study, whereas protein excretion was a less important factor (p=0.07). By contrast the
latter was the main factor accounting for the variability in the data in both NIDDM
and IDDM in the retrospective analysis. Why this factor should assume less
importance in the prospective study is uncertain, though protein excretion was
lg.24hr 1 less.
What should the therapeutic targets be for NIDDM subjects with renal failure? The
mean blood pressure in 'Non-progressors' in the prospective study was 142/82
mmFlg giving a MAP of 102 mmHg, and is comparable to the target of 100 to 105
mmHg set by Mogensen and colleagues (1991). Those achieving such a level in our
study had a mean decline of GFR of 0.44 ml.min."1month"1. More stringent criteria
have been set by the American Diabetes Association and the National Kidney
Foundation (Consensus Development Conference 1994) where a MAP of 92 mmHg
is suggested for those diabetic subjects with chronic renal insufficiency and a protein
excretion exceeding lg.24hr"'. This study has also demonstrated that serum
cholesterol below 6 mmol.L"1 is associated with a much reduced rate of decline of
GFR, 0.04 ml.min."1 month"1 compared to 1.14 ml.min/'month"1 in those over 6
175
mmol.L"1. These data suggest that the targets for NIDDM subjects with renal
impairment should be a MAP of 100 mmHg and a serum cholesterol of < 6 mmol.L"1.
As in many other studies neither protein intake (as determined here by urinary urea
excretion) nor glycaemic control influenced the rate of decline of GFR. The small
numbers studied make it difficult to draw conclusions on ethnic differences in the
rate of decline of GFR. Afro-Caribbean NIDDM subjects did progress more slowly
than their Caucasian counterparts, a finding which agrees with the work of Cowie
(1993). In the prospective study the Asian subjects had slower rate of decline of GFR
than the other groups, though there were only 4 individuals. No benefit was seen
from renal artery angioplasty in any subject and raises the question as to whether
angiography seeking a RAS is justified, where it is known that diabetic nephropathy
already exists.
Proteinuria may be both a promoter and marker of disease progression in diabetic
nephropathy. Anecdotally those individuals with the greatest protein excretion often
show the most rapid rate of decline of GFR (e.g. Cases 5, 16 and 18 this study).
Although the retrospective study lends weight to these claims, such a finding is not
universal (Gall et al. 1993; Sawicki and Berger 1994). A more reliable marker of
progression may derive from the components of the mesangial matrix and the
basement membrane, both of which are increased in diabetic nephropathy. Both type
IV collagen and mixed laminin fragments were examined in this study. The serum
and urinary levels of the former were significantly greater in the nephropathic group
compared to both the diabetic and normal control groups. Unfortunately there was
considerable overlap in the serum levels between the groups and it was not detectable
in the urine of many nephropathic subjects. Furthermore it did not discriminate
between the 'Progressors' and the 'Non-progressors'. Although the level of MLF in
the serum was very similar in both diabetic groups it may prove a more reliable
urinary marker of nephropathy, given that it was detectable in all but 2% of the
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nephropathic subjects, compared to 64% diabetic controls (all low levels) and 96% of
normal subjects. There is also a suggestion that the levels are higher in those showing
the most rapid decline ofGFR.
The early identification of NIDDM subjects at risk of developing nephropathy is
essential but beyond the scope of this discussion (see Introductory chapter). Once
identified, all subjects should have an isotopically determined GFR, together with the
simultaneous measurement of serum creatinine. Where a timed collection for urinary
albumin (overnight or 24-hour) is routinely performed the creatinine clearance could
be determined, although this may be logistically difficult in many clinics and
compliance a problem for those with visual impairment or in the elderly. Ideally GFR
should be measured annually with simultaneous creatinine until the GFR falls to 80
ml.min"1 (this study would suggest 50 ml.min1). For individual subjects EDTA
clearance could be correlated directly with predicted GFR (from Cockcroft-Gault)
and those subjects showing a close correlation could be followed by predicted GFR
alone, unless GFR exhibited a sharp decline when confirmation using EDTA
clearance may be desired. Those subjects showing a poor agreement between the
methods should continue to be followed with EDTA clearance. The results of this
study suggest that endogenous creatinine clearance may be a helpful indicator of
progression in obese subjects. Until such time as the specific factors contributing to
the decline of GFR are determined and corrected (and this may never be achievable)
clinicians will continue to watch helplessly whilst renal function is lost. That the
decline of renal function has been accurately charted will prove of little comfort to
either the physician or the patient.
The study has its limitations. Principal amongst these are the relatively small
numbers studied and the period of observation. That said, there is no study in the
published literature which follows as many cases ofNIDDM with this degree of renal
impairment. Outwith a collaborative study, it is unlikely that any one centre has
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significant numbers of NIDDM subjects where the GFR is <50 ml.min"1. A longer
period of follow-up with a greater number of GFR measurements would have been
desirable to increase the accuracy of the determination of the rate of decline of GFR.
Neither was feasible in this case.
Future studies in NIDDM will need to determine whether subjects do show a
progressive reduction in the rate of decline of GFR as is seen in IDDM. Intervention
studies with lipid-lowering therapy are required in more advanced nephropathy in the
light of the very slow rate of decline seen here in those with low serum cholesterol.
Given that the introduction of such therapy is becoming increasingly commonplace,
efforts should be made to monitor the changes in GFR with an isotopic method, if
randomised controlled studies are not to be carried out.
The value ofMLF as urinary markers of diabetic nephropathy and possibly of disease
progression merit further study. It may prove that specific laminin fragments, or
other basement membrane components, such as fibronectin, have a role in identifying
those likely to progress more rapidly.
The recent discovery that the ACE gene insertion/deletion polymorphism may be a
marker of therapeutic responsiveness to ACEI in IDDM is potentially an exciting
one. Although the DD genotype was associated a more rapid rate of decline of GFR
the variation within each group was wide (Parving et al. 1996b). It remains to be seen
what will be found in NIDDM, where the therapeutic efficacy of ACEI is much less
well established than in IDDM.
Whilst aggressive anti-hypertensive therapy and perhaps lipid lowering drugs may
slow the overall rate of decline of GFR in diabetic nephropathy, only a greater
understanding of the genetic, physiological and biochemical events at the cellular
level will is likely to provide an explanation as to why certain individuals progress
rapidly and inexorably to renal replacement therapy.
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Appendices
Table A2.1 : Clinical and demographic data entered onto computer



















Peripheral vascular disease -details








BMI = weight (kg)/height2 (m)
GFR = {140-age(years) x body weight (kg) x K/serum creatinine(pmol.L"1)
where K is 1.23 for men and 1.05 for women
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Measured variable Method
Serum creatinine Alkaline picrate (kinetic Jaffe)
Serum total cholesterol Cholesterol oxidase
HDL cholesterol Heparin/manganese precipitations
LDL cholesterol Friedwold formula
Serum triglyceride Lipase/peroxidase
Plasma glucose Glucose oxidase
Serum calcium Cresolphthalein complexone
Serum phosphate Molybdo phosphate (UV detection)
HbAl Corning gel-electrophoresis
HbAlc DCA 2000 Autoanalyser
Urine protein Pyrogallol red
Urine urea Urease
Urine creatinine Jaffe (as for serum)
Urine phosphate Molybdate (as for serum)
Urine sodium Indirect ion selective electrode (ISE)
Table A4.1 : Methodologies for the variables measured in the study
All serum and urine samples, with the exception of glycosylated haemoglobin, were












Serum cholesterol 0.635 p=0.01
Serum triglyceride 0.270 NS






Table A4.2: Univariate regression analysis. EDTA GFR is the dependent
















Key:1/Sc=r cipro alcreatinine;EDTA=clear n e;CrClcreatin neclea ce TableA5.1:Regressionequationsformea uresfr nafunctionithdiff r ntraci lg oup
Gender Female(n=13) Male(n=58) Weight <85kg(n=52) >85kg(n=19) Serumcreatinine <300|amol.L-l(n >300|amol.L-l(n
cGFRvsEDTAGFR1/ScEDTACrClvsEDTAGFRcG RvsCrCl r=0.06 r=0.79 r=0.84 r=0.49
52)r=0.72 19)r=0.36
r=0.07 r=0.73 r=0.75 r=0.67 r=0.62 r=0.69
r=0.14 r=0.84 r=0.72 r=0.89 r=0.80 r=0.25
r=0.41 r=0.78 r=0.83 r=0.49 r=0.68 r=0.37
Key:Sc=serumr atinine;cGFR=estim tedGFR;CrCl=c atinincleara c TableA5.2:Correlationmatrixbetweenthdiffer ntme suresfr n lfunctiooge d r,w ightans rumcreatini
Table A6.1 : Materials and solutions used in type IV collagen and mixed laminin
fragments assays.
Type IV Collagen
1. Anti CL-IV antibody coated beads
Mouse anti-human CL-IV antibody coated polystyrene beads
2. Enzyme labelled anti CL-IV antibody solution
Horseradish peroxidase labelled monoclonal antibody (0.8 pg.ml'l).
3. Colour reagent (TMBZ)
3,3',5,5' -tetramethyl benzidine (14.72 mg.lOOml'l.)
4. Solvent for colour reagent (DMF)
N,N-Dimethylformamide
5. Buffer for colour reagent
100 mM Acetate buffer (pH 5.5)
6. Substrate
10 mM Acetate buffer (pH 5.5) with 0.015% Hydrogen Peroxide
7. Stopping reagent
1.33 N Sulphuric acid
8. Dilution buffer for standard




lOOmM Phosphate buffer (pH 7) containing 1M NaCl
228
Washing solution:
100 ml concentrated buffer was added to 900 ml of deionised water and mixed
gently.
TMBZ-DMF
The tetramethyl benzadine was dissolved in 0.5 ml ofN,N dimethyl formamide.
Substrate solution
0.4.ml of the TMBZ-DMF was added to 40 ml of 100 mM Acetate buffer (pH 5.5)
and mixed gently.
Mixed laminin fragments
1. Blocking agent 0.5% casein in PBS/0.04% Tween 20
2. Coating buffer 400 ng.mF1 of laminin fragment N3 in 0.05 M
carbonate buffer (pH 9.6). Carbonate buffer - 0.015 M anhydrous sodium
carbonate/0.035 M anhydrous sodium hydrogen carbonate.





containing 100 mM EDTA {pH 9.6}
7. Substrate
buffer containing 0.05 mM MgCl2
Rabbit IgG to purified laminin N3 fragments
Alkaline conjugated goat anti-rabbit IgG
0.2 M Dipotassium hydrogen phosphate
0.3 mM SLPr-phosphate in diethanolamine

































































Figure A2.1 : Examples of linear progression, non-linear progression
and non-progression of renal function as determined
by estimated GFR
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Figure A5.1 : Relationship between the simultaneously measured plasma
clearance of 51Cr EDTA and glomerular filtration rate pre¬
dicted from Cockcroft-Gault and corrected for surface area for
all subjects (n = 71 observations; r=0.76; p<0.0001; y = 0.86x



























1 1 1 1 1 1 1
0 10 20 30 40 50 60 70
0 10 20 30 40 50 60 70
Mean of cGFR and EDTA GFR
(ml.min'l)
Figure A5.2 : Difference between EDTA GFR and calculated GFR vs mean of the
two methods at baseline in the three racial groups. Mean difference
shown as horizontal bar. Regression lines shown for Afro-Caribbean
and Asian groups.
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Figure A5.3 : Relationship between the ratio of endogenous creatinine
clearance to EDTA GFR and 24 hour protein excretion. All
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Figure A6.1 : Interrelationships of serum and urinary levels of Type IV collagen and mixed laminin
fragments. The shaded areas are below the limit of detection of the assay.
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